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xxv 
C57BL/6J mice Standard mouse used in scientific research, see 
section 4.3.4 
CAC Citric acid cycle (also known as Krebs cycle or 
tricarboxylic acid cycle) 
CGM Continuous glucose monitoring 
Clearance Rate at which a substance is removed 
Cleaving Process by which C-peptide is removed from 
proinsulin, causing insulin to be released 
CNS Central nervous system 
Compartmental model Mathematical model which uses compartments to 
represent aspects of the system 
Control system state space 
form 
Standard form for mathematical model equations 
given in section 2.3.2 
C-peptide By-product of insulin secretion 
Critically damped (system) System which returns to its steady state as quickly 
as possible 
CVGI Cardiovascular gastro-intestinal (department at 
AstraZeneca) 
Deconvolution Process whereby system input is determined from 
its output and knowledge of the system 
Deterministic System whose response is uniquely determined 
by the input and parameters, with no random 
component 
Glossary and abbreviations 
xxvi 
ELISA assay Enzyme-linked immunosorbent assay; biological 
test used to measure insulin and C-peptide levels 
Enzyme Biological catalyst 
Euglycaemic-
hyperinsulinaemic clamp 
An experiment where glucose is maintained at a 
normal concentration and insulin is maintained at 
a high concentration for a period of time 
First order ODE Ordinary differential equation containing only first 
derivative terms 
First pass effect Amount of drug or substance removed before 
being measured 
First phase response Initial reaction of a system to an impulse 
Gear’s stiff algorithm Algorithm for solving ordinary differential 
equations, see section 2.5 
GIM Glucose insulin model; software tool developed 
from the Cobelli model, see section 5.7 
GLS Generalised least squares 
Globally identifiable Parameter with a unique value or a system whose 
parameters all have unique values 
Glucagon Hormone which raises blood glucose levels and 
stimulates conversion of glycogen into glucose 
Gluconeogenesis Process for synthesis of glucose from non-
carbohydrates 
Glossary and abbreviations 
xxvii 
Glucose effectiveness Removal of glucose based only on glucose 
concentration 
Glucose-insulin homeostatic 
system 
System responsible for blood sugar regulation in 
the body 
GLUT Group of glucose transporters 
Glycogen Polymer of glucose used to store glucose in the 
liver 
Glycogenesis Process for creating glycogen 
GSIS Glucose-stimulated insulin secretion 
Haemacel Compound used to maintain constant volume of 
distribution 
Han Wistar rats Standard rat used in scientific research, see 
section 4.3.1 
Hepatic artery Main source of oxygenated blood into the liver 
Hepatic portal vein Main source of blood to the liver, via the 
gastrointestinal tract and spleen 
HOMA model Homeostatic model assessment model, see 
section 5.3 
Hyperglycaemic Having an elevated level of glucose 
Hyperglycaemic clamp Experiment where glucose is maintained at a high 
concentration for a period of time 
Hyperinsulinaemic Having an elevated level of insulin 
Glossary and abbreviations 
xxviii 
Hypoglycaemic Having a lowered level of glucose 
IDDM Insulin dependent diabetes mellitus 
Impulse response Output of a system when presented with a brief 
input signal (an impulse) 
Incretins Hormones which stimulate the release of insulin 
Insulin action Effect of insulin on a system 
Insulin resistance Level of insensitivity to insulin 
Insulin sensitivity Level of effect insulin has on glucose 
Islets of Langerhans Groups of cells in the pancreas where β-cells 
reside 
Interstitial insulin Insulin which is not in the blood 
IVGTT Intravenous glucose tolerance test 
Krebs cycle Part of the process for converting ADP into ATP in 
mitochondria (also known as citric acid cycle or 
tricarboxylic acid cycle) 
Leptin Hormone responsible for limiting appetite 
Lipids Group of molecules which allow energy to be 
stored; includes fats and fatty acids 
Locally identifiable Parameter with only a finite number of possible 
values or system whose parameters have only a 
finite number of possible values 
Maple Symbolic mathematical modelling software [2]  
Glossary and abbreviations 
xxix 
Mathematica Symbolic mathematical modelling software [3] 
Mathematical model Model using mathematical equations to describe 
a system 
MATLAB Numerical mathematical modelling software [4] 
Maximum entropy method Method for deconvolution 
Michaelis-Menten kinetics Standard model for enzyme kinetics 
Minimal Model Model of the glucose-insulin system, see Chapter 
6 
Nelder-Mead algorithm Optimisation algorithm 
NHS National Health Service 
NIDDM Non-insulin dependent diabetes mellitus 
Observable System (or part of a system) whose state can be 
reconstructed from observation of its outputs 
ODE Ordinary differential equation 
OGTT Oral glucose tolerance test 
OLS Ordinary least squares 
ORC Observability rank criterion 
Parameter Variable within a mathematical model 
Parameter estimation Process of determining values of variables within 
a mathematical model 
Pharmacodynamics Study of action which drugs have on a system 
Glossary and abbreviations 
xxx 
Pharmacokinetics Study of the profile of drugs within a system 
PID (controller) Proportional-Integral-Derivative (controller) 
PKPD Pharmacokinetic pharmacodynamic 
Plasma glucose Glucose measurement taken from blood plasma 
Plasma insulin Insulin measurement taken from blood plasma 
Proinsulin Form in which insulin is stored, attached to C-
peptide 
p value Probability of an event occurring due to random 
chance (usually based on Student’s t distribution) 
Quasi-Newton algorithm Optimisation algorithm 
Residual Output from objective function (e.g. generalised 
least squares) when fitting a mathematical model 
RRP Readily releasable pool (of insulin) 
Runge-Kutta algorithm Algorithm for solving ordinary differential 
equations 
Sensitivity analysis Method for determining a system’s response to a 
change in parameter values 
SF Stiffness factor 
Steady state State to which a system will return after 
perturbation; equivalent to basal level in 
biological terms 
Glossary and abbreviations 
xxxi 
Stiffness Measure for how dynamic (or otherwise) a system 
is 
Stochastic System whose response is not uniquely 
determined by the input and parameters as it has 
a random component 
Structural identifiability Analytical test to determine whether, given 
perfect, noise-free, continuous observations from 
an experiment, model parameters can be 
meaningfully determined 
Substrate Substance on which an enzyme acts 
TCA cycle Tricarboxylic acid cycle (also known as Krebs cycle 
or citric acid cycle) 
Type 1 diabetes Diabetes characterised by an auto-immune 
disorder causing loss of β-cells 
Type 2 diabetes Diabetes characterised by impaired β-cell function 
(though not due to an autoimmune disease as in 
type 1 diabetes) and reduced insulin sensitivity 
UN United Nations 
Unidentifiable Parameter with an infinite number of possible 
values or a system with at least one parameter 
with infinite possible values 
Uppsala model Model of the glucose-insulin system developed by 
a group based in Uppsala, see section 5.8 
Volume of distribution Size of a compartment in a compartmental model 
Glossary and abbreviations 
xxxii 
WHO World Health Organisation 
WinNonLin Numerical mathematical modelling software [5] 
WLS Weighted least squares 
ZDF rat Zucker diabetic fatty rat; model for subjects 
entering type 2 diabetes, see section 4.3.3 
Zucker rat Rat deficient in leptin receptors which is a good 
model for type 2 diabetes, see section 4.3.2 
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Chapter 1: Introduction 
1.1 Aims 
The primary aim of this work is to develop, using data obtained from rat models, 
an integrated mathematical model of glycaemic control that predicts both short-
term and long-term glucose regulation [6]. It is an additional aim of this thesis 
that it should be understandable by non-specialists. This will ensure that any 
person with an interest, regardless of scientific background, can understand the 
work. 
1.2 Objectives 
 To review and evaluate the different mathematical models of 
glycaemic control. 
 To modify/develop existing mathematical models and determine 
how existing glucose and insulin data from animal (rat and mouse) 
studies fit. 
 To apply the new model to the evaluation of glucose stimulated 
insulin secretion using new data. 
 To develop an integrated desktop utility for modelling and 
analysing glycaemic control and insulin secretion in animal models of 
diabetes. 
 To develop methods for determining pancreatic degeneration and 
function from measurable, but indirect, parameters such as glucose, C-
peptide and insulin levels. 
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 To include in the model physiological control parameters that 
address counter-regulatory systems, such as lipid levels and β-cell 
mass. 
 To apply the model to the design of future studies evaluating 
pancreatic changes and effects on glycaemic control [6]. 
1.3 Justification 
Diabetes is a huge and growing problem throughout the world. 171 million 
people suffer from it worldwide; this is estimated to double by 2030 [7]. In 2008, 
2.3 million people in the UK had diabetes, and it is expected to rise to 4 million 
by 2025. Diabetes in the UK costs an estimated 10% of total NHS costs [8]. 
Mathematical modelling can be used to help understand glucose regulation in 
health and diabetes. Drug development speed can be increased by identifying 
key pathways that will have the greatest effect on improving glucose control. 
Robust and well-validated models can potentially predict experimental outcomes 
without the need for further experiments to be performed, making processes 
cheaper and faster. They can also be used to analyse experimental data in order 
to gain more benefit from the experiments as well as helping to improve the 
design of future experiments. Thus modelling can also help in replacing, reducing 
and refining animal testing. 
Mathematical modelling involves equations that can reproduce and predict how 
a system will behave. To model the complex glucose and insulin system, 
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including feedback and non-linearities, with few data points is a challenging task. 
The glucose and insulin system can be looked at both in the long term (days, 
weeks and months) and the short term (hours and minutes); to combine these in 
one model and create a complete model of the glucose and insulin system is 
clearly a complicated and non-trivial task. 
1.4 Thesis layout 
Background information on mathematical modelling is provided in Chapter 2 and 
the biology of the glucose-insulin system is detailed in Chapter 3. Methods 
employed for data collection and the data used to create and validate the 
models created by the author of this thesis are introduced in Chapter 4. A 
selection of existing models of the glucose and insulin system is presented and 
critiqued in Chapter 5 to give an overview of the field as it stands. Chapter 6 : 
Minimal Model contains details of the most widely-used model in the field and 
new analysis of the Minimal Model performed by the author of this thesis. 
Chapter 7 presents the author's deconvolution of C-peptide concentrations to 
obtain insulin concentrations which were used to help design the model 
presented in Chapter 8, which is for short-term modelling of the glucose-insulin 
system. It is developed in Chapter 9 to additionally model long-term aspects of 
the glucose-insulin system. The software tool produced by the author is 
explained in Chapter 10. Figure 1.1 shows the relationship between chapters. 
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Figure 1.1 - Overview of chapters
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Chapter 2: Modelling 
This chapter introduces all the basic concepts of mathematical modelling and 
approaches to modelling that will be used and examined in the rest of this thesis. 
These include strategies for building models, structural identifiability analysis, 
model simulation, parameter estimation and sensitivity analysis. 
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2.1 Introduction 
A mathematical model is a representation of a system. Mathematical models are 
invariably simplified versions of the actual physical processes modelled and thus are 
approximations of the systems they represent. Mathematical models are useful 
because they make systems easier to study. For example they may allow situations 
which cannot be created in reality to be studied, outcomes to be predicted without 
experiments being carried out and situations to be analysed more clearly as 
mathematical variables can be controlled more easily. 
This thesis considers mathematical models of biological systems, specifically the 
glucose-insulin homeostatic system and other closely related systems. Two types of 
models are discussed in this thesis, animal models and mathematical models. A few 
are animal/biological models, where one animal (commonly the rat) is used as a 
substitute for a human. Most are mathematical models, that is mathematical 
descriptions of the system. The models which the author has developed and 
presented in this thesis are mathematical models.[9-11] 
2.2 Modelling approach 
In order to create a mechanistic mathematical model, the system must be 
represented by a set of equations. There are different ways in which this may be 
approached, though all tend to follow a similar approach which involves gathering 
information about the system, generating a model (or models) and validation. 
The approach adopted in this thesis is based on approaches from several sources [9-
11].   
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Figure 2.1 is a flowchart giving an overview of this approach; each stage is explained 
below. 
Experiment &
Observations
Physiological System
Model Formulation
Structural 
identifiability
Parameter 
Estimation
Parameter Validation
Interpretation
Sensitivity Analysis
Purpose/Aims & 
Objectives
Reparameterisation
Model Analysis
V
a
lid
a
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o
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Figure 2.1: Flowchart of modelling approach adopted in this thesis 
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2.2.1 Physiological System 
In creating a mathematical model, it is necessary to consider what is being 
modelled: data or the physical system itself [10]? In the first case, equations are 
based purely on inputs and outputs with no consideration for the mechanisms 
involved in the system, a numeric/descriptive model, and are essentially a curve-
fitting exercise. In the second case, equations are based on information about how 
the system works (i.e. physical, chemical or biological laws), which ensures that all 
parts of the model are relevant and justifiable and is necessary to make the model 
robust and applicable across a variety of situations. 
The models developed by the author of this thesis aim to be system, rather than 
data-driven, models. The biology of the glucose-insulin system is discussed at length 
in Chapter 3 and is used to help design the models in later chapters. 
2.2.2 Purpose/Aims & Objectives 
A large number of factors influence the way that a model is designed. It is important 
at the outset to ensure that the purpose of the model is clearly defined and that the 
desired outputs from the model are specified. The specific demands on this model 
are discussed in Chapter 5, Chapter 8 and Chapter 9. 
2.2.3 Experiments & Observations 
Knowing the limitations of the experimental environment helps to ensure that a 
model is appropriate for its purpose. For example, a model with a large number of 
parameters will possibly require more data and other types of measurements than 
can be gathered from available experiments. It may therefore be necessary to limit 
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the number of parameters in a model based on the potentially available 
experimental data. This is discussed further in the section on Structural 
Identifiability below. 
2.2.4 Model Formulation 
Once information about the system has been gathered, a model can be formulated. 
Where physical or biological laws related to the system are known, well accepted 
equations can be used; for example, laws governing enzyme kinetics are described 
by the Michaelis-Menten equation described in the Michaelis-Menten kinetics 
section below. For parts of the system where laws are unknown, numerically-
derived equations based on data can be used. 
This is the stage where decisions must be made about the form of the model; 
further detail about some of these decisions is given in the Model form section 
below. 
2.2.5 Model Analysis 
Depending on the model and the system being modelled, it is important to check 
that the model's behaviour matches the underlying system as well as passes 
mathematical tests to ensure the resulting parameters are valid. An example of this 
is that if the system returns to a steady state the model should also return to that 
steady state. It is good practice therefore to analyse the model's properties, in 
particular steady state analysis, to ensure that the model accurately represents the 
system and is stable [12-14]. Further tests, such as structural and sensitivity 
analyses, can be performed. 
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2.2.6 Structural Identifiability Analysis 
Structural identifiability analysis plays an important role in testing whether a model 
is appropriate, in a parametric sense, for a given experiment. It is a test to 
investigate whether, given perfect, noise-free, continuous observations from an 
experiment, model parameters can be meaningfully determined. This is important 
because an unidentifiable parameter has an infinite number of possible values 
which will all produce the same model output, rendering it meaningless. If any 
model parameters are unidentifiable, action to resolve this is needed; whether 
through obtaining the parameter value from another source (e.g. via the literature 
on separate, external experiments), re-parameterising the model such that it is 
“lumped” into a reduced set of identifiable parameters or redesigning the 
experiment to provide more observations from other parts of the system. Methods 
of determining structural identifiability are described in Structural identifiability 
techniques below [14-19]. 
2.2.7 Parameter Estimation 
Structural identifiability is a necessary precursor to parameter estimation (or 
parameter fitting) to ensure that any unidentifiable parameters have been 
appropriately reworked. Parameter estimation is the process of taking the 
postulated model and the experimental data and determining unknown model 
parameter values. Some parameters can be determined via alternative methods to 
parameter estimation; for example in a model of friction on a car wheel, 
gravitational acceleration need not be found from experimental data. In biological 
systems the majority of parameters are not documented in the literature or easily 
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obtainable from other experiments so most, or all, will need to be determined via 
parameter estimation. A method of parameter estimation is described in the 
Parameter estimation section below [10, 11, 18, 20-22]. 
2.2.8 Parameter Validation 
As part of parameter estimation, it is important to assess the confidence in the 
fitted parameter values as structural identifiability only tests the structure of the 
model, rather than the measurements given to the fitting process. If there is low 
confidence in the parameter values estimated, then it is necessary to redesign 
either the experiment or the model. This topic is explained in detail in Chapter 10, 
as it is important for users of the tool to understand how reliant they can be on the 
parameter values generated. 
2.2.9 Sensitivity Analysis 
Sensitivity analysis involves measuring how sensitive the model output is to changes 
in parameter values. This is useful in helping redesign experiments and models 
when there is low confidence in the parameter values as it can locate dynamic 
phases of the model which are key in obtaining higher confidence. This is described 
in detail later in this chapter [11, 20, 23, 24]. 
2.2.10 Interpretation 
Analysis and prediction are strongly linked to the model purpose as they are the 
primary reason for the development of a mechanistic model. In this case, the model 
has been designed largely to enable examination of the glucose-insulin system 
which allows for analysis of experiments, such as an IVGTT(Intravenous Glucose 
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Tolerance Test), and prediction of future experimental outcomes to this and other 
forms of intervention. 
2.3 Model form 
2.3.1 Linear and non-linear models 
A linear model is one where the output is directly proportional to the input, 
whereas a non-linear model does not have output directly proportional to the 
input. A linear model, such as the model of C-peptide kinetics in this thesis (see 
Chapter 7), will be structurally simple in a mathematical sense but may not contain 
adequate dynamics to model some systems. A non-linear model, such as the model 
of glucose and insulin kinetics in this thesis Chapter 8, may provide a more accurate 
representation of a system, but will be more complex in structure. 
2.3.2 General model form for equations 
The standard control system state space form for representing mathematical 
models is as follows in equation 2.1: 
 
 
                                   
                   
             
2.1 
where      is time, p  is a vector of the model parameters     (a real number 
vector of size p), x  is the state vector    , y  is the vector of observations     
and u  is the input to the system. In a non-linear model f  is the co-ordinate function 
that represents the dynamics of the system, g  is a function applied to states that 
affects the inputs and h  is a function of the states; in a linear model, f, g  and h  are 
a matrix of scalars multiplied by the states [25]. 
Chapter 2: Modelling 
13 
Linear models have an exact analytical solution whereas very few non-linear models 
have known analytical solutions. Therefore when solving non-linear models 
numerical methods are often required. This is explained in section 2.5, Simulation. 
2.3.3 Compartmental modelling 
Compartmental models are used extensively in the modelling of biological systems 
[14]. In this type of model systems are represented by a finite set of subsystems, or 
"compartments", with flows linking those parts of the system which interact (see 
Figure 2.2). How the system is divided into compartments depends on factors such 
as the scale of the system and purpose of the model; for example a simple model 
could use a single compartment to represent all of the blood in the human body, 
whereas a more complex model might use one compartment per organ (such as the 
PBPK model in [26]). 
x1
k1e
x2
k21
k12
bu(t)    
 
Figure 2.2: Example compartmental model 
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The equations defining the compartmental model shown in Figure 2.2 are given in 
equation 2.2. 
 
 
        
            
      
  
   
  
   
 
 
      
            
  
  
  
             
2.2 
where x1 and x2 are state variables representing concentration in compartments 1 
and 2 respectively, x1 is the only observable state (shown by the matrix in the 
equation for y), y is the output function, k12 is the flow rate from compartment 1 to 
compartment 2, k21 is the flow rate from compartment 2 to compartment 1, k1e is 
the extraction rate from compartment 1, b is the input gain (bioavailability/volume 
of distribution) and u is the input to compartment 1 [14]. 
In biological system modelling, it is often the case that each compartment 
represents a concentration of a substance or quantity of a substance; this is the 
case in the models developed by the author and presented in this thesis as most of 
the data available are in the form of concentrations (e.g. glucose concentration in 
blood) or quantities (e.g. quantity of glucose in the subject). The substance in each 
compartment is assumed to be evenly distributed within the compartment, 
meaning that the concentration at any location in the compartment is assumed to 
be the same as at the sampling site (i.e. sample concentrations are representative 
of concentrations throughout the compartment). With this assumption in mind, the 
volume of distribution of a compartment is the volume in the compartment over 
which a substance is (evenly) distributed, i.e. the size of the compartment [9, 14]. 
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2.3.3.1 Michaelis-Menten kinetics 
Michaelis-Menten kinetics are an approximation for substrate-only enzyme kinetics, 
describing the reaction rate as substrate and enzyme interact. The Michaelis-
Menten equation is given by equation 2.3, below: 
 
 
     
        
       
 2.3 
where v  is reaction rate, vmax  is the maximum theoretical reaction rate, S is 
substrate concentration and KM  is the Michaelis-Menten constant, i.e. the 
substrate concentration at which v  is at 50% of vmax. 
A key feature of this equation is that it reaches a saturation level which 
asymptotically approaches vmax, as shown in Figure 2.3. 
 
Figure 2.3: Michaelis-Menten equation plotted with concentration of substrate along x-axis 
and reaction rate along y-axis 
The Michaelis-Menten equation is more widely applicable in situations where 
processes saturate, for example certain predator-prey relationships where the 
number of species saturate [27]. It is used in this thesis for clearance rates of 
glucose and C-peptide, as explained in Chapter 7. 
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2.4 Structural identifiability techniques 
A mathematical model is said to be “structurally identifiable” if, given a perfect, 
noise-free, continuous set of observations, all the parameters in the system can be 
uniquely determined [15, 17, 19]. If a model is unidentifiable there will be an 
infinite number of possible combinations of values for unidentifiable parameters 
that will produce the same output, making these parameter values meaningless in a 
practical context. 
In biological systems the data is far from noise-free, so a structurally identifiable 
model does not guarantee that these parameters will be meaningful. Identifiability 
ensures that the model has structurally meaningful parameters and, with the right 
conditions, uniquely identifiable parameters. This test should be seen as a precursor 
to having a sound mathematical model. If the model is not structurally identifiable, 
the unidentifiable parameters are meaningless. 
Mathematically, structural identifiability can be defined as follows. Given the 
model, from equation 2.1, and a parameter value     where  is an open set, 
    , of feasible values, find all parameter values      and the corresponding 
models of the form: 
 
 
                                    
                   
             
2.4 
such that: 
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                     2.5 
Individual parameters can be classed as unidentifiable, locally identifiable or 
globally identifiable. A parameter is globally identifiable if it has a unique value; it is 
locally identifiable if it can take its value from only a finite set of possible values. For 
an entire model to be globally identifiable, all parameters must be globally 
identifiable. For a model to be locally identifiable, all parameters must be either 
globally or locally identifiable with at least one parameter locally identifiable. If one 
or more parameters are unidentifiable then the entire model is unidentifiable. 
There are several methods of determining the structural identifiability of a model. 
The Laplace transform approach, which involves considering the Laplace transform 
of the model equations, can only be applied to linear models and is explained in 
section 2.4.1 below. The Taylor series approach involves calculating the Taylor 
series coefficients of the model observations; this can be applied to both linear and 
non-linear models and is explained in further detail in section 2.4.2 below. The 
similarity transformation approach has two methods: one for linear models and one 
for non-linear models which is detailed further in section 2.4.3 below. The Lie-
symmetry approach involves a similar mathematical approach to the similarity 
transformation approach, but has the advantage that it can be implemented easily . 
It is discussed further in section 2.4.4 below. 
2.4.1 Laplace transform approach 
The Laplace transform approach is simple, but appropriate only for linear systems 
[28]. It involves obtaining Laplace transforms of the model equations which are 
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then rearranged to find the system transfer function, i.e. the relationship between 
the input and output of the system. The coefficient of each term in the transfer 
function is theoretically measurable, meaning that if a single solution can be 
obtained for the parameters from these coefficients the parameters are measurable 
and unique [9, 14]. 
2.4.1.1 Method 
 Ensure the model equations are in the standard control system state space form 
given in equation 2.1; as the system must be linear, f, g  and h  will be matrices 
multiplied by the states. 
 Obtain Laplace transforms of the model equations, such that : 
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 Rearrange and combine the Laplace transforms to obtain a relationship 
between the input and output: 
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 Use equation 2.7 to identify the transfer function, T(s): 
where 
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 Assume that coefficients of the powers of s in the transfer function, T(s), are 
known. Any coefficients which consist only of a single parameter are identifiable 
however any coefficients which consist of a combination of two or more 
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parameters are unidentifiable on their own. The analysis then entails 
determining the solution set for the parameters from these coefficients. 
2.4.2 Taylor series approach 
The Taylor series approach is appropriate for both linear and non-linear systems. It 
involves successive differentiation of the output function with respect to time to 
obtain a Taylor series expansion of the model output, of the form in equation 2.9, 
about a known time point (generally t  = 0). 
 
                              
        
  
  
    2.9 
where   
          
    
   
 
   
  [22]. 
The coefficient of each term in the expansion is theoretically measurable, meaning 
that if a single solution can be obtained for the parameters from these coefficients 
the parameters are measurable and unique  [19]. 
For linear systems with n parameters and no input (or a single impulse input) at 
most 2n -1 successive differentiations are needed [9]. For general non-linear 
systems, such as the ones in this thesis, there is no strict upper bound for the 
number of successive differentiations. This means that this approach can only prove 
a system is identifiable, not that it is unidentifiable. 
2.4.2.1 Method 
 Ensure the model equations are in the standard control system state space form 
given in equation 2.1. 
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 Repeat the following steps until all parameters have been uniquely determined 
or solving to find parameters becomes intractable: 
 Successively differentiate y(t,p) to obtain higher derivative than the  
previous iteration (i.e. y'(t,p) in the first iteration, then y''(t,p), etc.). 
 Evaluate this result at a known time point (e.g. t  = 0) by substituting 
identifiable parameters already known from previous iterations. 
 Solve for p in                , where      ,       , ...,       . 
If the system of equations is solvable for a parameter, pi, then the parameter is 
globally structurally identifiable. If pi cannot be solved for then the parameter may 
or may not be unidentifiable; this means that the Taylor series approach cannot be 
used as a test for unidentifiability. 
2.4.3 Similarity transformation approach 
The similarity transformation approach essentially involves using a smooth, 
infinitely differentiated mapping to connect the state trajectories (the input/output 
behaviour) of two identical models. This is done by creating a smooth mapping, λ 
defined in equation 2.16, between the two models using terms obtained from the 
observable function y, see equation 2.4  This mapping is a link between the state 
trajectories of each model and, hence, the parameters in the models [17]. 
 All of the models examined in this thesis using this method are uncontrolled, i.e. 
have no inputs or the inputs do not affect the output, therefore this technique is 
applicable in all of these cases [17]. 
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In order for this method to be valid the model must satisfy the Observability Rank 
Criterion (ORC), described below.  
2.4.3.1 Observability Rank Criterion 
A system is said to be observable if all the possible initial states of the system can be 
observed, i.e. reconstructed from the observation. Systems that do not meet this 
criterion are said to be unobservable [19, 25]. 
The Observability Rank Criterion (ORC) is a test for observability. Consider a linear 
model of the form: 
  
 
         
     
         
2.10 
The observability matrix, Q0, for this model is defined in equation 2.11. The model is 
observable if and only if the rank of Q0  is n, i.e. the number of states. 
 
 
   
 
 
 
 
 
 
  
   
 
      
 
 
 
 
  2.11 
For non-linear models, the ORC is defined slightly differently [17]. Consider a non-
linear model of the form given in equation 2.1. The definition of Lie derivatives for 
the function h is (Lie derivatives are the change in h along the vector field of f): 
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then successive Lie derivatives are found: 
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The observability matrix, Q0, is then defined as: 
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The model is again observable if and only if the rank of Q0  is n [29]. 
2.4.3.2 Method 
Consider the following theorem from [25]: 
Assume that the model of equation 2.4 is locally reduced at       for all    . 
Consider the parameter values       p an open neighbourhood             in , 
and any analytical mapping        defined on      such that: 
 
 
(i) 
(ii) 
(iii) 
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  λ         
  
  
           
  λ         
  
  
           
  λ                 
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for all    . Then there exists        such that equation 2.4 is globally identifiable 
at   in the experiments                   if and only if conditions (i), (ii), and (iii) 
imply     .  
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 Ensure that the model equations are in the standard control system 
state form given in equation 2.1. 
 Check the model fulfils the Observability Rank Criterion (ORC), 
detailed in the Observability Rank Criterion section above; if it does not, 
this technique will not be applicable. 
 Select a candidate matrix, H, of smooth functions, µ. 
 A good starting point will be Q0 from the ORC, however it may be 
possible to select other µ to simplify computation, as long as the 
resulting matrix H has rank n. 
 Determine the smooth mapping, λ, by considering: 
                 2.16 
Where       is the candidate matrix with      ,      , ...,      . 
 Solve for λ to find p in terms of   : 
 
 
               
  
  
            2.17 
If, from this system of equations, a parameter, pi, can be directly equated to    then 
the parameter is globally structurally identifiable.  
2.4.4 Lie-symmetry approach 
The Lie-symmetry approach uses a similar mathematical approach to the non-linear 
similarity transformation approach described above, as it uses Lie algebra. It has the 
advantage over other algorithms in that it is more procedural in nature and 
therefore can be implemented easily without full understanding of the deep 
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mathematical theory behind it, so for a full explanation of the mathematics see 
[15]. It is important to note however that this method proves only local structural 
identifiability - it cannot prove whether a model is globally structurally identifiable 
or unidentifiable. This method is employed in Chapter 8 and the analysis of the 
short-term model with this approach is included in Appendix 4. 
2.4.4.1 Method 
 Ensure the model equations are in the standard control system state space form 
given in equation 2.1. 
 Check the model fulfils the Observability Rank Criterion, detailed in the 
Observability Rank Criterion section above; if it does not, this technique will not 
be applicable. 
 Find the determining equations for the model; this can be done easily using the 
Lie symmetries package in Mathematica. 
 Solve the determining equations to obtain equations for the symmetries of the 
differential equations, representing perturbations in time, the states and the 
parameters. 
 If it can be seen, from these equations, that there are no non-trivial 
transformations that are time-invariant and preserve the initial conditions, then 
the model is at least locally identifiable. 
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2.5 Simulation 
Solving Ordinary Differential Equations (ODEs) is essential for mathematical 
modelling as it allows model equations to be solved using parameter values to 
produce an output that can be compared to real output of the system being 
studied, i.e. it allows the system to be simulated. In the case of linear systems, there 
are exact analytical solutions to the ODEs, which make simulation relatively simple 
and generally computationally inexpensive. As most models presented in this thesis 
are non-linear, however it is not useful to cover solving linear ODEs here. Very few 
non-linear differential equations have known analytical solutions, and this is also 
true for all of the models presented in this thesis. This means that the only way to 
solve these models is by employing numerical methods. 
There are many different methods for solving a model numerically. The main factors 
in selecting an appropriate algorithm are speed of computation, accuracy and ability 
to deal with stiff systems. A stiff system is a system where there is a large range of 
timescales; see the Stiffness section below. The algorithms used in this thesis are 
Runge-Kutta and Gear’s Stiff. 
An explicit fourth/fifth order Runge-Kutta method is implemented in MATLAB under 
ode45. This was used when the problem was non-stiff (i.e. for short-term 
modelling) and was useful as it had short computation time. When the problems 
were stiffer, a modified second/third order Runge-Kutta algorithm – ode23tb – 
was used as, although it was slower, it performed simulations in an acceptable time 
frame, usually less than a second [4]. 
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The Gear’s Stiff algorithm is implemented in acslX and is appropriate for stiff 
systems – as well as non-stiff systems [30, 31]. From experimental runs on the 
model presented in Chapter 8 it was seen to execute more quickly than MATLAB's 
ODE solvers. 
The algorithms have an acceptable level of accuracy for this purpose with a 
tolerance of 0.1% [4] which is at least an order of magnitude lower than the 
experimental error in the data sets (see Chapter 4). 
2.5.1 Stiffness 
In general, the stiffness of a system is a measure of the range of time scales the 
whole system operates on. This usually means that some parts of the model may 
change over a period of seconds or minutes (fast variables) while others change 
over a period of hours or days (slow variables). The wider the range of these 
timescales, the stiffer the system. The stiffness of a system is important when 
making choices such as selection of an appropriate numerical ODE solver [30, 31]. 
A measure of the stiffness of a system is given by the stiffness factor. To find the 
stiffness factor of a non-linear system, it is necessary to linearise the system at a 
given time point (often t  = 0, to see starting conditions of the model) by creating a 
Jacobian matrix: 
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The eigenvalues, λ, of this matrix can then be found by solving: 
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            . 2.19 
The stiffness factor is then defined as: 
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 2.20 
Stiffness factors are normally provided as orders of magnitude, e.g. O(106). Models 
where the stiffness is greater than O(102) are normally considered "stiff" [9, 32]. 
2.6 Parameter estimation methods 
In order to obtain estimates for model parameters from real data it is necessary to 
“fit” the model to the data. This is performed using a technique called parameter 
estimation [10, 11, 18, 20-22]. The stages in this process are: 
1. An initial estimate for each of the unknown parameters is taken; these may be 
taken from known physiological values, graph peeling or from knowledge of the 
expected order of magnitude for the parameter. The importance of how close 
the initial guess is to the real value is dependent on the model and the real 
parameter (i.e. the actual physiological parameter). 
2. The model is simulated with the chosen parameter estimates. 
3. The residuals are calculated. These are a measure of the error between the 
simulated model output and the real data which are explained in the Least 
squares residual method section, the method of determining residuals used in 
this thesis, below. 
4. Then an optimisation algorithm is used to calculate the next attempted value. 
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5. Steps 2-4 are repeated until the optimisation algorithm considers the residuals 
to have reached a minimum (or maximum depending on the method used). 
2.6.1 Least squares residual method 
Residuals are the error between the real data and model output, as shown 
graphically in Figure 2.4. 
 
Figure 2.4: Non-linear residuals  [33] 
The least squares residual method involves taking the difference between the real 
and simulated data at each time point, squaring the difference to remove any 
negative values then summing the values across all time points and dividing by the 
number of time points to normalise the value. This assumes the data are normally 
distributed with the model predicting the mean. This is known as Ordinary Least 
Squares (OLS) and is given by: 
  
          
 
 
   
 2.21 
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where E  is the residual,             are the real data points and            
are the simulated data points. 
If all the data are of a similar order of magnitude, OLS will generally provide 
acceptable results. However with data of different magnitudes (e.g. glucose and 
insulin) it is undesirable for any data set to have an unfair bias on the parameter fit 
due to the larger magnitude of its values as variance is likely to change with the 
magnitude of the data. Therefore a Weighted Least Squares (WLS) method may be 
used instead. There are two options for weighting each time point: based on the 
real data value or the simulated data value; in either case, the change is then 
relative rather than absolute. To weight a given time point, the chosen value can be 
squared to provide a greater penalty for moving further away from it. For most of 
the modelling in this thesis, it is assumed that the model output is correct and the 
real data are noisy and have other influencing factors. Therefore a Generalised 
Least Squares (GLS) method, with the weighting based on the simulated data values 
as shown in equation 2.22, is used [11].  
 
   
      
 
   
 
   
 2.22 
where   are the real data,    are the simulated model data at time point  .   
 is 
therefore acting as the weighting. The aim is to get to the global minimum which is 
also the structurally identifiable set of unique parameters. However, due to the 
noisy environment, this is not guaranteed. 
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2.6.2 Optimisation algorithms 
An optimisation algorithm, in this context, is a method of updating parameter 
estimates to try to minimise (or maximise) residuals. There are many different 
optimisation algorithms, however the main ones used in this thesis are the Nelder-
Mead [34] and Quasi-Newton [35] algorithms. The Nelder-Mead algorithm is 
implemented in MATLAB as the routine fminsearch and the Quasi-Newton 
algorithm is the default algorithm for the routine fminunc. The choice of which to 
use depends on several factors, for example the Nelder-Mead algorithm is generally 
more stable than the Quasi-Newton algorithm, however it has the drawback that it 
often settles in local minima/maxima rather than global minima/maxima. When 
using the Nelder-Mead algorithm, it is therefore important to have initial estimates 
which are as close as possible to the global minimum/maximum [36]. 
2.6.3 Statistical analysis 
As a measure of how meaningful a parameter value is, it is useful to have statistical 
confidence values for the parameter estimates. These can be obtained from the 
covariance matrix of the fitted parameters, which can be estimated from the 
optimisation algorithm in MATLAB. To do this it is necessary to obtain the Hessian 
matrix, an estimate of which is optionally produced by fminunc in MATLAB using 
the BFGS (Broyden-Fletcher-Goldfarb-Shanno) algorithm [30]. The covariance 
matrix can then be calculated as: 
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where   is the set of parameter estimates, N  is the number of time points, n  is the 
number of parameters fitted, E  is the output from the residual function and H  is 
the Hessian matrix. 
Individual parameter confidence values can then be obtained as: 
 
         
   
 
       2.24 
for          where      
   
 
 
 
 is a two-tailed Student's t distribution for confidence 
level α  and N-np  degrees of freedom [21]. 
The package acslX, which was used for parameter fitting in part of this thesis, uses a 
similar method for calculating confidence values automatically [31]. 
2.7 Sensitivity analysis 
This is the process of finding out what the most "important" parameters in a model 
are. In this case, “important” refers to the parameters which have the greatest 
effect on the model output, i.e. those to which the model is most sensitive. This is 
not only model-dependent, but also dependent on the parameters, initial 
conditions and system input. When performing a sensitivity analysis nominal/mean 
parameter values are used. In the context of a biological system, an experiment is 
performed and the system is examined over the duration of the experiment [23, 
37]. 
Sensitivity analysis is also useful for determining which parameters are sensitive to 
change and at which time points. Time points where a large number of parameters 
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are particularly sensitive are good choices for increased sampling to ensure a good 
parameter estimate [23, 38]. 
There are several ways of looking at sensitivity. The simplest method is to vary each 
parameter (either independently or as part of a group) to see the effect on the 
resulting model output. 
A more complex method used in this thesis involves examining the sensitivity 
matrix, S(t, p) given in equation 2.25. This is a set of Jacobian matrices of the model 
with respect to the model parameters and time points, i.e. one matrix per model 
state. These matrices contain actual parameter values which can be examined, or 
plotted graphically against time, to show which have the greatest effect at each 
time point. 
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where              is a vector of time points,              is a vector of all 
parameters, and x  is a scalar output of the state. 
If it is not possible to compute S(t,p) analytically, equation 2.26 may be solved to 
compute sensitivity values numerically [23, 37] using: 
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This matrix shows absolute sensitivities, therefore it is useful to normalise the 
sensitivity matrix to form a matrix of relative sensitivities, Sr. This is done by 
multiplying by the parameter vector, p, and dividing by the state,     to give: 
  
       =        
          
 
          
  2.27 
In order to compute this matrix it is necessary to differentiate the model equations. 
This can be a laborious process so it is useful to have a way of producing these 
matrices automatically. This can be achieved through automatic differentiation 
which is explained fully in Chapter 8. Essentially, instead of creating a sensitivity 
matrix which contains parameters and a specific set of time points, as in equation 
2.25, it is possible to create a time-dependent matrix which contains states and 
parameters. This matrix, shown in equation 2.28, is a set of ODEs which can be 
solved alongside the model equations, x(t, p), making it easy to calculate 
sensitivities if a new experiment is presented to the model. 
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where t  is now the current time point (during the model simulation) and is 
therefore a scalar, rather than a vector. 
2.8 Summary 
The process and methods that have been described in this chapter are used 
throughout this thesis to help model the dynamics of the glucose-insulin system. 
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There are many other techniques and methodologies which may be useful; those 
presented here were selected based on the author's engineering background and 
knowledge and understanding of the techniques.
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Chapter 3: Biological Overview 
This chapter discusses the components of the glucose and insulin homeostatic 
system. The aim of this chapter is to provide an introduction to the system as a 
whole in the context of being able to mathematically model the process. There 
are many factors affecting this biological system; these factors and their 
importance are discussed. 
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3.1 Introduction 
The glucose and insulin homeostatic system is complex, involving many organs 
including the liver, pancreas and kidneys. Glucose has critical importance to the 
body, as it is used by every cell and is the primary source of energy for the 
central nervous system (CNS). If the glucose level goes too low (hypoglycaemia) 
it can lead to coma and death, however glucose is also toxic and if it rises too 
high (hyperglycaemia) this can lead to long-term damage. Insulin regulates 
glucose uptake in many different tissues, including the liver, adipose (fat) tissue, 
and skeletal muscle [39-47]. 
3.2 Glucose 
Glucose is a monosaccharide, i.e. it consists of one sugar group (Figure 3.1), and 
is one of the most important molecules in biology [48]. 
 
Figure 3.1: Glucose molecule  [49] 
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Glucose is important for several reasons: 
 it can be used to produce energy very quickly for cells to use [48, 50 ]; 
 it can be mobilised very quickly from glycogen, a polymer of the 
monosaccharide, in the liver [43, 48, 50]; 
 it is created and used by most organisms, therefore is abundant in plants 
and animals and consequently it can be obtained as a food source very 
easily [48, 50 ]; 
 it can be used as an energy source in the absence of oxygen; 
(anaerobically), as well as in the presence of oxygen (aerobically) [48]; 
 it can be built up into other molecules for storage (energy) and structures 
(e.g. starch) [48]. 
3.2.1 Respiration 
Glucose is utilised by the same mechanism in most cells - respiration - therefore 
it is important to understand the basics of this mechanism. 
Energy required in cells is derived from exothermic hydrolysis of adenosine 
triphosphate (ATP) to adenosine diphosphate (ADP) and inorganic phosphate 
(Pi).This means that ATP is the unit of energy in a cell; the more ATP there is (or 
more specifically the higher the ATP/ADP ratio) the more energy is in the cell. 
When ATP is hydrolysed to ADP, heat energy is produced. The reverse process - 
where ADP is converted to ATP to produce stored energy - is known as 
mitochondrial respiration, or in some fields metabolism [48]. 
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The basic inputs for respiration are oxygen (O2) and glucose and the outputs are 
kinetic energy and carbon dioxide (CO2). Transporters drive active uptake of 
glucose into the cell (discussed in Glucose transporters below). Glucose is 
converted to pyruvate via the glycolytic pathway before entering the 
mitochondria and producing two molecules of ATP; mitochondria are organelles 
(cellular subunits) which produce ATP in the process. Pyruvate is converted to 
acetyle coenzyme A which then enters the citric acid cycle (CAC), also known as 
the tricarboxylic acid cycle (TCA cycle) or the Krebs cycle where a further 34 
molecules of  ATP are generated per molecule of glucose [43, 48, 51 ]. This 
process is shown in Figure 3.2 below. 
 
Figure 3.2: Diagram of respiration  [52] 
3.2.2 Uses in humans 
In humans, a critical and main use for glucose is in the CNS as it requires a rapid 
source of energy due to its fluctuating demands. Nerve cells require a large 
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amount of energy to function, so are specially adapted to utilise glucose at a 
greater rate, e.g. increased mitochondrial density[45]. The CNS uses around 45-
60% of glucose in the body, in an overnight fasted state [46]. 
Skeletal muscles are another big user of glucose in the human body. Depending 
on exercise the muscles use approximately 15-20% of the glucose being used at 
that time, in an overnight fasted state[46]. When not contracting, skeletal 
muscles mainly use energy from lipids in the blood. These contain higher 
amounts of energy than glucose but take longer to process as they require more 
oxygen to generate ATP. Fat utilisation hits its peak contribution to muscle ATP 
generation when energy requirement is at 40% of the maximum possible, i.e. 
moderate exercise. When exercise increases, more glucose is used to support 
muscle function[53]. 
Other major users of glucose in the body include the kidneys at 10-15%, blood 
cells at 5-10% and other tissue (including fat) 5-10%, in an overnight fasted 
state[46]. 
3.3 β-cells 
The pancreas contains a group of cells that produce hormones (endocrine cells), 
which are located in the islets of Langerhans. These were found in 1869 by Paul 
Langerhans [54]. They make up about 1-2% of the pancreas and weigh about 1g 
to 1.5g in a normal human. The islets contain several different types of cells, 
including α- and β-cells [46]. 
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3.3.1 Glucagon 
α-cells make about 30% of the islets of Langerhans [55] and produce glucagon. 
The function of glucagon is to raise blood glucose levels [42]. Its main place of 
action is the liver, where it stimulates glycogenolysis which is the process of 
turning glycogen into glucose [53]. 
3.3.2 Insulin 
3.3.2.1 Creation of insulin 
β-cells make up about 60% of the islets of Langerhans and produce insulin, which 
lowers blood glucose levels [42, 55]. Insulin is actually produced as proinsulin, 
which consists of C-peptide attached to insulin. Proinsulin is inactive and does 
not lower blood glucose. 
3.3.2.2 C-peptide 
When proinsulin is activated, C-peptide is cleaved from it using carboxypeptidase 
and a series of prohormone convertases [54, 56]. This causes C-peptide and 
insulin to be released into the hepatic portal vein in equal molar quantities. 
An important feature of C-peptide is that it is cleared by the kidneys and not by 
the liver, like insulin. All secreted C-peptide can therefore be assumed to reach 
systemic circulation  [57-61]. 
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3.3.2.3 Secretion of insulin 
Glucose enters β-cells via transporters passively (see Glucose transporters 
below) and therefore the level of glucose in β-cells is proportional to the blood 
glucose level [42].  
In a β-cell these reactions occur as shown in Figure 3.3 and are explained as 
follows [54, 62]: 
 Glucose enters the β-cell via GLUT2 (see Glucose transporters below). 
 Respiration occurs, converting glucose to ATP. 
 ATP closes KATP gates which allows potassium (K) out of the β-cell. This 
creates a negative charge in the β-cell and depolarises the membrane. 
 Depolarisation of the membrane causes the sodium channel to open, 
allowing calcium ions into the β-cell. 
 Calcium entering the β-cell releases calcium stored in the endoplasmic 
reticulum (small tubes inside cells). 
 Calcium releases the insulin stored in the β-cell. 
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Figure 3.3: Diagram showing how glucose potentiates insulin release  [62]. 
Incretins 
Although insulin release is mainly stimulated by glucose, other mechanisms for 
stimulating insulin release exist. Incretins stimulate insulin release by activating a 
receptor on the β-cell which opens the calcium gates of the β-cell. This allows 
calcium into the β-cell, which triggers the release of insulin [63]. 
One example of an incretin is GLP-1 [63], which is released from the gut and 
activates the GLP-1 receptor on the β-cell [41].  
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3.3.2.4 Storage of insulin 
There are a lot of uncertainties in our knowledge around the storage of insulin, in 
particular concerning the quantity of insulin stored [42, 62, 64]. 
Insulin is stored and transported within β-cells in granules. These granules are 
stored in various places in the β-cell, though where exactly and how they move is 
uncertain. Energy (ATP) is required to move the granules from where proinsulin 
is created to the membrane and then to dock them to the membrane. When the 
insulin is required, energy is also needed to cleave the insulin and C-peptide from 
the pro-insulin molecule and to release the insulin into the blood. 
The Rorsman & Renström review [42] states that there could be four states of 
insulin: 
 undocked (stored in the cytoplasm): ~73%; 
 almost docked: ~20%; 
 docked: ~6%; 
 "Rapid Release Pool" (RRP): ~<1%. 
This means that glucose stimulation can cause different levels of response. The 
RRP consists of a small number of granules attached to the β-cell membrane 
which can be released very quickly. Rorsman & Renström [42] believe that the 
fast release of insulin from the RRP could be what causes a high peak of insulin 
secretion immediately following a glucose stimulus, known as the first-phase 
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response. The second-phase response is thought to be created by mobilisation of 
the undocked and almost docked granules [42, 65, 66]. 
3.4 Disposal of glucose 
3.4.1 Glucose transporters 
There are 4 main passive transporters of glucose, commonly known as GLUTs 
[54, 67, 68]. 
GLUT 1 is responsible for low levels of glucose uptake to maintain respiration in 
all cells. Expression of this transporter is reduced when there are increased levels 
of glucose. It exhibits Michaelis-Menten type kinetics [48, 54]. 
GLUT2 is expressed in the pancreas, liver, hypothalamus, small intestine and 
kidneys. It is a high capacity transporter of glucose and is often referred to as the 
glucose-sensing transporter. In the pancreas, it transports glucose into β-cells 
without requiring insulin to be present, which allows the β-cells to sense the 
level of glucose and respond with a corresponding quantity of insulin. In the liver, 
it allows the flow of glucose in and out of the hepatic cells [48] . 
GLUT3 is expressed mainly in neurons and, like GLUT1 and GLUT2, operates 
independently of insulin [48, 54]. 
GLUT4 is an insulin-dependent transporter and is expressed in adipose tissue and 
skeletal muscle tissue. It is the main controlling mechanism for glucose outside 
the liver. It is very important in modelling the glucose and insulin system because 
of its large role in glucose uptake and insulin-dependence [69, 70]. 
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3.4.2 Insulin sensitivity and resistance 
Insulin sensitivity is the effect of insulin on the disposal of glucose; higher insulin 
sensitivity means that more glucose will be disposed of with the same amount of 
insulin. The main transporter involved in this is GLUT4. Insulin resistance applies 
to the same process, but higher insulin resistance means that less glucose will be 
disposed of with the same amount of insulin. Therefore being less insulin-
sensitive and more insulin-resistant are equivalent; conversely, more insulin-
sensitive is equivalent to less insulin-resistant.[41] 
3.4.3 Liver 
Glucose enters the hepatic cells via GLUT2. Here it is converted into glycogen by 
glycogenesis, which is the largest glucose uptake mechanism dependent on 
insulin. Glycogen can be quickly converted back to glucose when required [43]. 
The portal vein comes from the gut and the pancreas into the liver; this means 
that glucose is absorbed from the gut and then is transported to the liver. As 
most sampling of blood glucose occurs after the liver, there is a "first pass" effect 
on the glucose as some of it is removed by hepatic extraction (approximately 
13% is retained by the liver in rats) as described above [71]. A similar action 
occurs with insulin clearance in the liver  [57]. 
3.4.4 Skeletal muscle 
GLUT4 is the main transporter of glucose into skeletal muscle tissue. It is 
activated by insulin receptors. This means that an increase in insulin will increase 
the amount of glucose entering the cells, causing an increase in glucose 
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utilisation [48, 69]. Glucose is utilised through respiration in skeletal muscle cells 
as well as being stored as glycogen. As there is a large amount of skeletal muscle, 
this is a major mechanism of glucose disposal. 
3.4.5 Adipose 
GLUT4 also transports glucose into adipose tissue. Here it is converted into fatty 
acids which can be stored in the adipose tissue as triglycerides. The storage of 
fatty acids will, in general, mean that the adipose tissues become larger. The 
important thing to note here is that, unlike glycogen, fatty acids cannot later be 
converted back into glucose [48]. Increased triglyceride concentration will 
decrease the insulin sensitivity of the adipose tissue, which means less glucose 
and fatty acids can be taken in by the adipose, thus increasing circulating fatty 
acids [69]. 
3.4.6 Blood flow 
The amount of blood flowing though the gut, that is through the hepatic arteries 
and hepatic portal vein, can vary [72, 73] from 14.60 14.60 ± 0.96 ml/min to 
27.35 ± 1.82 ml/min between fasted and fed rats [74]. It is hypothesised that gut 
blood flow plays an important role in disposal and absorption of glucose and 
clearance of insulin (see Chapter 7 for further details). 
3.5 Lipids 
Lipids are a store of energy and therefore have the same capability as glucose in 
increasing the ATP/ADP ratio. However they have a different rate of utilisation 
and insulin secretion profile to that of glucose [75]. 
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3.5.1 Lipid effects on insulin sensitivity 
In the short term, high levels of lipids have the effect of lowering insulin 
sensitivity, which can be seen as an inhibitory effect of lipids on glucose uptake 
via GLUT4 [41, 69]. 
3.5.2 Lipid effects on insulin secretion 
In the long term, high levels of lipids have a toxic effect on β-cells. This causes a 
cycle, as insulin lowers lipid levels and as β-cells become damaged they cannot 
produce enough insulin to lower the lipid levels. This means that the lipid levels 
remain high and cause further damage, and so on [69, 70]. 
3.5.3 Insulin effect on lipids 
It is known that increased insulin levels increase uptake of fatty acids into tissue. 
For more detail, see [69]. 
3.6 Diabetes 
Diabetes mellitus – commonly referred to simply as diabetes – is a huge problem 
worldwide and it is growing. The World Health Organisation states the following: 
"Diabetes is a major threat to global public health that is rapidly getting worse, 
and the biggest impact is on adults of working age in developing countries. At 
least 171 million people worldwide have diabetes. This figure is likely to more 
than double by 2030 to reach 366 million." [7]. 
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This means that it is one of the fastest growing diseases in the world. They also 
note that diabetes is a life-threatening condition and that "worldwide, 3.2 million 
deaths are attributable to diabetes every year" [76]. 
The UN also recognise the impact of diabetes and have a resolution on the 
disease; this includes designating World Diabetes Day (14th November) as a UN 
Day and inviting member states and organisations to observe it each year as well 
as "[encouraging] Member States to develop national policies for the prevention, 
treatment and care of diabetes"  [77]. 
Diabetes is a disease which occurs when a person is unable to control their blood 
glucose level. The WHO defines diabetes – as opposed to the related problems of 
impaired glucose tolerance and impaired fasting glucose – as shown in Table 3.1. 
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Table 3.1: WHO recommendations for diagnostic criteria for diabetes [7]. 
There are 3 main types of diabetes which are distinguished based on cause, not 
severity [7, 54]. 
3.6.1 Type 1 
Type 1 diabetes is thought to be caused by an autoimmune disease which leads 
to destruction of insulin-producing β-cells in the islets of Langerhans [54]. This 
means that the individual cannot produce insulin to regulate their blood glucose 
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levels. It is also known as “Juvenile Diabetes” as the disease usually occurs in 
childhood, and most children with diabetes are Type 1 diabetics. 
3.6.1.1 Treatment 
Type 1 diabetes is most often treated  through regular subcutaneous insulin 
injections, though insulin pumps may also be used, leading to the alternative 
name of IDDM (Insulin-Dependent Diabetes Mellitus), and must be continued 
throughout the person’s life as there is currently no widely-used cure. Pancreas 
or islet cell transplants may be used but there are many limitations, including a 
lack of donors, very serious potential complications (as with any transplant) and 
the need for immunosuppressants post-transplant both to avoid rejection of the 
organ and to prevent a relapse of Type 1 diabetes. For these reasons, transplants 
are rarely used and tend to be reserved for extremely severe cases [78]. 
A CGM (Continuous Glucose Monitor) is a device implanted subcutaneously 
which automatically measures blood glucose levels at regular intervals (e.g. every 
1 or 5 minutes). With this development, trials have commenced to try and link a 
CGM to an insulin pump and other trials including both an insulin pump and a 
glucagon pump to produce an artificial pancreas [79]. The research has fallen 
into two groups: reactive controllers and model-based predictive controllers. The 
leading reactive controller is a PID (proportional-integral-derivative) controller, 
discussed in Chapter 8. The model-based predictive controllers use mathematical 
models to predict future glucose levels, based on current and previous 
measurements, and hence the insulin required at a given future time-point, to 
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control insulin release. There are several groups working on this second type of 
controller using a range of different methods; many of them are funded by the 
JDRF (Juvenile Diabetes Research Foundation) [80, 81]. 
3.6.2 Type 2 
Type 2 diabetes is characterised by impaired β-cell function (though not due to 
an autoimmune disease as in Type 1 diabetes) and reduced insulin sensitivity. 
This means that Type 2 diabetics may produce some insulin, but it will be 
insufficient to regulate blood glucose levels effectively. It is important to note 
that reduced insulin sensitivity alone is not sufficient to cause Type 2 diabetes as, 
in the majority of cases, the pancreas is capable of adapting to changes in insulin 
sensitivity, unless its function is also impaired. It is unclear, however, whether 
the reduction in insulin sensitivity precedes, follows or is concurrent with 
impaired β-cell function or what the causes of either are. Insulin sensitivity is 
linked to free fatty acid levels (see section 3.5 Lipids), however there may be 
other causes. β-cell function is a combination of the number of β-cells (β-cell 
mass) and the secretory capacity of a β-cell; as it is difficult (or not currently 
possible) to determine in a Type 2 diabetic whether the mass or the capacity has 
been reduced, in this thesis the general term “β-cell function” will be used to 
refer to the overall combination of these factors. Reduction in β-cell function is 
often attributed to glycolipid toxicity, i.e. the damaging action of glucose and/or 
lipids on β-cells. This is a major problem in Type 2 diabetics as insulin cannot 
control the level of glucose and lipids, which results in further reductions in 
insulin secretion. 
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3.6.2.1 Treatment 
Treatment ranges from diet and exercise regimes to drug and insulin therapy like 
that for a Type 1 diabetic; however insulin therapy is used in only a small 
minority of cases, leading to the alternative name NIDDM (Non-Insulin-
Dependent Diabetes Mellitus). Type 2 diabetes is generally found in older 
patients (i.e. those over 40 years old) and, as such, is sometimes also known as 
adult-onset diabetes. Recently, there has been a rise in diagnoses of Type 2 
diabetes in children which can be directly related to increasing childhood 
obesity, as obesity is a major risk factor for diabetes. Other risk factors include 
lack of exercise and excessive alcohol consumption; as a result Type 2 diabetes is 
often considered to be “preventable” by adopting a healthy lifestyle [41, 54, 78]. 
3.6.3 Gestational diabetes 
The final recognisable type of diabetes occurs in pregnant women who have not 
been previously diagnosed with diabetes, but who have elevated blood glucose 
levels during their pregnancy. The cause is currently unknown, but it generally 
disappears after the baby’s birth and is usually managed through changes to diet 
and exercise [54]. 
3.6.4 Implications of diabetes 
Glucose being a potentially toxic substance has meant that animals have evolved 
very fine levels of glucose control. This level of control is important firstly due to 
glucose providing the main source of energy to the CNS and secondly to ensure 
non-toxic levels of glucose are maintained [54, 70, 82]. 
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3.6.4.1 Short term 
In the short term, the danger mainly lies with hypoglycaemia (low blood sugar 
levels), which could be classed as below 3 mmol l-1. Glucose is essential for the 
CNS and reductions in the level of glucose can cause drowsiness and confusion. A 
large reduction in the amount of glucose can lead to diabetic coma, which can 
cause prolonged seizures, brain damage and death [54]. 
If a person has other conditions, this can lead to further complications if blood 
sugar becomes low. It can cause heart attacks, strokes and exacerbate cardiac 
problems. If the person is diabetic and has eye problems, it can lead to retinal 
haemorrhaging and subsequent blindness [54]. 
3.6.4.2 Long term 
In the long term, the main problems occur from vascular disease caused by 
chronically high levels of blood glucose, hyperglycaemia. It is thought due to the 
loss of endothelial cell function this can lead to the thickening and weakening of 
the smooth muscle cells of the vascular wall. However the exact mechanisms by 
which this damage occurs are unknown [45, 54]. For this reason, although 
modelling of diabetes could eventually help to allow tighter control of glucose 
levels, the effect this would have on complications is unknown. 
Chapter 3: Biological Overview 
54 
Microvascular damage 
Microvascular damage – where small blood vessels are damaged – can lead to 
heart disease, poor eyesight or blindness, kidney damage and loss of sensation in 
the affected areas. 
Diabetic cardiomyopathy is a form of heart disease where the heart muscle itself 
begins to fail, potentially leading to arrhythmia or death [41, 54, 70]. 
Diabetic retinopathy (retina damage) occurs when the retinal blood vessels 
become damaged due to sustained hyperglycaemia. Over time this leads to lack 
of blood in the retina, causing new blood vessels to grow in the vitreous humour 
(the clear fluid that fills the eye). These, in turn, burst and bleed into the eye, 
causing further damage to the retina [54, 70]. 
Diabetic nephropathy (kidney damage) occurs when the capillaries in the kidneys 
where blood filtration occurs harden and lose functionality due to high blood 
glucose levels. Additionally, tubular cells in the kidneys are damaged, leading to 
poor reabsorption of amino acids, glucose and albumin which creates water 
balance problems, Diabetes Insipidus. Importantly, this means less glucose is 
reabsorbed into the body, however diabetics at this stage have very poor 
glycaemic control. The risk of diabetic nephropathy is increased with high blood 
pressure and high cholesterol. Over a long period of time (15 years or more) 
diabetics can end up with kidney failure and may require dialysis or kidney 
transplant [54, 70]. 
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Diabetic neuropathy (nerve damage resulting in loss of sensation) may occur in 
the short term and be reversible; however long-term hyperglycaemia leads to 
irreversible neuropathy. The elevated glucose levels result in long nerves dying 
back, causing sensation to be lost in the extremities; feet are at particularly high 
risk. The neuropathy can also cause paralysis and pain [54]. 
Macrovascular damage 
Macrovascular damage is caused when proteins in arterial walls are degraded, 
causing the walls to become thicker. This leads to circulation difficulties and 
cardiovascular disease – including angina, heart attacks and stroke – which is the 
most common cause of death in diabetics. Direct risk factors are not strongly 
established, however there are known mechanisms by which both 
hyperglycaemia and hyperinsulinaemia could cause macrovascular disease [54]. 
Other effects 
Diabetic foot is a combination of microvascular and macrovascular damage, 
including poor circulation and neuropathy. This causes loss of sensation, poor 
motor control, ulceration and callusing. These problems can lead to infection, 
which may result in the need for amputation [54, 70]. 
Another important long-term effect of hyperglycaemia is hypertension (raised 
blood pressure). It is “up to twice as common in diabetes as in the general 
population, and affects some 10-30% of Type 1 and 30-50% of Type 2 diabetic 
patients” [54]. In Type 2 diabetics, it is linked to insulin resistance and 
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hyperinsulinaemia; this is thought to be because insulin stimulates the growth of 
vascular smooth muscle [83]. 
3.7 Discussion 
The biological system for glucose homeostasis is complex with many factors 
involved. It is important to focus on the critical factors that affect the system to 
enable identification of key components for modelling. The glucose homeostatic 
system is very finely controlled due to the necessity for glucose in the body and 
damage that can be caused if glucose is not maintained at the correct level.
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Chapter 4: Data Collection 
4.1 Introduction 
This chapter introduces the tests that were performed at AstraZeneca, Alderley 
Park, Cheshire, UK and elsewhere to collect data on glucose and insulin 
homeostasis. It explains the methods behind the data measurement and 
collection and discusses the limitations of and difficulties with collecting such 
data. 
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4.2 Animal experiments 
All animal experiments in the UK are carried out only when no alternative can be 
found and only when it is essential for scientific understanding, medical progress 
and protecting people, animals and/or the environment [84, 85]. Whenever 
possible, AstraZeneca and other facilities that use animals try to replace, reduce 
and refine animal work. This is known as the “three Rs” of animal work. 
Replacement means finding alternatives where possible; reduction means 
minimising the number of experiments carried out and refinement means 
designing experiments to minimise stress and the number of procedures, to 
improve animal welfare and maximise informative data. Modelling can play an 
important role in all of these by attempting to predict outcomes from 
experiments – thus reducing the need for animal work – and designing better 
experiments. 
AstraZeneca complies with Home Office regulations as well as its own internal 
ethical review procedures  [86-88]. The Animals (Scientific Procedures) Act 1986 
is based on a number of historical acts focusing on animal protection and 
procedures involving animals, including the Cruelty to Animals Act 1876 and 
Protection of Animals Act 1911. It falls under the jurisdiction of Home Office 
Inspectors. It stipulates that animal studies can only be performed by trained 
personnel who hold a Personal Licence, i.e. are endorsed as competent by the 
Home Secretary on the recommendation of a Project Licence Holder. Personal 
Licence holders must work under the guidance of a Project Licence Holder within 
Chapter 4: Data Collection 
59 
a specific “project”, which must have a Project Licence. This Project Licence 
includes a 5-year work plan with aims, scientific plans, details of models and 
techniques used and an outline of control measures to maintain animal welfare. 
In addition, the site where the animal work is undertaken must have a Certificate 
of Designation which states that the available facilities are suitable and that it 
meets the recommended guidelines with an infrastructure of veterinary care, 
husbandry and animal welfare trained staff to support the studies. The site or 
project may be inspected by Home Office Inspectors at any time and animal 
usage statistics must be submitted to the Home Office annually [84]. Additionally 
AstraZeneca has rigorous procedures for the prevention, detection and 
monitoring of abnormal occurrences which may affect animal welfare. 
4.3 Species used to gather data for this thesis 
4.3.1 Han Wistar rats 
Han Wistar rats are bred for research and have no complications (i.e. have no 
genetic or other medical problems). As such, they are a standard species used in 
laboratories across the world as models of normal, healthy animals[89]. 
4.3.2 Zucker rats 
Zucker rats are deficient in leptin receptors [90-92]. This anomaly was noticed 
when it was discovered that these rats had an unusually high glucose level. There 
are two types of Zucker rat, the lean Zucker and the obese Zucker. The obese 
gene is recessive. Subsequently colonies were selectively bred to maintain this 
particular phenotype. Leptin is a hormone which is usually released from 
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adipocytes (fat cells) and reduces appetite. This means that these animals 
constantly eat as long as food is available and, as a result, they become 
overweight and both hyperglycaemic and hyperinsulinaemic. The animals are 
hyperinsulinaemic in an attempt to control their high levels of glucose. Due to 
them having high levels of lipids they are insulin resistant therefore insulin has 
little effect. This makes them a good animal model for Type 2 diabetes. 
With a restricted intake of food, their glucose and insulin profile can remain close 
to that of a normal rat. The intake of food can be controlled by having a 
restricted time window in which food is available. Zucker (obese/fatty) rats were 
used in these experiments. 
Leptin receptor deficiency can also affect humans and is very severe, where they 
constantly seek out and consume food [93, 94]. 
4.3.3 ZDF (Zucker Diabetic Fatty) rats 
ZDF rats are from the same strain as Zucker rats [95], but with a more severe 
problem. They are unable to maintain a high level of insulin production and 
release in order to overcome the insulin resistance; the exact cause of the 
inability to produce insulin is unknown. Without intervention, a ZDF rat will 
suffer from β-cell failure and therefore failure to control glucose levels, 
ultimately leading to severe hyperglycaemia and subsequent death. Therefore, 
one of the hypotheses as to why ZDF rats are more severely diabetic is that they 
have faulty β-cells [95]. 
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These animals are used as a model of subjects entering Type 2 diabetes and 
progressing through the disease. Both Zucker and ZDF rats are used in acute and 
chronic studies. 
4.3.4 C57BL/6J Mice 
AstraZeneca uses C57BL/6J mice as it is the most widely-used strain in research 
and can be used for diet-induced obesity experiments [96]. The mice in the 
studies used different diets in order to model, in animals, different diabetic 
conditions. Data was collected over a period of days to show disease 
progression. 
4.4 Tests used to generate data modelled in this thesis 
4.4.1 IntraVenous Glucose Tolerance Test 
The intravenous glucose tolerance test (IVGTT) is a test for β-cell function [97]. It 
involves giving a bolus of glucose and measuring the resulting glucose and insulin 
concentrations in blood samples taken at frequent intervals. The insulin 
concentration measured is considered to be the quantity of insulin produced and 
the amount of glucose in the blood is seen as a measure of how effective the 
insulin is at removing glucose. The standard protocol for performing such a test 
(in both humans and animals) is represented in Figure 4.1 and explained here: 
 A period of fasting before the experiment (at AstraZeneca this is usually 4 
hours, however some studies examined in this thesis involve fasts of up 
to 16 hours); 
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 Animals are weighed and anaesthetised with an intra-peritoneal injection 
of sodium-thiobutabarbitol; 
 Fasting levels of glucose and insulin are measured; 
 Glucose is injected into the subject (at AstraZeneca, this usually ranges 
between 0.2 and 2g/kg of lean body mass of rat); 
 For rats, measurements are taken at 1, 2, 5, 10, 15, 20 and 30 minutes 
after the glucose is injected; in a human, this period is longer – usually up 
to 120 minutes – as insulin and glucose are not cleared as quickly in 
humans due to a slower heart-rate and other factors. 
  
Figure 4.1: Example IVGTT protocol  [86] 
This type of study is very intensive and usually requires one or two scientists 
working constantly on a small number of animals. The number of data points 
which can be obtained is limited by blood sample volumes that can be taken 
following the Home Office guidelines. 
There are many different ways of assessing the results from an IVGTT. 
Sometimes the AUC (Area Under the Curve) from baseline or the whole AUC is 
used as a measure of function. Alternatively AIR (Acute Insulin Response) and 
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disposition index may be used [40, 98] and possibly the Minimal Model, see 
Chapter 6. 
AIR (Acute Insulin Response) – is the area under the curve for the first 8 minutes 
of an insulin profile in humans. In rats it is sometimes taken as either 3, 5 or 10 
minutes [99]. This is a measure of how much of a first-phase response the 
pancreas provides. 
Using a measure of insulin sensitivity, which can be a measure from the Minimal 
Model or other means such as a clamp study, it is possible to define the 
disposition index as follows: 
 
 
                                                4.1 
The disposition index is a measure of insulin secretion in relation to insulin 
sensitivity, which indicates how well the subject/animal is maintaining its glucose 
level.  If the disposition index remains the same from one occasion to another it 
means that the insulin secretion of the subject relative to the insulin sensitivity 
remains basically constant and, therefore, the subject is not losing the ability of 
insulin to control blood glucose disposal. This does not necessarily mean that 
insulin sensitivity and insulin secretion have remained constant as, if insulin 
sensitivity decreases and insulin secretion increases, the disposition index will 
remain unchanged and glucose control is maintained [100]. 
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4.4.2 Oral Glucose Tolerance Test 
The Oral Glucose Tolerance Test (OGTT) is used to measure regulation of blood 
glucose and can also be used to test insulin secretion. It can be used as a test for 
diabetes [7]. It is considered to be less artificial than other tests as it mimics 
more normal glucose intake [101]. AstraZeneca use it when a large number of 
animals is required for a study as it is less invasive and time consuming than 
either an IVGTT or a hyperglycaemic clamp experiment. The standard protocol 
for performing such a test (in both humans and animals) is: 
 Fasting for 4 hours before the experiment; 
 Animals were dosed with 2g of glucose per kilogram of body mass (2% 
glucose solution at 10ml/kg); 
 Blood glucose measurements were taken using a Roche Accuchek® 
instrument and 5μl whole blood samples with an ELISA assay for insulin at 
0, 15, 30, 45, 60, 75 and 90 minutes after the glucose was administered. 
The limitations on the number of samples taken are due to the blood volume 
sampling limits and the timing of the blood sampling. A typical situation would 
involve one scientist dosing, then another two scientists involved with sampling 
at each interval. These three scientists would each sample blood from one 
animal every minute. Therefore with three scientists a maximum of thirty 
animals could be studied [102]. 
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4.4.3 Hyperglycaemic clamp 
This experiment is known as the gold standard for testing β-cell function [103] 
and can also be used for insulin sensitivity [104]. The idea of clamping is that the 
glucose and insulin levels are at a steady state and are therefore not affected by 
the dynamics of the system. A hyperglycaemic clamp involves infusing glucose 
into a subject to create a steady state of glucose which is higher than the 
subject's usual basal level. Depending on the experiment, this is either a certain, 
set level of glucose (e.g. 11mmol) or a set amount above that subject’s basal 
level (e.g. 6mmol above a basal level of 5.5mmol, giving 11.5mmol). This glucose 
level is maintained and when the insulin level is thought to have stabilised, 
usually after approximately 60 minutes, the ratio between the insulin level and 
the infused rate of glucose at steady state is said to be the insulin sensitivity. 
The clamping experiment data used in this thesis are from hyperglycaemic 
clamps. This usually involves the following preparation: 
 Animals were fasted at 16:00 the day before the experiment in a clean 
cage with no access to food but with access to water; 
 At 08:00 on the day of the experiment, animals were weighed and 
anaesthetised with an intra-peritoneal injection of sodium-
thiobutabarbitol; 
 Four catheters were placed in the jugular vein for infusions of glucose, 
compound, haemacel (to stabilise the volume of distribution in the 
subject) and top-ups of anaesthetic; 
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 A further catheter was placed in the left carotid artery for blood sampling 
and recording arterial blood pressure; 
 Body temperature was maintained at 37.5˚C and 45 minutes was allowed 
after surgery for stabilisation. 
Two types of glucose measurement are taken in hyperglycaemic clamps - one 
which is quick and provides near-instant feedback and another which is slower 
but more accurate - which will be referred to as blood glucose and plasma 
glucose, respectively. For the data used in this thesis, blood glucose 
measurements were taken by a Roche Accuchek® using 10l of blood and 
obtained in a few seconds. Plasma glucose was measured using 300l of blood 
and took longer to sample as plasma had to be spun off. After each plasma 
glucose sample, insulin and C-peptide measurements are also taken. Figure 4.2 
shows the protocol for the hyperglycaemic clamp. 
Before the clamp is initiated, a plasma sample is taken for basal levels of glucose, 
insulin and C-peptide. At time zero, glucose is usually infused at 375mg kg-1 min-1 
for 1 minute. The infusion rate is then lowered and blood glucose values are used 
to clamp the glucose at the required level. Blood glucose is sampled roughly 
every minute during this initial period. When the clamp has been maintained at a 
constant level of glucose between 70 and 90 minutes of the experiment, this is 
considered to be “steady state”; this is where standard analysis of this 
experiment is performed, such as the disposition index.  Just before the end of 
the experiment 200ug/kg arginine is dosed, in order to release all of the insulin 
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left in the β-cells, as a measure of the total insulin that could be secreted. At the 
end of the experiment the animals are culled. 
Knowledge of this procedure is important for the modelling. For example, at the 
start of the clamp there is as a “375mg kg-1 primer” which could be 
misinterpreted as being a bolus injection rather than an infusion; this has 
implications for how the input function for the model is described. 
It is also important to understand the limitations of such an experiment. So many 
of the data collected in this experiment are dependent on the blood volumes of 
the samples; for example, it is not possible to get as many insulin measurements 
as glucose measurements since  insulin measurements require 300l of blood 
compared to the 10l required for glucose measurements [86]. Hyperglycaemic 
clamps are also very labour intensive and require one or two scientists per 
subject. 
 
Figure 4.2: Protocol for hyperglycaemic clamp experiment 
- 90 - 30 - 20 - 10 0 10 20 30 40 50 60 70 80 90 
25% Glucose (i.v. 375mg/kg 1 - min prime + variable  
infusion to maintain plasma glucose @ 11mM) 
Vehicle/Compound (i.v. constant infusion)  
Time (min) 
1 2 3 4 7 8 9 6 
200 - 300   l blood samples*  
for analysis of plasma  
glucose; insulin & c - peptide 
5 
Clamp Steady State 
Basal Hyperglycaemic Clamp (11mM)  Stabilisation 
* Further micro -samples (~10   l) were taken at regular intervals throughout the protocol to mo nit r blood glucose using a Roche  Accuchek  
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4.4.4 C-peptide intravenous experiment 
Unlike the other tests described here, this test was performed specifically for the 
purpose of modelling. This will be described in more detail in Chapter 7. This test 
involved injecting human C-peptide into anaesthetised Han Wistar rats.  Injected 
C-peptide has the same kinetic characteristics as the endogenous C-peptide but 
can be distinguished from the endogenous C-peptide in the assay which 
distinguishes between human and rodent C-peptide. It is important to note here 
that it requires similar sample sizes to insulin and is therefore sampled only 
infrequently [105]. 
4.4.5 Chronic study 
Data for long-term modelling in Chapter 9 were obtained from studies 
performed over an extended period of time, in this case 40 days. These studies 
consist of feeding animals on particular diets and restricting when the animals 
can feed, generally to a 4-hour window, outside which food is removed from the 
cage. On selected days, profiles of glucose and insulin are taken in a similar way 
to OGTTs but with measurements taken over a 24-48 hour period. An example 
protocol is shown in Figure 4.3: 
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Figure 4.3: Example protocol for a chronic C-peptide study [86] 
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4.4.6 Summary 
The following table summarises the main points about each test described above. 
Test Primary Result Secondary Result Limitations 
IVGTT 
 
β-cell function Insulin sensitivity (from 
modelling) 
 Intensive 
 Only practical with small number of subjects 
OGTT Glucose regulation   Small number of data points 
Hyperglycaemic clamp β-cell function Insulin sensitivity  Intensive 
 Only practical with small number of subjects 
C-peptide intravenous 
experiment 
C-peptide kinetics   Intensive 
 Only practical with small number of subjects 
Chronic study Disease progression Any obtained from 
incorporated experiments 
(e.g. OGTT) 
 Extended period of time required 
Table 4.1: Summary of tests described in this chapter
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4.5 Sampling and assays 
As mentioned with the hyperglycaemic clamps, glucose samples can be 
measured in two different ways: either with a small sample with an Accuchek® 
[106] or with a larger sample from blood plasma and a glucose analyser. The 
measurements from the glucose analyser are considered to be more accurate so 
the blood glucose measurements are often corrected or calibrated using the 
plasma glucose measurements. 
C-peptide and insulin are measured using Millipore and Mercodia ELISA (Enzyme-
Linked Immunosorbent Assay) kits [107, 108]. These assays have a non-linear 
response to the substances put in them, therefore when performing these assays 
a known quantity (standard) of the substance is run at the same time as the 
sample to generate standard curves (see example in Figure 4.4). The scientists 
often aim to dilute the unknown plasma samples so that the results will end up 
on the linear part of the standard curve. When this is not possible, a polynomial 
is frequently employed to describe the curve, which is then used to reference the 
measurement from the kit to the corresponding amount of that substance; 
however this may reduce the accuracy of the assay so it is avoided where 
possible. 
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Figure 4.4: Example of a standard curve on a log-log scale 
for an ELISA assay  
[86] 
All these assays have different degrees of accuracy (see Table 4.2). AstraZeneca 
uses a range of assays to perform measurements. The Accuchek® device, used 
for blood glucose measurements, has a higher accuracy at high glucose levels 
than at low glucose levels [106]. Plasma glucose is measured using a Yellow 
Springs Glucose Analyser and insulin and C-peptide are measured using ELISA 
kits. 
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Assay Accuracy 
Accuchek® 58.5% of samples within 5% or 0.28mmol/l 
of reference value 
99.3% of samples within 20% of reference 
value [108, 109] 
Yellow Springs Glucose Analyser To at least 5.8% 
ELISA kits To at least 6.8% for C-peptide 
To at least 3.8% for insulin[108] 
Table 4.2: Assay accuracies 
Although the assays have the stated accuracies, there are other sources of error 
which may result in errors in the final measurements; these include inaccuracies 
in pipetting volumes and a “freeze-thaw” effect (where the sample has been 
frozen and then thawed later which may degrade the sample, which is 
particularly relevant for C-peptide and insulin). However all practical steps are 
taken to minimise these types of errors, such as using mechanical pipetting and 
avoiding freezing samples where possible [86]. 
The standard curve and the level of quantification means that errors may not 
always be proportional to the sample value. It is important to take all these 
issues into consideration when modelling.  
4.6 Data sets 
A variety of data sets from several sources are used in this thesis. A list of data 
sets and sources is provided in Table 4.3 below; the first is also detailed fully in 
Chapter 7. n denotes the number of animals in each group. 
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Name Experiment Type Lead AstraZeneca Scientist 
RuthCPeptide C Peptide Intravenous 
Injection 
Ruth MacDonald 
 Anaesthetised - Han Wistar rats 
6nmol/ml (n=3),3nmol/ml (n=3),0.8nmol/ml (n=2) 
Measurements taken at 0, 1, 2, 5, 10, 15, 20, 25 and 30 
minutes 
C Peptide Measured 
RuthClamp Hyperglycaemic Clamp Ruth MacDonald 
 Anaesthetised - Han Wistar rats 
Fed (n=5), 4 Hour Fast (n=4),8 Hour fast (n=4) 
Measurements detailed  in RuthCPeptide above 
AliceIVGTT IVGTT Alice Yu 
 Anaesthetised - Han Wistar rats 
Fed (n=5), 4 Hour Fast (n=4),8 Hour fast (n=4) 
Measurements detailed in RuthCPeptide above 
AmieIVGTT IVGTT Dr Amie Gyte 
 Anaesthetised - Han Wistar rats 
Fed (n=7) 
0.2 (n=3) 0.5 g/kg(n=3) 1g/kg (n=1) Glucose dose 
Measurement times -10, 0 ,1, 2, 5, 10,15,25 
Plasma Glucose, Plasma Insulin, Plasma C-peptide 
GeorgiaIVGTT IVGTT [102] Dr Georgia Frangiousdakis 
 Conscious - Han Wistar rats 
4 Hour Fast (n=18) 
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Name Experiment Type Lead AstraZeneca Scientist 
0 (n=8) 0.5 g/kg (n=6) 1g/kg (n=4) Glucose dose 
Measurement times -10, 0 ,1, 2, 5, 10,15,25 
Plasma Glucose, Plasma Insulin, Plasma C-peptide 
StevenOGTT OGTT Dr Steven Wang 
 Conscious - C57BL/6J mice 
(n=20) 2g/kg 4 days of profiles for each over 8 days. 
Measurements at 0, 15, 30, 45, 60, 75 and 90 
Blood Glucose, Plasma Insulin 
JoChronic Chronic Jo Teague 
 Conscious - Zucker and ZDF rats 
38 Days - 4 hours Meal Feed Zucker (n=30), Adlib Zucker 
(n=30), Ad lib Obese ZDF (n=10), Meal fed Obese ZDF (n=32) 
Measurements at 0,2,4,6,8,12,16,20,24 hrs on days 
3,13,16,27,37 
Blood Glucose, Plasma Insulin  
Table 4.3: Data Collection – data sets
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Chapter 5: Previous Models 
This chapter is a review of the details of previously developed mathematical 
models of the glucose-insulin system. This provides context for the model 
detailed in this thesis and indicates where some useful ideas for elements of the 
model have originated. The models described are detailed in chronological order, 
beginning in 1961 with a very simple, linear system and continuing, over the last 
45 years, to a recent development from Swedish modellers. 
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5.1 Bolie Model 
In 1961, Bolie created one of the first (if not the first) mathematical models of 
the glucose-insulin system, using dog data [110]. Due to the limited ability at the 
time to simulate complex models, it was necessarily very simple in nature (see 
Figure 5.1 below). 
x
α
β
δ
p
y
γ
q
 
Figure 5.1: Conceptual diagram of the Bolie Model  
It had only two compartments, one for glucose (y) and one for insulin (x). It 
consists of a pair of first-order differential equations which comprise a second-
order system: 
 
 
  
  
         
  
  
         
5.1 
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where x is insulin concentration; y is glucose concentration; α, β, γ and δ are 
"regulatory coefficients" which, when multiplied by volume of distribution, 
represent insulin clearance, glucose-stimulated insulin secretion, insulin 
sensitivity and glucose effectiveness respectively; p is rate of insulin injection 
divided by volume of distribution and q is rate of glucose injection divided by 
volume of distribution (see Chapter 2). 
The model was simulated using an analogue computer (see Figure 5.2 below). 
 
Figure 5.2: Bolie Glucose Insulin Analogue Computer  [110] 
The main drawback of this model was that it was linear, and therefore both 
glucose and insulin levels could become negative - a physiologically impossible 
situation. In developing this model, Bolie noted a key point: that the glucose and 
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insulin system is critically damped and therefore returns to a steady state quickly 
and efficiently [110]. 
5.2 Minimal Model 
The Minimal Model was created in 1979 by Bergman & Cobelli [111, 112] and has 
been referenced in over 900 papers in 2009 to date [40]. It is so-called because it 
was designed to comprise the smallest number of parameters possible while 
adequately representing the glucose-insulin system. It is now widely accepted as 
a three-state model with parameters for insulin sensitivity and glucose 
effectiveness, and a delay compartment for insulin action. In terms of limitations, 
the Minimal Model is only valid for IVGTTs and there are also mechanistic issues - 
for example, no first-phase insulin secretion - and structural issues with the 
model - for example, it does not return correctly to a steady state [113]. 
As the Minimal Model is such an important model in this field it is discussed in 
detail in Chapter 6. 
5.3 HOMA Model 
In 1985, Matthews, et al. developed another model of the glucose-insulin system 
known as the HOMA (Homeostatic Model Assessment) model [114, 115]. This 
takes fasting (i.e. steady-state) values of glucose and insulin and uses them to 
produce output in the form of a graph, from which estimates of β-cell function 
and insulin sensitivity can be obtained. It is a very simple model, consisting of 
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only two simple equations  5.2 which are derived from the underlying physiology 
of the glucose-insulin system shown in Figure 5.3. 
                         
                           
5.2 
where HOMA1IR is insulin resistance, HOMA1%B is β-cell function, FPI is fasting 
plasma insulin and FPG is fasting plasma glucose. 
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The underlying physiological basis of the HOMA model. The feedback loop between the liver and the β-cell is 
central to the model. Plasma glucose concentration in the basal state is regulated by hepatic glucose output, 
which is insulin dependent (B). Insulin concentration is dependent on β-cell response to glucose (A). Insulin 
signals glucose uptake in fat and muscle (C and D). Glucose disposal is modelled in brain (E) and kidney 
(F)as being dependent only on glucose, and in fat and muscle as being dependent on glucose and insulin 
concentrations (C and D). 
Figure 5.3: Physiological basis of the HOMA model [116]  
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The model was updated in 1996 – to produce the HOMA2 model – which uses 
non-linear solutions to produce a more accurate output graph shown in Figure 
5.4, but results in more complex equations [116]. 
 
Figure 5.4: A: HOMA from 1985 B: HOMA2 from 1996 where S is insulin 
sensitivity and B/β is β-Cell function [116] 
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The authors note that both models have been widely misused. For example, the 
models have been validated only against humans, by testing for correlation 
between model output for insulin resistance and euglycaemic clamp data, and 
model output for β-cell function and hyperglycaemic clamp data; however the 
models have been applied to animal data without validation [116]. 
A key limitation of these models is that they do not model the system 
dynamically and provide only insulin sensitivity and β-cell function estimates. 
However, the fact that the models use only steady-state values acknowledges 
that these are an indication of the state of a subject. In turn, the model shows 
that the interplay between insulin secretion and glucose disposal produces 
different steady-state values, which is an important concept in dynamic models. 
5.4 AIDA Model 
The AIDA model was developed in 1992 by Lehmann & Deutsch for the purpose 
of educating Type 1 diabetes patients about how best to manage their condition 
[117, 118]. It has a large number of parameters, including body-weight and meal 
size (see Figure 5.5).  
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Figure 5.5: AIDA Model Diagram [117] 
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Parameters can be adjusted and simulations performed through a web interface, 
and there is also a free downloadable tool which performs basic parameter 
estimation. As there are a large number of parameters, example parameter sets 
which can be adjusted slightly to fit an individual are also provided. The output is 
in the form of graphs showing blood glucose and plasma insulin over the course 
of a day (see Figure 5.6 below). 
Figure 5.6: Screenshot of AIDA model software tool with demo subject 
This model has a large number of different factors which contribute to the 
output, including compartments for insulin, insulin action, different types of 
insulin (short- or long-acting), gut absorption, carbohydrate ingestion rate and 
renal clearance. Most of these factors are based on previously known 
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physiological values. The model is specifically for Type 1 diabetes patients, who 
do not produce insulin, and therefore does not have any insulin secretion terms; 
the only insulin included in the model comes from insulin injections (which are 
used for treatment). 
This model is interesting for two reasons: it includes more complex features of 
the glucose-insulin system which others do not (e.g. renal clearance), and its aim 
as a freely-available modelling tool to help Type 1 diabetes patients is also 
different to other models, which are generally aimed at clinicians and other 
modellers. 
5.5 β-Cell Mass Model 
The β-Cell Mass Model is one of very few attempts to model the glucose-insulin 
system in the longer term [119]. It was created by Topp, et al. in 2000 to help 
predict the aetiology of diabetes, i.e. over weeks and months rather than hours, 
and to explain self-regulation of the glucose-insulin system using β-cell mass. 
Although not validated against real data, the parameters in the model were 
taken from physiological values or the literature on previous models. The model 
sets up the glucose-insulin system in an elegant three state mathematical model. 
There are many aspects of the β-cell mass model which are relevant to the 
model presented in this thesis so it is examined in greater detail in Chapter 9. 
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5.6 Picchini Clamp Model 
This model was created in 2005 by Picchini, et al. to mathematically model the 
response to a euglycaemic-hyperinsulinaemic clamp experiment [120, 121]. The 
model was validated using human data. A stochastic approach to modelling was 
used as it was found that the model itself was unable to explain the apparent 
randomness in the data. The deterministic part of the model contains two state 
variables: glucose and insulin concentrations. The glucose state contains glucose 
effectiveness and insulin sensitivity; the insulin state includes proportional 
secretion of insulin and hepatic glucose output, see Figure 5.7. The stochastic 
element of the system was applied to the insulin-sensitive parts of the model, i.e. 
the hepatic glucose output and insulin sensitivity. It was modelled using a Wiener 
process (also called Brownian motion) which is a continuous-time stochastic 
model describing the random movement of particles. This can be seen in the 
equation 5.3: 
 
        
                  
  
    
    
        
                                
                            ) 
 
5.3 
with                and                               .         
are input state variables,       are volumes of distributions.     varies randomly 
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as         , where     is Gaussian white-noise process. Then the system 
noise is        can be written as        [120]. 
The Picchini et al. model is important because it relatively successfully models 
glucose and insulin concentrations in a subject undergoing a euglycaemic-
hyperinsulinaemic clamp experiment; however it is not applicable in other 
situations. The stochastic approach is also interesting and was chosen by Picchini 
because the subjects were conscious and therefore their utilisation of glucose 
varied somewhat randomly over time. A stochastic approach is useful when 
there is a lot of random variation and it provides a quantification of the 
randomness in the system; however if there is little variation in individual 
subjects a stochastic approach is not applicable. Additionally, stochastic models 
take longer to simulate than deterministic models as they generally require the 
model to be simulated repeatedly with different random seeds. 
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Figure 5.7: Schematic representation of the Picchini clamp model  [121] 
Chapter 5: Previous Models 
90 
5.7 Cobelli Model 
Cobelli began work on model-based predictive control in order to create an 
artificial pancreas [122]. In order to do this, a meal simulation model of the 
glucose-insulin system was developed, with first-phase insulin response based on 
Andrea Mari’s work [123] and second-phase insulin response and insulin effect 
compartment from the Minimal Model [111, 112]. The model has two 
compartments for glucose and two for insulin (plasma and periphery), piecewise 
functions simulating insulin secretion (i.e. separate equations for different 
phases of insulin secretion) and non-linear Michaelis-Menten kinetics for glucose 
disposal (see Figure 5.8). It also includes renal extraction of glucose and hepatic 
insulin clearance. 
 
Figure 5.8: Conceptual diagram of the Cobelli 
model 
[122] 
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This model was important in the field of glucose-insulin system modelling 
because it was used to validate, in simulation, a model-based predictive 
controller for the artificial pancreas [80]. It was used to investigate the effects of 
the controller on simulated patients. On the basis of this, approval was granted 
by the FDA (Food and Drug Administration; regulatory authority for drugs in the 
USA) to begin human testing with the artificial pancreas with the caveat that a 
clinician would have to approve the insulin infusion [81]. 
The Cobelli model was developed into a software tool called GIM (Glucose 
Insulin Model) using MATLAB [124].  GIM also shows the effect of a PID 
controller on the glucose-insulin system, which is particularly relevant to this 
thesis. 
A key limitation of the Cobelli model is that it is relatively complex, compared to 
other models described here. It also has set values for parameters including 
basal levels of glucose which define the piecewise function for insulin secretion 
and therefore may not mechanistically truly reflect insulin secretion. 
5.8 Uppsala Model 
This model was developed in Mats Karlsson’s group at Uppsala University, 
primarily by Hanna Silber. It was first published in 2007 [125] and there have 
since been several follow-up papers [126-128]. The authors used a population 
approach to modelling the system and the structure was compartmental. The 
model included two glucose compartments (plasma and periphery) and a single 
insulin compartment. It also had “effect” compartments for glucose 
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effectiveness, glucose effect on insulin secretion, insulin effect on glucose 
disposal and first-phase insulin secretion based on glucose dose, see Figure 5.9. It 
used a fitted forcing function for glucose absorption in an OGTT which was called 
the “flexible input model”; for this, twelve time periods were specified, each of 
which could have a different absorption rate of glucose into the blood plasma. 
The model was validated using human data from OGTTs and IVGTTs. 
This modelling strategy considered the system in a more mechanistic way than 
previous models to take account of the interplay between biological processes 
and to help hypothesis testing [129]. This is an aspect of modelling which has 
been incorporated into the model presented in this thesis in Chapter 7. 
Additionally, as the model is pharmacology-based, mass is not lost through the 
model and it maintains mass balance. However, it is a complex, multi-state 
model which requires more data than most other models to fit certain elements 
and parameters such as glucose absorption in the OGTT setting [129]. As there is 
an abundance of data for human IVGTTs and OGTTs, which are what this model 
was designed for, this is reasonable but for animal models this is not so practical 
and a more minimal model is required. 
The equations are quite lengthy. Figure 5.9 gives an overview of the model for 
the full equations, see papers [125-129].
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Figure 5.9: Schematic representation of the Uppsala model [125] 
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5.9 Summary 
The following table summarises the main points about each model described 
above. 
Model Structure Timescale 
Main positive 
attributes 
Main negative 
attributes 
Bolie Linear 
two-state 
Hours  Simple. 
 Linear. 
 Potential for 
physiologically 
impossible 
outputs. 
Minimal Non-
linear 
three-
state 
Hours  Small number of 
parameters. 
 Well-established. 
 Only valid for 
IVGTT. 
 Mechanistic and 
structural issues. 
 Not 
physiologically-
based. 
HOMA Two non-
dynamic 
equations 
Instantaneous  Simple. 
 Small number of 
measurements 
required. 
 Physiologically-
based. 
 Non-dynamic. 
 Only estimates 
insulin sensitivity 
and β-cell 
function. 
AIDA Non-
linear 
multi-
state 
Hours/days  Includes complex 
features, e.g. 
renal clearance. 
 Physiologically-
based. 
 Only relevant for 
Type 1 diabetes 
patients. 
β-cell 
mass 
Non-
linear 
three-
state 
Weeks/months/ 
years 
 Suitable for long-
term modelling. 
 Physiologically-
based. 
 No short-term 
aspects 
incorporated. 
Picchini 
Clamp 
Stochastic 
non-linear 
two-state 
Hours  May be 
appropriate for 
large variations in 
glucose levels in 
subjects, where 
deterministic 
modelling fails. 
 Physiologically-
based. 
 Inappropriate 
where there is no 
random variation 
in glucose levels. 
 Longer simulation 
time compared to 
deterministic 
models. 
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Model Structure Timescale 
Main positive 
attributes 
Main negative 
attributes 
Cobelli Non-
linear 
multi-
state 
Hours  Includes complex 
features, e.g. 
hepatic insulin 
clearance. 
 Relatively 
complex. 
 Not entirely 
physiologically-
based. 
Uppsala Non-
linear 
multi-
state 
Hours  Physiologically- 
and 
pharmacology-
based. 
 Complex. 
 Requires a large 
amount of data. 
Table 5.1: Summary of models presented in this chapter 
Several of these models are not physiologically-based, meaning that they work 
only in the situation they were specifically designed for - for example, the 
Minimal Model works only for IVGTTs and is invalid for OGTTs and clamp 
experiments. Such models are not true models of the system and model only the 
specific test; it is therefore important that a model of the glucose-insulin system 
should be physiologically-based. Table 5.1 also shows that there is no single 
model which is appropriate for use in both short- and long-term modelling of the 
glucose-insulin system. Finally, especially for animal modelling where data points 
tend to be sparse, a simple, but dynamic, model is required. For these reasons, it 
appears that there is a need for a model of the glucose-insulin system which is 
physiologically-based, incorporates short- and long-term aspects of the system 
and which is both simple and dynamic. The model presented in this thesis in 
Chapter 8 and Chapter 9  aims to fulfil all of these criteria.
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Chapter 6: Minimal Model 
This chapter is concerned with the structural identifiability of the Minimal Model 
and parameter estimates for Han Wistar rats using (AliceIVGTT) data. It shows 
the Minimal Model is structurally identifiable with insulin and glucose as 
observables, as well as with only glucose as an observable under certain 
assumptions. It also shows the results of the parameter fitting performed using 
MATLAB on actual experimental data from IVGTT on fasted and non-fasted 
anaesthetised Han Wistar rats, including consideration of the sensitivity of each 
of the parameters. The results show a reasonable fit using both glucose and 
insulin, however the model fails to produce physiologically relevant insulin 
parameters when using only glucose as an observable. 
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6.1 Introduction 
The Minimal Model was developed by Bergman and Cobelli in 1979 (see [111, 
112]) , however it is still the most widely-used mathematical model in this field; 
this 2007 article states that there have been 900 citations, as of 2009, in the 
literature relating to the Minimal Model [40]. The authors compared seven 
candidates for the glucose part of the system model and attempted parameter 
fitting, selecting the one they considered the most appropriate in terms of 
identifiability (meaning parameter estimation), meaningfulness of parameters 
and "goodness" of fit: the Minimal Model. Its name comes from its minimal 
approach, which the authors define as being "the simplest mathematical 
representation able to account for glucose disappearance kinetics"[112] . 
Two computer programs have been written to perform the modelling and 
simulation automatically [130, 131]. These programs apply a technique whereby 
they use the glucose levels as a forcing function on the insulin and fit only the 
insulin data, then the glucose data are fitted using the insulin as a forcing 
function. This means that the model is never fully coupled, hence insulin and 
glucose never directly interact in the model; this could thus be viewed as the 
application of two separate models. 
6.1.1 Intended Use 
This model is designed to be used in one situation: by an IVGTT, which tests -
cell function (insulin secretion capacity). An injection of glucose stimulates the 
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release of insulin, which is then measured to determine the -cell function. This 
paradigm is sometimes referred to as GSIS (Glucose Stimulated Insulin Secretion) 
[132]. 
Prior to an IVGTT experiment, the subject is normally fasted so they are at basal 
glucose and insulin levels; in humans, this fasting is generally overnight for 12 
hours [112]. When glucose and insulin levels are measured after glucose 
injection, changes will be purely the result of the injection and the endogenous 
levels, not of meals before the experiment. 
6.1.2 Description 
The Minimal Model is a three-compartment model two of which are insulin 
compartments - plasma and interstitial - and the other is a glucose compartment. 
The plasma insulin and glucose compartments are where insulin and glucose 
respectively are measured (i.e. in the periphery). The interstitial insulin 
compartment simulates the delay between insulin secretion and the effect on 
glucose levels.  
Figure 6.1 shows these compartments and how they are connected. 
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Figure 6.1: Minimal Model structure 
The Minimal Model can produce results for insulin sensitivity, glucose 
effectiveness and insulin and glucose clearance. It can also be used to calculate 
the delay of insulin effect. 
6.1.3 Equations 
The Minimal Model is defined with the following equations: 
Chapter 6: Minimal Model 
100 
 
      
  
                    
6.1 
      
  
                      
6.2 
       
  
  
                   
         
  
6.3 
where: 
( )G t  plasma glucose 
( )I t  plasma insulin 
( )X t   interstitial insulin 
1p  
glucose effectiveness (removal of glucose based on only glucose 
concentration)
 
2p  clearance of interstitial insulin 
3p  
insulin kinetic into the interstitial insulin compartment from the plasma 
insulin compartment
 
  secretion rate of the second phase of insulin 
n  clearance rate of insulin 
h  threshold value for insulin release. 
Table 6.1: Parameters in the Minimal Model 
The Minimal Model in standard control system state form, as defined in Chapter 
2 , is given in equations 2.1, 6.2 and 6.3. Note that h used in the standard model 
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from  Chapter 2,  has been replaced by a c to avoid confusion with the h  already 
used in equation 6.3 above. 
 
 
 
 
 
 
 
where 
       
 
  
 
  
 
 
                        
                              
                      
     
 
                        
                              
         
     
  
              
   
   
   
  
          
               
                     
6.4 
The bolus glucose injection is the initial state of the glucose compartment 
therefore G0 is the peak of the glucose profile. Io is the first-phase insulin 
secretion, as the Minimal Model does not have a term for this. 
To remove potential problems with symbolic tools and to fit in with the similarity 
transformation approach to structural identifiability, the t  term in equation 6.4 
is replaced by a fourth state, x4, which simulates a ramp function. The "time" 
state is known and therefore seen as being observable. This produces equations 
6.5. 
  
       
 
 
 
 
 
 
 
 
                        
                              
                       
 
     
 
                        
                              
         
 
     
   
6.5 
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6.1.4 Improvements 
Various approaches have been used in attempts to improve the model, which 
have achieved limited success in different situations. One example is the 
alteration of the time term to an integral term [113]. This removes the problem 
of having the insulin level increasing with time if plasma glucose (G) is greater 
than the threshold value for insulin release (h) as it integrates the glucose over a 
set amount of time causing a build-up. 
6.2 Structural identifiability analysis of the Minimal Model 
A full explanation of the methods for determining structural identifiability can be 
seen in Chapter 2 [17, 19]. Here, the Taylor series and similarity transformation 
approaches are applied to the Minimal Model to determine whether or not it is 
structurally identifiable. 
6.2.1 Taylor series approach 
6.2.1.1 Glucose and insulin as observables 
Here we examine the Minimal Model with both glucose and insulin as observable 
functions. The unknown parameters, from equation 6.5, are              and h. 
The known parameters, also from equation 6.5, are Ib, I0, Gb and G0. 
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It can be done by successively differentiating both glucose and insulin then using 
both of these sets of equations as this produces simpler equations than looking 
at each separately. The analysis was initially performed using Mathematica, see 
Appendix 2, to produce the following coefficients of derivatives,    is glucose and 
  is insulin: 
          
  
               
  
                
               
  
                                        
 
                         
6.6 
          
  
          
  
                 
  
  
                     
               
6.7 
Mathematica solved this system of eight equations: the first four coefficients for 
both observations of glucose and insulin to yield unique solutions for 
                  . This proves the Minimal Model is globally structurally 
identifiable with glucose and insulin as observables and under the assumption 
that Gb  and Ib are both known. 
6.2.1.2 Glucose as the only observable 
Here we consider the Minimal Model with glucose as the only observable 
function, i.e.      which is glucose. To reflect this, c, from equation 6.5, must 
be replaced by: 
    
 
 
 
 
 
 
 
 
  6.8 
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Again the unknown parameters, from equation 6.5, are              and h. The 
assumed known parameters, also from equation 6.5, are Ib, I0, Gb and G0. 
In this case, Mathematica was unable to produce a unique solution for the 
parameters, even when using 10 equations, see Appendix 2. Maple produced 
some solutions after 9 differentiations but not beyond that, also in Appendix 2. 
This suggests that, although both were ultimately unsuccessful, Maple was 
better than Mathematica at dealing with the complexity of differential equations 
in this situation; however this does not necessarily mean that it will be better for 
other problems of similar complexity. 
As neither Mathematica nor Maple were able to obtain full solutions with a 
reasonable number of Taylor series coefficients, the problem was considered to 
be computationally intractable. The lack of solutions meant it was not possible to 
prove the identifiability of the system one way or the other using this technique, 
so a different approach was required to determine if the system was or was not 
structurally identifiable conclusively. For this reason, the similarity 
transformation approach was also applied and is detailed below. 
6.2.2 Similarity transformation approach 
6.2.2.1 Glucose as the only observable 
Here we again consider the Minimal Model with glucose as the only observable 
function. As with the Taylor series approach above, c, from equation 6.5, must be 
replaced by: 
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  6.9 
Again the unknown parameters, from equation 6.5, are              and h. The 
known parameters, also from equation 6.5, are Ib, I0, Gb and G0. 
The method for applying the Similarity Transformation Approach is described in 
Chapter 2. See Appendix 2 for the Mathematica implementation of the method. 
As Ib and Gb are not known from the glucose and insulin observables, it is 
assumed that they will not be identifiable with glucose as the only observable. 
With this in mind, the candidate smooth functions, µ, were chosen as follows to 
ensure simple computation (as described in Chapter 2 ): 
                  
             
   
   
  
       
   
   
  
       
6.10 
After checking the model fulfils the Observability Rank Criterion (ORC) for non-
zero  , the candidate vector, H, is therefore: 
      
  
  
              
                                       
  6.11 
The smooth mapping can be found by using the equation:  
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            6.12 
and rearranging it so it is equal to zero, then solving it. This gives the smooth 
mapping which is quite complex so it would be useful to simplify it. Evaluating at 
t = 0,    and   cannot be zero, therefore there is only one valid solution. See 
Appendix 2 for the analysis for this model and the extraction of coefficients. 
The result is therefore that the model is structurally globally identifiable even 
with glucose as the only observable. This means that unique parameter values 
can be obtained from only glucose measurements, providing basal levels of 
glucose(G(0)) and insulin I(0) are known. In turn, this means it is possible, in 
theory to estimate parameters for the model using only glucose measurements 
and therefore to simulate insulin levels without direct measurements. 
6.3 Stiffness of the Minimal Model 
The idea of the stiffness of a system is introduced in Chapter 2. It is a measure of 
the range of timescales that a system operates in. Here we examine the stiffness 
of the Minimal Model using the method described in Chapter 2. 
The Jacobian matrix, A as specified in equation 6.13, for the Minimal Model 
evaluated at time t = 0 is: 
 
   
       
        
           
    
  6.13 
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The corresponding eigenvalues are 0, -n, -p1 and -p2. These have average 
absolute values of 0, 0.10, 0.08 and 0.02 respectively, using values from [111]; 
however, for the purposes of stiffness, a zero eigenvalue is treated as O(100) or 
one [9, 32] so the values will be treated as 1, 0.10, 0.08 and 0.02. Therefore the 
stiffness factor, SF as defined in equation 6.14 is: 
 
   
 
    
    6.14 
The stiffness factor is therefore O(101) and hence the model can be considered 
non-stiff. 
As an additional note, the Minimal Model has a discontinuity when G  drops 
below h. As shown in equation 6.3, at this point the term         is not 
included in the model, which gives the Jacobian matrix as: 
 
   
       
        
     
    
  6.15 
As this term does not affect the eigenvalues, the stiffness is therefore not 
affected by the discontinuity. 
6.4 Parameter fitting 
6.4.1 Data 
The data set used for parameter fitting was (AliceIVGTT) in Chapter 4. The data 
were obtained from anaesthetised Han Wistar rats (fed, fasted for 8 hours or 16 
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hours over-night) which were given a bolus injection of glucose (0.5 or 
0.375mg/kg). Readings were taken at 1, 2, 5, 10, 15 and 25 minutes after the 
injection of glucose. 
The data were transferred from the original spreadsheet format to a Microsoft 
Access database format. This made it easier to import into MATLAB and other 
packages as required for analysis. 
6.4.2 Model function 
As the Minimal Model is not stiff (O(101) as shown above there is no requirement 
for an ODE solver that will solve stiff systems. Therefore, MATLAB's ode45 
solver was used (Chapter 2). 
6.4.3 Error function 
The error function is an important component in fitting as it determines how the 
fitting function “sees” the data. Therefore the better the error function is, the 
quicker and more accurate the fit will be. 
The error function used was based on a weighted least squares method (Chapter 
2) and is given in equation 6.16. 
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where    is the glucose data,  is glucose simulated,   is insulin data and    is the 
simulated insulin data  As the glucose and insulin values were sometimes 
different in magnitude it was important to consider relative, rather than 
absolute, errors to avoid larger values disproportionately affecting the error 
function and therefore the parameter fit. Therefore, the output from the model 
function was weighted on the real data points in order to give glucose and insulin 
equal weighting in the fitting process. 
6.4.4 Fitting function 
The fitting function used was MATLAB’s standard fminsearch, which is an 
implementation of the Nelder-Mead Simplex method. The function options were 
altered to reduce error tolerance of the results. 
The Minimal Model only works with the initial value set at the peak insulin value 
hence, when fitting the data. With the data used, there is a value at time zero 
which is before the glucose bolus has had chance to affect the system hence it 
was necessary to remove the data point at time zero as the insulin peak had not 
yet been reached.  
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6.5 Results 
6.5.1 Glucose and insulin as observables 
 
 
 
Figure 6.2: Examples of Minimal Model parameter fits
Chapter 6: Minimal Model 
111 
 
Group 
g0 
(mmol/l) 
i0 
(ng/ml) 
p1 
(min-1) 
n 
(min-1) 
p2 
(min-1) 
p3 
(min-1) 
h 
(mmol/l) 
γ 
(min-1) Residual 
Insulin 
sensitivity 
8 Hour Fasted -  0.5g/kg StdDev 0.80 7.87 0.0156 0.0485 0.0233 0.0000076 6.57 0.00202 0.20 1.3819 
8 Hour Fasted -  0.5g/kg Average 14.22 9.90 0.0876 0.0663 0.0154 0.0000194 8.65 0.00522 1.34 0.8010 
Fed - 0.375g/kg StdDev 0.53 4.80 0.0193 0.0373 0.0064 0.0000033 0.00 0.00111 1.88 0.8303 
Fed - 0.375g/kg Average 13.16 19.82 0.0792 0.1673 0.0054 0.0000117 2.00 0.00606 4.60 0.4202 
Fed - 0.5g/kg StdDev 0.27 3.02 0.0278 0.0245 0.0075 0.0000164 1.05 0.00677 0.62 2.2161 
Fed - 0.5g/kg Average 15.76 22.34 0.0959 0.1382 0.0047 0.0000195 3.05 0.01359 2.83 1.2876 
O/N fast - 0.5g/kg StdDev 2.49 2.23 0.0064 0.0468 0.0163 0.0000021 1.66 0.00567 1.51 0.0037 
O/N fast - 0.5g/kg Average 13.80 6.40 0.0925 0.1050 0.0183 0.0000110 4.75 0.00598 1.99 0.0025 
Grand StdDev 1.60 8.08 0.0172 0.0527 0.0142 0.0000084 3.72 0.00515 1.76 1.2023 
Grand Average 14.13 14.40 0.0884 0.1216 0.0110 0.0000148 4.44 0.00747 2.78 0.5683 
Table 6.2: Parameter Fitting Results (Groups) 
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 Group 
g0 
(mmol/l) 
i0 
(ng/ml) 
p1 
(min-1) 
n 
(min-1) 
p2 
(min-1) 
p3 
(min-1) 
h 
(mmol/l) 
γ 
(min-1) 
Residual 
SI - Insulin 
sensitivity 
Fed Average 14.3 20.9 0.0863 0.155 0.0051 0.000015 2.45 0.00929 3.84 0.345 
Fed StdDev 1.45 4.05 0.0229 0.0337 0.0063 1.06E-05 0.83 0.00566 1.67 0.905 
Fasted Average 14.0 7.9 0.0904 0.0884 0.017 1.46E-05 6.42 0.00565 1.71 0.568 
Fasted StdDev 1.84 5.16 0.0104 0.048 0.0178 6.42E-06 4.48 0.0042 1.13 1.2 
Grand Average 14.1 14.4 0.0884 0.122 0.011 1.48E-05 4.44 0.00747 2.78 0.345 
Grand StdDev 1.6 8.08 0.0172 0.0527 0.0142 8.44E-06 3.72 0.00515 1.76 0.905 
T-Test (Two Tailed homoscedastic) 0.748 0.0002 0.676 0.0125 0.134 0.935 0.0582 0.2  0.5 
Table 6.3: Parameter Fitting Results (fasted and fed groups) 
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Recall from the Structural identifiability analysis of the Minimal Model section 
above, the unknown parameters were              and h. See Table 6.2 and 
Table 6.3. 
   (glucose effectiveness). The value obtained across the whole group was 
indeed consistent at 0.088 min-1 (SD 0.017), showing little variation in 
comparison to other  parameters, indicating that other factors created the 
different insulin and glucose profiles. However, the magnitude of this value 
means that it does play a part in the dominant glucose disposal. 
6.5.1.1 Glucose 
G0 (initial glucose concentration). This is fitted to the first data point. A point of 
contention here is that if the peak was missing when sampling the data, this 
value would be incorrect.  
A way to improve this would be to use the quantity of glucose injected with the 
volume of distribution to obtain an estimate for the total quantity of glucose. 
6.5.1.2 Insulin 
I0 (initial insulin concentration). Little variation within groups and this is fitted to 
the first data point. It may have missed the peak due to no instantaneous 
measuring. The same problem arises as it may be missing the peak. The insulin 
secretion in fasted animals is far lower than in fed animals. 
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n (clearance rate of insulin).  This varied between fed and fasted animals, being 
higher in the fed animals than in the fasted animals. This is an interesting 
observation, that will be gone into in more depth in Chapter 7. 
h (threshold level at which insulin is secreted ; i.e. insulin is secreted only if the 
glucose is above this level). Most of the subjects did not reach basal levels so 
they may not have reached this threshold.  h also has a effect on insulin 
secretion, that is the smaller the value of h the greater the insulin secretion. 
  (secretion rate of insulin). This was not statistically different between groups 
(see Table 6.3). 
6.5.1.3 Interstitial insulin dynamics 
p2, p3 (clearance rate of insulin and insulin kinetic into the interstitial  
compartment from the plasma insulin compartment). The lack of data points 
could account for the large variation in values seen for these two parameters. p2 
and p3 are used to create the Insulin Sensitivity, SI, however with the large 
variation in these fitted parameter values it is not possible to achieve a reliable SI 
value.  
This is not as expected as the purpose of insulin is to affect glucose, however this 
was not seen. This may be a problem with applying the model to an IVGTT, a 
problem with the parameter fit (i.e. that the minimum is local and not global) or 
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a problem with the model more generally. It is therefore important to clarify this 
matter by checking a sensitivity analysis (see section 2.7). 
6.5.2 Glucose as the only observable 
To simulate having glucose as the only observable was simply a matter of 
removing insulin from the error function. This effectively means that the 
optimisation technique cannot “see” the insulin, but the model will still produce 
the predicted insulin output for inspection. 
However, this did not predict any realistic insulin results as neither the shape of 
the curve or the values were close, showing that it is necessary to have the 
insulin data in order to achieve a good model fit. The problem lies in the fact that 
the p2 and p3 parameters are sensitive to the number of glucose data points 
available. 
An additional problem is that it may not be possible to obtain an accurate view 
of insulin from this test by looking only at glucose measurements. This is likely to 
be due to the level of insulin in the rats at the start of the experiment making 
very little difference to glucose decay, as it has reached saturation and glucose 
effectiveness is playing the main role in removing glucose.  
Even though the model was structurally identifiable in this situation, this does 
not prove that it is necessarily possible. If the model had been structurally 
unidentifiable, the parameters would not have had a unique solution and, 
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therefore, they would have been meaningless and the insulin output may have 
been incorrect. 
6.6 Sensitivity Analysis  
The sensitivity analysis was performed in Berkley Madonna [1] using a basic 
technique of taking the average of fitted parameters then modelling with 
parameter values an order of magnitude smaller and an order of magnitude 
larger. This should ensure that the whole range of likely values is covered and 
gives an idea of how accurate the parameters will be from visual inspection if 
they change subtly. 
Figure 6.3: Relative sensitivity analysis of glucose with all parameters (time in minutes) 
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Figure 6.4: Relative sensitivity analysis of insulin with all parameters(time in minutes) 
 
 
 
Figure 6.5: Relative sensitivity analysis of glucose with all parameters except p1 & 
p3(time in minutes) 
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Figure 6.6: Relative sensitivity analysis of insulin with all parameters except p1 & p3(time 
in minutes) 
Figure 6.2 – Figure 6.6 show the results from relative sensitivity analysis. The 
parameters have affected the different compartments as follows: 
The glucose compartment is affected by G0 as it has a clear and direct effect on 
the starting level of glucose. The effects are dramatic when the order of 
magnitude is changed. The glucose maintains an exponential decay from its 
starting point, however the insulin response is even more dramatic with the 
second phase response being altered greatly. In addition, p1  has a large effect on 
glucose, though not as much as G0, so it also effects the insulin second phase 
response (see Figure 6.3 and Figure 6.6). 
Chapter 6: Minimal Model 
119 
 
The insulin compartment is largely affected by I0 but only has a limited effect on 
glucose. This is to be expected as the insulin profile in an IVGTT test happens 
rapidly, plus the insulin may be at saturation. Moreover n and h have a great 
effect on insulin, but only a very small effect on glucose. Furthermore   has a 
large effect on insulin secretion, in particular in the second phase insulin curve 
(see Figure 6.4 and Figure 6.6). 
p2 has almost no effect on glucose or insulin, hence its value will not be found 
reliably in the parameter fitting. p3  subtly alters the glucose and, to a lesser 
extent, the insulin response. In order to achieve an accurate result, very accurate 
results from a large number of data points would be needed. 
6.6.1 Conclusions 
Parameters sensitive to change: G0, p1, I0, h, n, . 
Parameters less sensitive to change: p2, p3. 
It is necessary to know the parameters that are sensitive to change as this 
confirms the variation in the parameter fitting results and shows that the 
parameters which are sensitive to change can be picked up by the parameter 
fitting. As small changes in parameters can make a big difference to the results, 
the smaller the range that the sensitive parameters can realistically range over 
the smaller the variation in the results. 
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Changes in the parameters p2 and p3 do not show much change in the glucose or 
insulin responses so obtaining highly accurate values for them is questionable. In 
the case of an IVGTT, the insulin may be having its maximum effect, hence the 
insulin profile will have only a subtle effect on the glucose dynamics. From this 
perspective, it is correct that these parameters are reliant on subtle changes in 
the glucose and insulin profiles. 
This also shows why the glucose-only observations did not work very well. In this 
situation the model was structurally identifiable which meant that there was the 
possibility of finding a unique set of parameter values that would have returned 
the correct insulin. However, it does not guarantee it. As parameter value 
changes in the insulin section of the model do not affect the glucose greatly, 
there is effectively not enough information contained in the glucose 
measurements alone to be able to obtain accurate insulin results. 
All of these comments relate specifically to the Minimal Model; alternative 
models with a different structure may produce different results and it may still 
be possible to obtain insulin values with glucose-only observations. 
6.7 Overall Summary 
6.7.1 Conclusions Between Groups 
Between the fed and fasted groups the only parameters that show statistical 
significance are I0 and n. This means that the first phase insulin secretion and 
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clearance rate of insulin are different between the 2 groups. This issue is 
investigated when we take into account C-peptide as detailed in Chapter 7. 
6.7.2 General Conclusions 
The Minimal Model has been shown to be uniquely structurally identifiable with 
both glucose and insulin measurements. It has also been shown to be uniquely 
structurally identifiable with only glucose measurements. Both of these 
statements have the caveat that basal insulin and glucose levels must be known; 
however, in the experiments where the Minimal Model is used (i.e. IVGTT) this is 
always the case. 
Although the system is structurally identifiable with glucose measurements only, 
the low sensitivity of the effect of insulin on glucose causes a failure to produce 
realistic insulin results. 
In the parameter fits performed here, the main driver for glucose disposal was 
glucose effectiveness. This could be attributed to several causes: 
 the IVGTT may not be a good experiment to measure insulin sensitivity 
due to the fast rate of glucose disposal; 
 the model may have fitted a local minimum where glucose effectiveness 
was dominant, but there could have been other local minima with high 
insulin sensitivity and low glucose effectiveness; 
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 there could be an issue with the model design as it may not be 
physiologically relevant. 
Chapter 7: C-Peptide Deconvolution and Modelling 
123 
 
Chapter 7: C-peptide Deconvolution and Modelling 
As C-peptide and insulin are secreted in equal molar quantities, as explained in 
Chapter 3, insulin secretion can be calculated using deconvolution of C-peptide 
concentrations. Methods of deconvolution used in this thesis, and explained 
here, are the Maximum Entropy method and the technique employed in 
WinNonLin. Whereas 100% of C-peptide is observed when measuring 
peripherally as none is absorbed by the liver, as shown through the work 
deconvolving C-peptide presented in this chapter, less than 100% of insulin 
leaving the pancreas is observed when trying to measure peripherally after the 
liver. Deconvolving data from IVGTTs and hyperglycaemic clamps shows that the 
fraction of insulin leaving the pancreas when measured peripherally after leaving 
the liver can be anywhere between 7% and 58%, depending on the subject and 
the deconvolution method used. For example, the Maximum Entropy method 
produced fractions of 38% for fed animals and 19% for 8-hour fasted (p < 0.05) 
while the WinNonLin method produced values of 36% for fed animals and 16% 
for 8-hour fasted (p < 0.005). The data also show there is a variable clearance 
rate depending on the level of fasting of the animals; it is hypothesised in this 
chapter that this is down to a change in hepatic blood flow. 
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7.1 Introduction 
Insulin is cleared primarily by the liver [133], which is fed by two blood vessels – 
the hepatic artery and the hepatic portal vein [134]. Hepatic blood flow is known 
to change for a variety of reasons, for example exercise and food intake [72]. 
Insulin clearance rates are also known to change, a large variety of factors affect 
this [103, 129, 135, 136] ; as insulin is cleared by the liver, it is hypothesised here 
that there is a connection between hepatic blood flow and insulin clearance rate. 
In order to measure insulin concentration as it appears directly from the 
pancreas it is necessary to sample from the portal vein, into which the pancreas 
feeds [134]. This is an intricate and invasive procedure and it is therefore difficult 
to measure insulin secretion directly, particularly in a clinical setting [137]. 
Additionally, the variable rate of insulin clearance makes it complicated to model 
accurately; other models presented in Chapter 5 do not take into account the 
changes in clearance rate. 
Accurate values of insulin concentration produced by the pancreas are necessary 
to establish insulin sensitivity [133]; without knowing how much insulin was 
originally present in the system, it is not possible to say accurately how much 
glucose is cleared per unit of insulin and therefore to calculate insulin sensitivity. 
Insulin sensitivity is important both for determining how effective a drug is at 
improving glucose uptake and for tracking disease progression in diabetic 
patients. 
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Some studies have found that the insulin clearance rate can be considered to be 
a constant under certain conditions. For example, Bergman found that the 
fraction of insulin cleared as it passes through the liver, known as the hepatic 
extraction ratio, is 33.4% ± 0.1 for an IVGTT and 64.5% ± 3.6 for an OGTT [59]. 
While this may be useful for simplifying calculations, it does not provide an 
explanation for what is happening mechanistically or allow us to predict what 
will happen in other situations. 
Insulin secretion must be determined to establish the relationship between 
glucose concentration and insulin secretion. This has been attempted in several 
previous models, each with their own different approach. The Minimal Model 
only simulates second-phase insulin response and for the first-phase response it 
uses the initially measured insulin level [113]. Cobelli used a combination of the 
Minimal Model’s approach and the derivative of glucose concentration from 
work by Mari to establish a relationship between glucose concentration and 
insulin secretion [80, 123]. 
In order to produce an accurate model of insulin secretion for future use in this 
work, it is important to have an accurate relationship between glucose and 
insulin 
7.2 C-peptide 
As explained in Chapter 3, insulin is synthesised in the ß-cells in the islets of 
Langerhans in the pancreas. It is held in granules as pro-insulin, an inactive form. 
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When pro-insulin is activated, C-peptide is cleaved from it by carboxypeptidase 
and a series of prohormone convertases [54]. This results in C-peptide and 
insulin release into the hepatic portal vein in equal molar quantities. 
An important feature of C-peptide is that it is cleared by the kidneys at a 
constant rate [57, 138]. As C-peptide is produced at the same rate as insulin, it is 
possible to calculate insulin clearance from C-peptide concentration using a 
technique called deconvolution, which is explained in the Deconvolution section 
below. 
7.3 Deconvolution 
Convolution is a mathematical operator on two functions which produces a third, 
often considered to be a modification of one of the original functions. This can 
be viewed as "filtering" one function through another. Convolution is 
mathematically defined as follows: 
 
                             
 
 
 
7.1 
where y is the output of the system, u is the input to the system, f  is the system 
impulse response and   is the convolution operator. 
Deconvolution is the reverse process where, given the output, y, and usually the 
system impulse response, f, the input, u, can be found. This is very useful in 
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mathematical models of biological systems where, given the output (y) and 
system equations (f ), deconvolution can be used to establish the input (u). 
In the case presented here, the output is the measured C-peptide concentration 
which is deconvolved to calculate the original insulin secretion. Two methods of 
deconvolution are used in this thesis and described below: the Maximum 
Entropy technique and the technique employed in the software package 
WinNonLin. These were selected as they have been successfully applied to 
biological systems previously [139, 140] and, as results from different 
deconvolution can vary, using two methods allows for comparison of results. 
7.3.1 Maximum Entropy 
A lot of the original work using maximum entropy was based on applications in 
astrophysics, looking at far away objects and correcting for telescopic lenses and 
gravitational lensing [141, 142], but it also has noted applications in biomedical 
systems [143]. A review of six different deconvolution techniques applied to 
certain well-accepted pharmacokinetic models and data was performed by 
Madden, et al., which noted the advantages of certain types of deconvolution 
approaches over others [144]. 
Entropy in this context is a measure of the amount of information or uncertainty 
in a signal. The Maximum Entropy technique seeks to minimise assumptions 
about a signal, while constraining the result to the observed signal, by 
maximising entropy. 
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7.3.1.1 Method 
The standard continuous measure for entropy, S, is: 
 
            
 
   
 7.2 
where pn is the probability of an event occurring. This can be adapted to form a 
discrete measure of entropy for a piecewise step input function: 
 
          
 
   
 7.3 
where        
                  
          
  which is combined with equation 7.2 to 
produce: 
    
  
   
 
         
  
  
 
 
   
 
7.4 
where xn is the normalised value of the input for the n
th sample and rn is the 
base-line value of the input and is calculated using a nearest neighbour average 
(i.e. (xn-1 + xn+1)/2). The inclusion of rn smoothes the function x  to make the signal 
more "natural" by removing any sharp spikes. The input is considered to be 
always positive as a negative input function would be nonsensical biologically. 
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This entropy function is used as the objective function for the optimisation 
algorithm. The input function in 7.3 is convolved with the system equations to 
produce the output function. The output function is then constrained against the 
real data. The constraining function is the χ2 constraining function: 
 
    
       
 
   
 
   
 7.5 
where          
and where E is the expected value, N is the number of samples, xi is the 
measurement, hi is the predicted value and    is the weighting, as this can be 
seen as a weighted least squares estimator (see Chapter 2). 
This is fed into a constrained optimisation algorithm, in this case the MATLAB 
fmincon method, which uses a quadratic programming sub-problem coupled 
with calculation of the Hessian of the Lagrangian via the BFGS formula [4, 139, 
145]. 
This Maximum Entropy implementation has been tested and used successfully by 
others [139, 145, 146]. 
7.3.2 WinNonLin 
WinNonLin [5] is a tool widely used in the pharmaceutical industry for the 
modelling of pharmacokinetic processes and systems. It incorporates a method 
of deconvolution that takes a linear system for drug kinetics and calculates the 
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input rate to the system. This is commonly used for estimating gut absorption 
rates and bioavailability of a drug from IV and oral drug dose profiles. The 
software is designed specifically for biological systems and is accepted and 
approved by the FDA (Food and Drug Administration), making it very appropriate 
for this application. 
7.3.2.1 Method 
The WinNonLin method is described in detail in the documentation of 
WinNonLin [5]. The basic concept is explained here. 
The WinNonLin deconvolution technique is an optimisation process, as is the 
Maximum Entropy technique; however unlike Maximum Entropy, which sets up 
data points and interpolates between them, it sets up an input function to the 
system. The input to the system is described as a piecewise linear "precursor" 
function of the following form: 
                     7.6 
where       
 
 
 
 
 
    
       
       
      
         
           
           
 . 
The optimisation is performed by varying the weights, xj. T0 ... Tj+2 are the time 
points at which observations are taken plus one point at time zero and another 
half way to the first point to allow for an initial peak at the start. This allows the 
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system to simulate a rapid absorption rate at the start, which is common in drugs 
being absorbed though the gut. 
This function is then convolved with a “dispersion” function which acts as a 
smoothing function. It is a normalised decaying exponential of the form: 
 
   
  
 
 
 
 7.7 
where δ is a smoothing coefficient. 
This effectively creates a smoothed curve function with n+2 points, where n is 
the number of data points. 
The WinNonLin deconvolution method was implemented in MATLAB; this made 
use of MATLAB’s own optimisation and simulation functions, which may be 
different to WinNonLin’s. However, the results from the MATLAB 
implementation were found to be very similar to those from WinNonLin (see 
Deconvolution Results below). The method for finding residuals in WinNonLin is 
not explained in the manual, so least squares was selected as the most 
appropriate. The implementation of this in Appendix 3. 
7.4 Data Collection 
In order to apply these two methods the system model needs to be known. Most 
modellers use one particular C-peptide model [57], which is a linear two-
compartmental model with first order clearance (Figure 7.1). From these models 
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we can assume this system to be linear so the impulse response is required. It is 
also necessary to know the parameter values for the model. This was achieved 
using an intravenous C-peptide injection and fitting the parameters in acslX using 
a PKPD toolkit developed at AstraZeneca.  
C1(t)
Plasma
C-Peptide
V1
(Volume of 
Distribution)
k1e
(C-Peptide 
clearance)
C2(t)
Periphery
C-Peptide
k12
k21
Pancreas
Kidneys  
Figure 7.1: C-peptide kinetic compartmental model 
Doses of 6nmol/ml (n=3),3nmol/ml (n=3),0.8nmol/ml (n=2) C-peptide  were 
administered and measurements taken at 1, 2, 5, 10, 15, 20, 25 and 30 minutes, 
see (RuthCPeptide) from Chapter 4. The mean of the parameter values were 
used for deconvolution, see Figure 7.2 and Table 7.1. 
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Figure 7.2: Parameter Fits of C-peptide 
 Parameter Final Std.Dev.   %Covariance
  V1 0.0796 0.0038 4.75
  K21 0.2540 0.0095 3.73
  K12 0.3410 0.0101 2.95
  KE 0.3150 0.0089 2.84  
Table 7.1: C-peptide fitted kinetic parameters 
The data used for deconvolution were collected from a series of different 
experiments: conscious and anaesthetised; ad-lib fed, 4-hour fasted and 8-hour 
fasted; and IVGTT and hyperglycaemic clamps. These are contained in the data 
sets (AliceIVGTT), (GeorgiaIVGTT) and (RuthClamp) (see Chapter 4). 
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7.5 Deconvolution Results 
Data from these studies were deconvolved using the two techniques described 
above. Full results are given in Appendix 3. Presented below, in Figure 7.3 and 
Figure 7.4, are typical examples of deconvolution outputs for IVGTT and 
hyperglycaemic clamp experiments respectively.
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Figure 7.3: Deconvolution of IVGTT data from rat 1 in (AliceIVGTT) (fed Han Wistar rat) from the original WinNonLin method, the WinNonLin MATLAB 
method and the Maximum Entropy method 
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Figure 7.4: Deconvolution of hyperglycaemic clamp data from rat 37 in (RuthClamp) (fed Han Wistar rat) from the original WinNonLin method, the 
WinNonLin MATLAB method and the Maximum Entropy method 
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As the fundamental techniques used for both the WinNonLin deconvolution and 
the MATLAB implementation of the WinNonLin deconvolution are the same, 
they produce very similar results; any errors can be explained by differences in 
the ODE solvers and optimisation techniques used. The results from both of 
these are approximately identical and therefore the MATLAB implementation is 
used for the remainder of the data analysis. 
Both the Maximum Entropy and WinNonLin techniques produce similar 
deconvolution outputs and also predict approximately the same level of insulin 
secretion. The data in Appendix 3 show that in 80% of cases WinNonLin 
produced higher values for insulin secretion than the Maximum Entropy 
technique. However, there was a maximum difference of 36% with the average 
difference between the values being only 8%. 
Figure 7.3 and Figure 7.4 also show the glucose levels in each rat and the ratio 
between C-peptide (insulin secretion) and glucose concentrations. This is useful 
as it shows the relationship between the pancreas and glucose levels when 
secreting insulin. From these graphs, it is important to note that the relationship 
is not proportional. It also shows that a large quantity of glucose in an IVGTT 
does not cause saturation in insulin secretion; in fact, a larger than proportional 
secretion occurs. 
It can also be seen, for both the IVGTT and the hyperglycaemic clamp 
experiments, that there is an increase in insulin secretion after sustained high 
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levels of glucose. This is particularly apparent for the hyperglycaemic clamp data, 
where glucose remains roughly constant while the ratio between glucose and 
insulin secretion increases. This information is used later to develop a short-term 
model of the glucose-insulin system. 
Finally, it is clear that from around 90 minutes into the hyperglycaemic clamp 
there is a sudden increase in insulin secretion. This is in fact down to arginine 
being injected, as described in Chapter 4, and therefore has little to do with 
glucose concentrations. 
7.6 Insulin clearance 
As C-peptide is secreted in the same molar quantity as insulin, working out the C-
peptide secretion rate gives the corresponding insulin secretion rate. When the 
IVGTT and hyperglycaemic clamp experiments were performed, plasma insulin 
concentrations were also measured; it is therefore possible to calculate the 
amount of insulin that appears and the clearance rate of insulin. This is done by 
fitting a simple one-compartmental model (Figure 7.5) described by the 
differential equation in equation 7.8. 
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Figure 7.5: Diagram of simple insulin clearance compartmental model 
       
  
                7.8 
where I is plasma insulin, ke is insulin clearance (min
-1), b is the fraction of 
secreted insulin that is observed after the liver in the periphery and u is the input 
function obtained from the C-peptide deconvolution. 
This was fitted in MATLAB using MATLAB’s unconstrained fitting algorithm, 
fminunc [36]. The fitting algorithm used transforms of the parameters to 
create upper and lower bounds [147, 148] using the following equations: 
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where p is a parameter,   is the transpose parameter used by the optimisation  
algorithm   is the lower bound and   is the upper bound. 
The unconstrained fitting algorithm was selected because MATLAB’s constrained 
fitting algorithm tended to find local minima around the constrained points. The 
model itself was simulated using the numerical algorithm ode45 as this is not a 
stiff system. The error function used was Weighted Least Squares, as detailed in 
Chapter 2, with weighting based on real data. The use of Generalised Least 
Squares, also in Chapter 2, as the error function was attempted, however this 
also tended to lead to local minima; this was due to the fact that parameters a 
long way off from the true minima caused the value of the error function to 
show little difference between different incorrect values of parameters. 
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7.6.1 Results 
Figure 7.6: Insulin clearance (ke) and fraction of insulin observed (b) in all rats using both 
Maximum Entropy and WinNonLin deconvolution techniques, grouped by fasting state 
with standard deviation error bars 
  Maximum Entropy WinNonLin 
Fasting state ke (min
-1) b (fraction) ke (min
-1) b (fraction) 
Fed 0.34 0.38 0.30 0.36 
4-hour fasted 0.35 0.25 0.40 0.28 
8-hour fasted 0.22 0.20 0.21 0.16 
16-hour fasted 0.20 0.21 0.19 0.16 
Table 7.2: Insulin clearance (ke) and fraction of insulin observed (b) in all rats using both 
Maximum Entropy and WinNonLin deconvolution techniques, grouped by fasting state 
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Figure 7.6 and Table 7.2 summarise the overall insulin clearance and fraction of 
insulin observed results obtained using both Maximum Entropy and WinNonLin 
deconvolution techniques on data from all data sets used here, (AliceIVGTT), 
(GeorgiaIVGTT) and (RuthClamp), as detailed in Chapter 4. 
The full data set was analysed using a two-tailed Student's t-test (see Appendix 
3). This showed that there is a statistically significant difference in the fraction of 
insulin observed (b) between fed and both 8-hour and 16-hour fasted rats for 
both the Maximum Entropy and WinNonLin methods (p < 0.05). There is also a 
statistically significant difference in insulin clearance (ke) between 4-hour fasted 
and both 8-hour and 16-hour fasted rats for both Maximum Entropy (p < 0.05) 
and WinNonLin (p < 0.005). There is no statistically significant difference 
between results from Maximum Entropy and WinNonLin based on the residual 
function. 
7.6.2 Discussion 
The results in Figure 7.6 and Table 7.2 show that the fraction of insulin observed 
(b) is well below 100%, meaning that there is a large proportion of insulin that is 
not observed in the periphery. This is possibly down to the pancreas releasing 
insulin into the portal vein, which goes straight to the liver and is therefore 
cleared before it reaches the periphery where the plasma is sampled. 
It can also be seen that there is a difference in the amount of insulin "lost" and 
the clearance rate of insulin based on the feeding state of the animals. This could 
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be hypothesised to be attributed to the changes in blood flow from fed to fasting 
states. 
7.7 Modelling hepatic blood flow 
7.7.1 Biology 
Blood from the gut is transported to the liver via the portal vein. The circulation 
to the pancreas is directly from the gut so the β-cells can sense glucose levels 
immediately after glucose has been absorbed by the digestive system [134]. The 
insulin from the β-cells is fed into the portal vein. From the liver, blood flows into 
the rest of the body via a complex series of blood vessels and can then 
recirculate into the liver through the hepatic artery and portal vein. The pancreas 
and, therefore, the β-cells are also served by other blood vessels such as 
branches of the splenic artery, independent from the gut. 
The blood flow in the portal vein can vary [72, 149] from 14.60± (0.96) ml/min to 
27.35 (± 1.82) ml/min between fasted and fed rats [74]. This is affected by 
several factors, including exercise (where blood is required in areas such as 
muscles) and digestion (where blood is required in other areas). As described 
earlier, insulin is cleared by the liver; therefore it could be hypothesised that the 
rate of clearance changes with alterations in blood flow. This problem has been 
found in pharmacokinetics where a drug flows in to the liver and is cleared. As 
different species have different rates of blood flow, they have different rates of 
clearance; this has been studied in depth before [150]. With insulin there is a 
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first pass effect which means that the insulin is cleared without it passing into 
the periphery and also a standard clearance rate of insulin. However the liver 
may have only one intrinsic rate of clearance [151]; adding variable blood flow 
into the model may provide a reason for the clearance. 
Knowing this, and knowing the first pass and observed clearance of insulin (from 
deconvolving C-peptide), it may be possible to calculate the hepatic blood flow. 
7.7.2 Model 
This model is a standard set of equations used by pharmacokineticists for hepatic 
blood flow [73, 138], given in equation 7.10; in this case, I is insulin, however it 
could also be a drug: 
   
  
 
       
        
 
 
  
  
        
      
7.10 
 
where Qh is hepatic blood flow, CLint is intrinsic clearance rate, V is volume of 
distribution of insulin and u is insulin secretion rate (i.e. C-peptide secretion 
rate). Note that there is no volume of distribution associated with u, due to the 
fact that the input is already defined as a concentration. 
There is a structural identifiability issue with this model which is apparent when 
looking at the model structure as the volume of distribution of insulin will be a 
ratio that is not determinable from the observables shown. This can be 
determined by inspection of the model or, as this model is linear, by the Laplace 
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transform approach to structural identifiability, see Chapter 2 [14]. Therefore it is 
necessary to find a value for the volume of distribution of insulin from the 
literature, which is known to be 0.08 l/kg [152]; this value is close to (i.e. within 
10% of) the volume of distribution of C-peptide 0.0796 l/kg. 
The average weights of the rats in each of the studies (Appendix 1) were: 
 (AliceIVGTT): 260g 
 (RuthClamp): 282g 
 (GeorgiaIVGTT): 300g. 
This gives an overall average weight of 280g, yielding a volume of distribution of 
insulin (V) of 0.0224l for the rat models used. 
7.7.3 Results 
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Figure 7.7: Conscious IVGTT from (GeorgiaIVGTT) ID65 - 4-hour fasted 0.5g/kg glucose bolus 
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Figure 7.8: Hyperglycaemic clamp from (RuthClamp) ID 42 - 8-hour fasted 
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Figure 7.9: Hepatic blood flow (qh) and intrinsic clearance (CLint) in all rats using both 
Maximum Entropy and WinNonLin deconvolution techniques, grouped by feeding state 
with standard deviation error bars 
  Maxium Entropy WinNonLin 
  qh (L/min) CLint (L/min) qh (L/min) qh (L/min) 
Fed 0.022 0.020 0.015 0.020 
4 Hours 0.012 0.032 0.011 0.033 
8 Hours 0.017 0.030 0.012 0.031 
16 Hours 0.006 0.025 0.005 0.027 
Table 7.3: Hepatic blood flow (qh) and Instinct clearance (CLint) observed in all rats using 
both Maximum Entropy and WinNonLin deconvolution techniques, group by feeding 
state. 
Although fitting to the hepatic blood flow model [73] produced similar fits to the 
simple insulin clearance model, see Figure 7.7 and Figure 7.8, the results for the 
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parameter estimates, see Table 7.3, showed considerably more variation, as seen 
by the standard deviation error bars in Figure 7.6 and Figure 7.9. There were 
fewer C-peptide results collected in the experiment than insulin ones due to the 
greater amount of blood needed to take C-peptide measurements. More C-
peptide results may reduce variability. The hepatic blood flow model does, 
however, produce realistic results for the hepatic blood flow [153]. Figure 7.10 
shows the hepatic blood flow for the animals at different states; the units were 
converted using the average weight of the animals in these studies, which was 
previously calculated as 280g (in section 7.7.2 above). The full results for this can 
be seen in Appendix 3. 
Ideally, CLint should remain constant as this is the liver clearance rate which 
should not be affected by blood flow or feeding state. However, there is a 
statistically significant difference in CLint between fed and 4-hour fasted rats. 
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Figure 7.10: Hepatic blood flow with normalised units 
7.7.4 Discussion 
It is shown that there are statistically significant differences between groups of 
rats for hepatic blood flow. Hepatic blood flow is near the expected value, 
however there is a statistically significant difference between the intrinsic 
clearance of insulin in the 4-hour fasted animals compared to the other groups. 
This could be due to either of two reasons: a factor which is unaccounted for in 
the model or a different mechanism from that hypothesised here for hepatic 
clearance of insulin. It is not possible to conclude which of these it is without 
testing different candidate models or doing further experiments to measure 
insulin levels or blood flow. 
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In order to estimate the hepatic blood flow, deconvolution has been used to 
calculate a “best guess” of insulin secretion based on a small number of data 
points from a limited number of animal experiments. The deconvolution results 
had little variation across animals, however the modelled hepatic blood flow and 
clearance showed large variation. Pushing the data to this point is interesting, 
however without further experiments to actually measure blood flow – such as 
using the Doppler ultrasound method [73, 149] – it is not possible to fully 
validate this process. 
From the point of view of using this approach as a tool to analyse data in the 
context of this thesis, being able to calculate hepatic blood flow is not as 
important as obtaining an accurate estimate for changes in insulin clearance.  
This is because other factors, such as the activity rate and drugs, may affect the 
blood flow.  Hence hepatic blood flow is not calculated in the software tool 
described in Chapter 10. 
7.8 Maximum Entropy vs. WinNonLin 
As noted in sections 7.6.1 and 7.7.3 above, the results from the residual 
functions for both the hepatic blood flow and insulin clearance models are 
comparable for each deconvolution technique and there is no statistically 
significant difference between the values each technique produces from the 
residual function. However there is a noticeable difference in the visual 
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appearance of the two sets of graphs produced; this is particularly apparent with 
a bolus injection of C-peptide as shown in Figure 7.11. 
 
Figure 7.11: Deconvolutions of C-Peptide 
As commented before, the WinNonLin technique is more prone to producing 
initial peaks than the Maximum Entropy technique, which employs a smoothing 
technique. 
The WinNonLin technique is known to be correct in situations such as a bolus 
input of C-peptide when the data were deconvolved back to the C-peptide; 
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however this does not mean that the WinNonLin results correct in other 
situations. 
The MATLAB implementations of both the WinNonLin and Maximum Entropy 
deconvolution techniques execute in comparable times: around 20 seconds for 
an individual rat on a AMD 6000+ processor. However, the WinNonLin 
implementation is much faster, taking only a few seconds per rat on the same 
processor. 
7.9 Overall Summary 
In this chapter, the important issue of variable insulin secretion was considered. 
Two methods of deconvolution were used to calculate insulin secretion; both 
provided reasonable predictions of insulin secretion. Both the Maximum Entropy 
and WinNonLin methods produced the same cumulative output of insulin, i.e. 
there was no statistically significant difference between the two. 
The fraction of insulin observed in ad-lib fed animals was statistically significantly 
higher (p < 0.05) than the 8-hour and 16-hour fasted rats (for both the Maximum 
Entropy and WinNonLin methods) which shows that the state of the animal is 
important when considering the measurement of plasma insulin alone.  
This confirms that using C-peptide as a biomarker of insulin secretion is evidently 
better than measuring insulin itself. 
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The hepatic blood flow hypothesis was partly successful as it returned realistic 
values for hepatic blood flow. However factors other than blood flow may be 
involved in insulin clearance. This process also pushed the data set to an extreme 
where it tried to obtain more information than is realistically possible given the 
limited number of data points available. 
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Chapter 8: Short Term Modelling 
This chapter’s aim is to produce a model which can simulate the glucose and 
insulin system accurately and is not confined to a diseased state or experiment. 
The attempted model will relate to the underlying biology and will fit existing 
data as well as predict the outcome of future experiments. In this chapter the 
model is produced then minimised into a simpler form and  successfully fitted to 
OGTT (Oral Glucose Tolerance Test), IVGTT (Intra-Venous Glucose Tolerance 
Test) and hyperglycaemic clamp data. Sensitivity analysis is also performed on 
the model.  
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8.1 Introduction 
This chapter develops a model for the regulation of glucose and insulin kinetics 
for short time-scales. It looks into the importance of a well-validated and robust 
model for short-term kinetics. 
8.1.1 Purpose of the modelling 
This short term modelling work is designed to achieve the following: 
 To derive a mechanistically appropriate mathematical model of short-term 
glucose and insulin kinetics, generically applicable across experimental 
protocols. 
 To perform parameter fits to experimental data to parameterise key aspects 
of the system. 
o The aim of this is to see the effect of external influences (such as 
drugs or disease) on the glucose-insulin system. 
 To allow potential experimental outcomes to be predicted. 
o For example, knowing that a drug has an effect on a particular model 
parameter, it is possible to see the effect of perturbing that 
parameter on the system before the experiment is done (i.e. to assess 
parameter sensitivity). 
 To test a new potential experiment to see the expected output and aiding 
experimental design. 
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o For example, by selecting appropriate time points for sampling and 
measurement of glucose and insulin and experiment duration for 
robust and accurate parameter estimation. 
8.1.2 Requirements of the model 
In order to create a model which improves upon existing models and create a 
unique new model, this model will aim to meet a list of desirable features: 
 The model should be universal, rather than designed for use with a 
specific test or for particular situations. 
o This will mean that the model is closer (mechanistically) to the 
underlying physical process it is trying to mimic. 
 The model does not have explicit parameters for steady state conditions 
(glucose and insulin basal levels are not “fixed” by a parameter). 
o This is to provide physiological reasons to explain why glucose and 
insulin basal levels may change, for example due to insulin 
sensitivity. 
 The model should be stable, robust and provide realistic model outputs. 
o This includes returning to a valid steady state at the end of the 
experiment and producing only outputs which are physiologically 
possible. 
 The model should be minimal in mathematical form and structure whilst 
incorporating all necessary components. 
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8.2 Model Minimisation 
The Minimal Model was introduced in Chapter 6. The concept behind the 
Minimal Model was that it was the simplest model that could adequately explain 
the experimental data[113]. The Minimal Model was designed by taking a set of 
possible candidate models and seeing which model fitted the data best, and 
produced a simple model with a good fit to the available experimental data, but 
which was not mechanistically valid and therefore would not necessarily 
adequately describe new experimental data. The model is therefore not 
necessarily applicable to experiments other than those used for the original 
modelling. 
Although this approach led to a model which was not mechanistically valid, it is 
desirable to have a model which is structurally minimal because this ensures that 
all parameters in the model are mathematically meaningful. This means that, 
when a parameter fit is performed, there will be a finite set of parameter values 
which will be at least mathematically valid and meaningful, even if they are not 
physiologically meaningful. Structural identifiability, described in Chapter 2, is a 
useful test for the meaningfulness of parameter values. 
The challenge is therefore to create a model that has sufficient dynamics that it 
can reflect a large range of scenarios and situations, but which is still as minimal 
as possible in structure. 
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8.3 Model Concept 
As mentioned above, it is important to keep the model minimal yet to be 
sufficiently dynamic to adequately explain the data and to be physiologically 
relevant in order for it to work under many practical situations. 
Humans have defined very fine levels of system control for systems like chemical 
plants. The human body requires a very fine level of control over the glucose-
insulin system, as described in Chapter 3. It is therefore logical to assume that 
the methods humans have created for obtaining fine levels of control of physical 
and engineering processes may be similar to those methods that have evolved in 
the human body. One specific type of controller produces outputs very similar to 
those of the pancreas, namely a PID (Proportional-Integral-Derivative) controller 
[12], see Figure 8.1. 
 
Figure 8.1: PID (Proportional-Integral-Derivative) controller 
Each part of this controller can be explained as follows: 
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8.3.1.1 Proportional: 
 In mathematical terms, this means that for every unit of plasma glucose, 
a fixed amount of insulin is released by the pancreas. 
 This element of the controller simulates the secretion of insulin in basal 
conditions. The proportional aspect maintains a basal level of glucose in 
the system and a basal level of insulin to match it. 
 In biological terms, this means that glucose enters the β-cells which, via 
glycolysis and oxidative phosphorylation, increases the level of ATP 
shown by [62]. In the proportional controller analogy, the ATP 
predominantly promotes granules of pro-insulin towards the membrane 
as described in Chapter 3. 
8.3.1.2 Integral: 
 In mathematical terms, this is the area under the curve (AUC) of the 
glucose concentration. 
 This element simulates the second phase insulin response: the shoulder 
of insulin observed after an IVGTT[42]. 
 In biological terms, this is similar to the proportional control and means 
that an accumulation of glucose causes the β-cells to secrete an 
additional quantity of insulin, possibly from the readily releasable pool in 
β-cells [65]. This represents the amount of insulin required to remove the 
glucose after a meal, sugar intake or clinical challenge. 
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8.3.1.3 Derivative: 
 In mathematical terms, this is the rate of change of glucose level. 
 This element represents the first phase insulin response: the relatively 
high amount of insulin that is seen initially in experiments such as IVGTT. 
 In biological terms, this could mean that the docked insulin granules on 
the cell membrane are predominantly released in a rapid response to a 
large increase in the amount of glucose present. It gives a measured 
response to sudden, large changes in concentration of glucose but has 
little effect when levels rise slowly [42, 66]. 
8.4 Model Structure and Equations 
The model presented here is a three-state compartmental model. A 
diagrammatic representation is shown in Figure 8.2. 
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Figure 8.2: Schematic diagram of the PID model of the glucose and insulin system. 
The model equations are as follows: 
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The model states and parameters are explained in Table 8.1 below. 
Parameter Description Units 
gr Glucose effectiveness min
−1 
gp Glucose production rate mmol l
−1 min−1 
ksi Insulin sensitivity, insulin-dependent glucose 
removal 
ml ng−1 
kp Proportional parameter for PID model μg mmol
−1 min−1 
ki Integral parameter for PID model μg mmol
−1 min−2 
kd Differential parameter for PID model μg mmol
−1 
kir Insulin clearance min
−1 
kiir Integral clearance rate, to simulate integral 
function 
min−1 
kiar Insulin action increase rate, to delay insulin 
action 
min−1 
G(t) Glucose concentration mmol l−1 
I(t) Insulin concentration μg l−1 
Ia(t) Insulin action mmol l
−1 min 
Ii(t) Insulin integral/delay μg l
−1 min 
Table 8.1: Model State Variables and Parameter Descriptions 
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8.4.1 Insulin Secretion 
The basal levels of glucose and insulin are not fixed points in the biological 
mechanism. Instead, they are determined by the effect they have on each other 
in their steady states. The β-cell Mass Model by Topp, et al. has been developed 
in this way [119]; the basal levels of each are not defined, but are determined by 
the combination of parameters used. The model shows what can happen in the 
system if a reduction of insulin sensitivity occurs over a period of days or months. 
This is a central point for model design as it is vital in ensuring that the 
parameters have relevance to the underlying biology. A classic PID controller 
could be related to a biological system by considering the set point as the basal 
glucose level and the error signal as the basal level minus the current level. 
Although having a set point for basal levels of glucose would produce similar 
results, it would not be a mechanistic representation of the underlying biology. 
In reality, this is not quite a valid analogy as a biological system does not have a 
defined set point, so the challenge is to design a model with similar terms to 
those present in a PID Controller, but without a set point. 
The terms in the PID controller relate to the biological process as follows: 
Proportional:  kp G(t) 
This term simply creates the basal level under static conditions. 
The proportional secretion rate is produced by taking the level present in the 
glucose compartment, shown in Figure 8.2. 
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Integral: ki Ii(t) 
This is non-trivial as the area under the glucose curve will increase over time, 
causing the system to become unstable. Hence the integral function must decay 
over time. 
It is created by taking the concentration in the glucose compartment as the rate 
of change of a virtual compartment Ii(t), as shown in equation 8.1.  
Derivative:   
     
  
  
This is a rate of change, so the absolute value of the glucose does not matter. 
This is simply taken as the rate of change of glucose, and is incorporated in 
equation 8.2. 
8.4.2 Delayed and Sustained Insulin Action 
As is evident from IVGTT experiments, a large initial amount of insulin action has 
little effect on the initial decrease of glucose. This can be explained in a number 
of ways, for example it may take the insulin time to bind to the receptor site 
[154]. 
Alternatively, consider a euglycaemic clamp experiment, where glucose is 
clamped by measuring the basal glucose level then infusing insulin at a constant 
rate and glucose at a variable, measured rate until the measured glucose level in 
the patient once more reaches a steady-state at the basal level, or in the case of 
a hyperglycaemic clamp, the set point. These experiments show a long delay 
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before insulin has affected the glucose level.  It is therefore necessary to take 
into account the delay in insulin action and the fact that the insulin level must be 
sustained for a period of time before having an effect. Using a previously well-
validated delay in [111] and [125], the insulin action compartment Ia(t) for this 
model will be the same as the interstitial compartment in the Minimal Model 
and is incorporated in equation 8.3 
8.4.3 Net Difference in Glucose 
The glucose compartment has a number of inputs and a number of outputs. The 
relative rates of supply and disposal of glucose in this compartment determine 
the basal level. This is modelled in a clear manner in the β-cell Mass Model [119]. 
It has an appearance rate that is made up of all unknown appearance rates and 
all the disposal rates that can be calculated. The appearance rate cannot be 
established without tracer experiments [154], however as appearance rate is 
related to the amount of glucose present, obtaining an absolute value is 
unimportant. 
Insulin has an effect on both the production rate of glucose and its disposal rate. 
However it is impossible to distinguish and quantify the effect on each when only 
peripheral glucose and insulin concentrations are measured as the end result, in 
terms of peripheral glucose concentration, is the same. 
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8.5 Model Analysis 
8.5.1 Structural Identifiability 
The problem with using a simplistic model, such as a 2-compartment model, is 
that it does not capture all the dynamics of the system - such as the variable 
insulin dynamics created by rapid changes in glucose [155] - and hence is not an 
accurate representation of the true physical process. On the other hand, a 
systems biology model would require a larger number of parameters which may 
allow different combinations of values to produce the same system output. In 
certain cases a variety of different parameter combinations could be used to fit 
the same data, making it impossible to tell which was actually correct. This would 
also make it impossible to validate the model especially with regards to 
determining a drugs mechanism of action and therefore render it practically 
useless. The solution is to create a model which is a balance between these two 
approaches, by using not only parameters that can be uniquely identified, but 
also incorporating a mechanistic structure that adequately describes the physical 
process and dynamics that are observed. This creates a need for a test on the 
postulated model to ensure that all parameters can be uniquely identified. 
Such a test exists in the form of structural identifiability analysis, see Chapter 2. A 
system is said to be structurally globally identifiable if, with infinite, noise-free 
observations, there is only one possible set of parameters that can produce the 
output. Although real data will be neither infinite nor noise-free, structural 
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identifiability in this form is a theoretical step on the way to approaching 
numerical identifiability or parameter estimation with greater confidence. 
8.5.2 Structural Identifiability Analysis of the Postulated Model 
Glucose and insulin measurements can be taken for this model. The insulin 
integral compartment is just a representation of an integral function. The model 
can be treated as an uncontrolled non-linear system. All the model parameters, 
(equations: 8.5 - 8.9 below) including initial conditions, were considered 
unknown. The system equations are given by: 
      
  
             
     
  
                  
     
  
      
      
  
             
     
  
                      
                                     
8.5 
8.6 
8.7 
8.8 
8.9 
There are various techniques for performing structural identifiability analysis 
[19]. The Lie-symmetry approach by Yates et al. [15], also described in Chapter 2, 
has been applied to the model introduced here as other techniques such as the 
Taylor series approach could not yield a solution due to the computational 
complexity of solving the parameters from the Taylor coefficients. The analysis is 
presented in Appendix 4 and was performed using Mathematica 7 [3]. 
Mathematica was selected for the analysis as it is excellent for complex symbolic 
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manipulation and performing the analysis by hand would be highly time-
consuming and error-prone, even for the relatively low state-space dimension of 
this model. 
System Observability is a prerequisite for the Lie-symmetry technique, so the 
Observability Rank Criterion (see Chapter 2) was applied to the model (see 
Appendix 4) with individual observations of G(t) and I(t), which showed it to be 
observable. 
Application of this approach concluded that the model is at least locally 
identifiable (as global identifiability cannot be established with the Lie-symmetry 
approach) when two specific parameters were known a priori: gp which 
represents glucose production, and kp, the proportional insulin secretion 
parameter. 
This leads to issues with the following parameters: 
gp - This represents the amount of glucose entering the system, which is typically 
unknown. It can be estimated, for example from a tracer experiment, as the 
clearance is fractional so an exact value is not necessary. The value used here is 
taken from [119]. 
kp - The proportional insulin secretion parameter is more difficult to estimate. 
However assuming that the integral component is negligible at steady state a 
rough estimate for kp can be obtained using the known insulin clearance in 
equation 8.10, which has been derived from the steady state. 
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8.10 
8.5.3 Steady States 
As mentioned in the previous section, unlike some previous models this system 
does not have steady states dependent on parameters such as glucose and 
insulin basal levels. The system should tend to steady states based on the system 
parameters and the feedback components present. 
At steady state, nothing is changing hence the derivative term,   
     
  
, is zero. 
With a classic PID controller, there is an error signal entering the controller; 
however this is not the case with this system as there is no “set point" to derive 
an error signal from. The integral control is therefore required to introduce 
decay. This makes the calculations slightly complex as the steady state for this 
parameter is non-zero. 
From the system equations (equations 8.1 to 8.4) the steady states can be 
calculated algebraically, for example from equation 8.1 we have: 
  
     
   
    
 
8.11 
Adding in the proportional control, the steady state for insulin becomes: 
  
    
            
   
 
8.12 
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From equation 8.3  the steady state for insulin action is given by: 
  
     
   
    
 
8.13 
and the resulting steady state for glucose is given by: 
      
  
          
 8.14 
8.5.4 Parameter Estimation & Simulations 
Parameter estimation was performed on IVGTT data from the data set 
(AliceIVGTT) as well as clamp data from (RuthClamp), both in Chapter 4, and 
human data from Bergman et al. in Chapter 6. The model was fitted using a PKPD 
tool developed in acslX [31] by James Yates and colleagues [15], which performs 
simulation and parameter fitting using a standardised modelling language and 
data input format. Outputs from this tool are shown in  Table 8.2, Figure 8.3, 
Figure 8.4 and Figure 8.5. The Quasi-Newton approach was selected for its 
optimisation algorithm and Gear’s stiff for its ODE solver Chapter 2. 
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Figure 8.3: PID model insulin and glucose parameter fit on human IVGTT 
 
Figure 8.4: PID model insulin and glucose parameter fit on rat hyperglycaemic clamp 
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Figure 8.5: PID model insulin and glucose parameter fit on rat IVGTT 
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Parameter 
Human 
IVGTT 
Han Wistar 
IVGTT 
Han Wistar 
Hyperglycaem
ic Clamp 
Units 
gr 0.00159 0.0438 0.0413 min
−1 
gp  [119] 0.033 0.033 0.033 mmol l
−1 min−1 
ksi 0.00231 0.00105 0.00107 ml ng
−1 
kp (Equation 
8.10) 
0.0275 0.009274 0.00896 μg mmol−1 min−1 
ki 0.00000158 0.000872 0.000256 μg mmol
−1 min−2 
kd 0.268 0.450 0.455 μg mmol
−1 
kir 0.169 0.351 0.118 min
−1 
kiir 1.38E-19 1.38E-19 1.38E-19 min
−1 
kiar 0.114 0.0296 0.258 min
−1 
G0 5.11 5.8 6.7 mmol l
−1 
I0 0.379 0.879 0.348 μg l
−1 
Ia0 0 0 0 mmol l
−1 min 
Ii0 0 0 0 μg l
−1 min 
Table 8.2: PID model parameter fit results 
The parameter kd is not well determined with respect to the hyperglycaemic 
clamp experiment, which could be due to the lack of data at the start of the 
clamp. According to the acslX tool, which automatically calculates confidence 
values for parameter estimates as described in Chapter 2 and  [21], all other 
parameter estimates, shown in Table 8.2 are within 20% with 95% confidence. 
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8.5.5 Discussion 
This model can produce a useful tool as it splits insulin secretion down to four 
parameters from the PID controller (kp, ki, kd and kir). However the structural 
identifiability analysis shows that there are two unidentifiable parameters which 
had to be fixed from previously known data or steady-state conditions, meaning 
there is scope for improvement in the model if these could be removed. 
As mentioned in Chapter 7, insulin clearance is affected by fed and fasted 
conditions and this is not taken into account in this model. Therefore, it would be 
useful to incorporate C-peptide kinetics into the model. 
OGTTs were not addressed here; as this model attempts to be universal, it 
should be open to many different experimental scenarios so it would also be 
useful to test it against OGTT data. As other refinements to the model were 
identified at this stage, it was decided that these should be made before the 
model was validated with OGTT data. 
8.6 Refinements 
No model designed is a perfect representation of the original system, and 
therefore modelling is an iterative process. The model described above was not 
globally structurally identifiable; this was solved by fixing one parameter to 
steady state and another to known physiological values. However, under the 
definition of structural identifiability, these parameters or a combination of 
parameters could have an infinite number of possible values and would 
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therefore be meaningless. This is therefore a good point to consider whether 
these parameters are necessary for the model to be meaningful physiologically. 
Consider first gr, the parameter representing glucose effectiveness, which is the 
amount of glucose removed from the system independent of insulin in a resting 
state. Looking back at Chapter 3, we think about where this can actually occur. 
GLUT1 and GLUT2 will do this uptake, however uptake will be low and possibly 
also linear, therefore it can be seen that this would not appear in the model as gp 
is the net glucose input to the system from the body. GLUT2 is a possible place 
for this uptake to occur; it appears in the pancreas and transports in small 
amounts of glucose for glucose sensing. However it is also expressed in large 
amounts to the liver and is the main input of glucose to the liver. This would be 
the obvious place where glucose effectiveness exists. However the glucose 
uptake in the liver is processed by an insulin-dependent pathway: glycogenesis. It 
may therefore be possible to say that there is no actual glucose effectiveness at 
rest.  Structural identifiability tells us that we cannot work out the difference 
between glucose effectiveness and other parameters; therefore it can be 
considered a redundant parameter. 
In a normal PID controller there is a set-point: the value to which a system seeks 
to return. It is therefore important that the controller always contains a term 
pushing it in the right direction. However in this model, no set-point exists but a 
constant level of insulin from the controller/pancreas must be maintained. 
Glucose is maintained above zero, therefore the integral term of the PID 
Chapter 8: Short Term Modelling 
177 
controller maintains a secretion of insulin. This comes out in the 
reparameterisation of the kp parameter    
        
      
 as it ends up as a fraction of 
the integral parameter. Again, the structural identifiability shows that the 
parameters will have an infinite set of possible values if kp or ki is left in; ki shows 
useful second-phase responses to the glucose stimulus therefore kp can be 
removed from the model. This makes the model simpler and more minimal and, 
as shown below, more robust. 
This reduces the model equations as follows: 
        
  
             
      
  
             
     
  
           
     
  
      
     
  
                       
8.15 
 
The parameters are explained in Table 8.3 below. 
Parameter Description Units 
gp Glucose production rate mmol l
−1 min−1 
ksi Insulin sensitivity, insulin-dependent glucose 
removal 
ml ng−1 
ki Integral parameter for PID model μg mmol
−1 min−2 
kd Differential parameter for PID model μg mmol
−1 
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Parameter Description Units 
kir Insulin clearance min
−1 
kiir Integral clearance rate, to simulate integral 
function 
min−1 
kiar Insulin action increase rate, to delay insulin 
action 
min−1 
F Input Gain (Bioavailability and Volume of 
Distribution) 
ml-1 
Table 8.3: Refined model parameter descriptions 
8.7 Simulation and Parameter Fitting 
As this model is meant to help biologists analyse the data they produce and 
predict future experimental outcomes, it is necessary for the model to be in a 
form where they can access and understand it easily. Therefore, a software tool 
was developed to do this. This will be discussed in greater depth in Chapter 10. 
This tool was used to model the following data sets: (AliceIVGTT), 
(GeorgiaIVGTT), (RuthClamp), (AmieIVGTT) and (StevenOGTT) (see Chapter 4). 
The algorithms and methods used are detailed in Chapter 10. 
8.8 Model Results 
Figure 8.6 to Figure 8.8 and Table 8.4 to Table 8.8 are the parameter fits for 
(AliceIVGTT), (GeorgiaIVGTT) and (AmieIVGTT). 
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8.8.1 IVGTT Results 
 
Figure 8.6: IVGTT parameter fit of a single subject 
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Figure 8.7: IVGTT parameter fit of glucose for all subjects 
 
Figure 8.8: IVGTT parameter fit of insulin for all subjects 
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Data-
base 
ID 
Subject 
Ref 
kd 
(μg mmol
−1
) 
ksi  
(ml ng
−1
) 
ki 
(μg mmol
−1
  
min
−2
) 
kiir 
(min
−1
) 
kir 
(min
−1
) 
kiar 
(min
−1
) 
gp 
(mmol 
l
−1
 min
−1
) 
F 
(ml
-1
) 
Residual 
62 9 0.829  
± 0.0676 
0.0416  
± 0.0808 
1.07  
± 0.0289 
12.1  
± 0.000685 
0.334  
± 0.00543 
2.39  
± 0.0911 
0.000197  
± 5.68 
0.0283  
± 0.0533 
0.065 
63 18 0.802  
± 0.0715 
0.00962  
± 0.141 
0.237  
± 1.05 
4.29  
± 1.06 
0.463  
± 0.0692 
0.311  
± 0.132 
0.000127  
± 3.91 
0.0262  
± 0.0417 
0.0283 
64 23 1.46  
± 0.132 
0.0339  
± 0.138 
1.75  
± 0.18 
7.21  
± 0.00749 
0.75  
± 0.16 
3.15  
± 0.0783 
0.0002  
± 0.000186 
0.0174  
± 0.0777 
0.0744 
65 26 1.28  
± 0.1 
0.049  
± 0.639 
1.28  
± 0.232 
9.31  
± 0.224 
0.557  
± 0.00158 
3.44  
± 0.588 
0.0002  
± 4.06 
0.0264  
± 0.0818 
0.0422 
66 35 1.56  
± 0.0665 
0.0358  
± 0.668 
0.886  
± 1.66 
14.5  
± 1.66 
0.294  
± 0.0403 
3.38  
± 0.643 
0.000215  
± 5.69 
0.0323  
± 0.0474 
0.0546 
67 42 0.492  
± 0.06 
0.0721  
± 0.489 
0.519  
± 0.638 
23.8  
± 0.628 
0.256  
± 0.0408 
2.06  
± 0.467 
0.000201  
± 5.32 
0.0353  
± 0.045 
0.0674 
68 49 1.31  
± 0.0397 
0.0231  
± 0.000332 
0.582  
± 2.75 
8.04  
± 2.74 
0.357  
± 0.00019 
1.76  
± 0.00882 
0.000228  
± 3.51 
0.0283  
± 0.032 
0.0702 
69 57 0.611  
± 0.0451 
0.0291  
± 0.352 
0.448  
± 0.527 
18  
± 0.534 
0.258  
± 0.0369 
1.1  
± 0.333 
0.000103  
± 3.34 
0.0342  
± 0.0355 
0.0501 
70 45 0.608  
± 0.157 
0.00934  
± 1.77 
0.13  
± 1.78 
3.6  
± 1.81 
0.142  
± 0.0974 
1.04  
± 1.73 
0.000244  
± 3.71 
0.0221  
± 0.13 
0.063 
71 46 0.509  
± 0.023 
0.00317  
± 0.163 
8.73  
± 3.4 
89.6  
± 3.09 
0.295  
± 0.424 
0.238  
± 0.249 
0.0802  
± 0.267 
0.0209  
± 0.0313 
0.0435 
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Data-
base 
ID 
Subject 
Ref 
kd 
(μg mmol
−1
) 
ksi  
(ml ng
−1
) 
ki 
(μg mmol
−1
  
min
−2
) 
kiir 
(min
−1
) 
kir 
(min
−1
) 
kiar 
(min
−1
) 
gp 
(mmol 
l
−1
 min
−1
) 
F 
(ml
-1
) 
Residual 
72 50 0.518  
± 0.0738 
0.00642  
± 0.276 
2.15  
± 4.81 
64.2  
± 4.82 
0.163  
± 0.0676 
0.482  
± 0.268 
0.000202  
± 4.37 
0.0206  
± 0.0542 
0.0489 
73 53 0.506  
± 0.0561 
0.00546  
± 0.235 
0.77  
± 0.0422 
26  
± 0.0492 
0.181  
± 0.049 
0.403  
± 0.232 
0.000599  
± 2.28 
0.0218  
± 0.0406 
0.0256 
74 54 1.66  
± 0.151 
0.0144  
± 0.616 
3.78  
± 4.97 
48.4  
± 4.97 
0.651  
± 0.0953 
0.922  
± 0.574 
0.000185  
± 5.71 
0.00481  
± 0.108 
0.0738 
75 55 7.76  
± 0.00413 
0.00345  
± 0.217 
0.0471  
± 0.117 
0.411  
± 0.171 
0.698  
± 0.0371 
0.26  
± 0.455 
0.16  
± 0.3 
0.00205  
± 0.041 
0.0687 
76 14 1.8  
± 1.71E+20 
0.0227  
± 0.242 
1.11  
± 0.995 
10.6  
± 0.0222 
0.413  
± 0.959 
8.2  
± 0.108 
0.000193  
± 7.75E-8 
0.024  
± 6.39E+20 
0.0338 
77 30 1.84  
± 0.0117 
7.46E-18  
± 18900000 
0.52  
± 0.0138 
23.6  
± 0.0125 
0.0935  
± 0.0224 
245E+16  
± 0.279 
0.000277  
± 0.0788 
0.024  
± 1790000 
0.03 
78 31 1.8  
± 23E+10 
0.0155  
± 0.0298 
1.34  
± 8.43 
8.95  
± 0.33 
0.636  
± 8.07 
11.7  
± 1.29 
0.000201  
± 0.0941 
0.024  
± 859E+10 
0.0143 
79 43 1.8  
± 142E+10 
0.051  
± 0.8 
0.778  
± 0.134 
15.2  
± 0.0897 
0.813  
± 0.000265 
3.66  
± 0.461 
0.000197  
± 0.00161 
0.024  
± 528E+10 
0.0866 
Table 8.4: IVGTT Four hour fasted 
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Data-
base 
ID 
Subject 
Ref 
kd 
(μg mmol
−1
) 
ksi 
(ml ng
−1
) 
ki 
(μg mmol
−1
  
min
−2
) 
kiir 
(min
−1
) 
kir 
(min
−1
) 
kiar 
(min
−1
) 
gp 
(mmol 
l
−1
 min
−1
) 
F 
(ml
-1
) 
Residual 
12 2.6 0.51  
± 0.0788 
0.0338  
± 1.8 
1.94  
± 0.467 
6.31  
± 0.00672 
0.595  
± 0.449 
5.41  
± 1.79 
0.0002  
± 0.0312 
0.0187  
± 0.0308 
0.0211 
13 2.8 1.63  
± 0.0428 
0.029  
± 0.0396 
1.58  
± 0.0848 
7.7  
± 0.0235 
0.289  
± 0.0927 
6.03  
± 0.0382 
0.000202  
± 2.66 
0.023  
± 0.0312 
0.0161 
14 3.13 0.0000000378  
± 0.163 
0.0546  
± 0.00952 
2190000000  
± 0.0157 
412  
± 0.0333 
15400000  
± 0.0211 
5.96  
± 0.00469 
0.000209  
± 0.112 
0.0196  
± 0.013 
0.024 
Table 8.5: IVGTT eight hour fasted 
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Data-
base 
ID 
Subject 
Ref 
kd 
(μg mmol
−1
) 
ksi 
(ml ng
−1
) 
ki 
(μg mmol
−1
  
min
−2
) 
kiir 
(min
−1
) 
kir 
(min
−1
) 
kiar 
(min
−1
) 
gp 
(mmol 
l
−1
 min
−1
) 
F 
(ml
-1
) Residual 
1 1.1 1.89  
± 0.0803 
0.026  
± 9.17 
1.95  
± 1.65 
6.13  
± 1.64 
0.326  
± 0.205 
7.01  
± 9.09 
0.0002  
± 8.68 
0.0241  
± 0.111 
0.028 
2 2.7 2.46  
± 0.000708 
0.0208  
± 0.0269 
2.54  
± 0.00735 
5.35  
± 0.017 
0.479  
± 0.00382 
7.99  
± 0.0159 
0.000201  
± 4.04 
0.022  
± 0.0222 
0.0119 
3 2.1 1.61  
± 0.0737 
0.021  
± 1.11 
1.28  
± 5.66 
9.22  
± 5.7 
0.208  
± 0.111 
5.09  
± 1.09 
0.000206  
± 4.28 
0.0205  
± 0.0367 
0.0161 
4 1.2 3.94  
± 0.0404 
0.0155  
± 0.0442 
3.69  
± 0.000805 
6.01  
± 0.00673 
1.05  
± 0.00104 
3.3  
± 0.0125 
0.000209  
± 0.0000514 
0.0195  
± 0.0272 
0.00886 
5 1.5 4.06  
± 0.155 
0.0228  
± 1.49 
3.37  
± 3.22 
4.16  
± 3.2 
0.879  
± 0.102 
5.44  
± 1.47 
0.000193  
± 5.61 
0.0291  
± 0.0158 
0.0191 
6 2.9 3.15  
± 0.0757 
0.025  
± 0.0879 
2.58  
± 0.0993 
3.7  
± 0.0296 
0.877  
± 0.11 
5.17  
± 0.0769 
0.000212  
± 3.9 
0.0241  
± 0.0331 
0.0109 
7 2.11 3.95  
± 0.0733 
0.0267  
± 1.19 
2.28  
± 0.835 
5.19  
± 0.834 
0.622  
± 0.0789 
6.06  
± 1.17 
0.000201  
± 3.55 
0.0287  
± 0.0339 
0.0255 
22 3 0.562  
± 0.0989 
0.037  
± 1.67 
1.17  
± 5.25 
9.52  
± 5.46 
0.235  
± 0.227 
4.72  
± 1.66 
0.000201  
± 6.1 
0.025  
± 0.0322 
0.00133 
26 8 1.18  
± 0.0687 
0.0236  
± 3.18 
0.679  
± 4.25 
22.9  
± 4.17 
0.071  
± 0.3 
7.68  
± 3.17 
0.000203  
± 3.74 
0.029  
± 0.0505 
0.0238 
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Data-
base 
ID 
Subject 
Ref 
kd 
(μg mmol
−1
) 
ksi 
(ml ng
−1
) 
ki 
(μg mmol
−1
  
min
−2
) 
kiir 
(min
−1
) 
kir 
(min
−1
) 
kiar 
(min
−1
) 
gp 
(mmol 
l
−1
 min
−1
) 
F 
(ml
-1
) Residual 
28 9 0.583  
± 0.0174 
0.0262  
± 0.00786 
0.61  
± 0.0451 
22  
± 0.13 
0.0517  
± 0.0538 
8.9  
± 0.0184 
0.000213  
± 2.69 
0.0226  
± 0.0103 
0.00262 
30 11 1.73  
± 0.0451 
0.0202  
± 4.17 
0.0609  
± 55.1 
229  
± 55.1 
0.0158  
± 0.0547 
8.86  
± 4.16 
0.000202  
± 5.14 
0.0218  
± 0.0439 
0.00884 
Table 8.6: IVGTT fed 
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Data-
base 
ID 
Subject 
Ref 
kd 
(μg mmol
−1
) 
ksi 
(ml ng
−1
) 
ki 
(μg mmol
−1
  
min
−2
) 
kiir 
(min
−1
) 
kir 
(min
−1
) 
kiar 
(min
−1
) 
gp 
(mmol 
l
−1
 min
−1
) 
F 
(ml
-1
) Residual 
15 SS1 1.8  
± 1.09E+10 
0.00886  
± 0.446 
1.57  
± 0.395 
7.65  
± 0.00374 
0.411  
± 0.395 
20.6  
± 0.287 
0.000201  
± 0.000365 
0.024  
± 4.08E+10 
0.0182 
16 SS2 1.8  
± 16.2 
9.44E-10  
± 23200 
1.58  
± 5.03 
7.65  
± 0.0964 
0.406  
± 5.03 
193000000  
± 23600 
0.000234  
± 0.265 
0.024  
± 1240 
0.014 
Table 8.7: IVGTT saline infused, saline bolus 
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Data-
base 
ID 
Subject 
Ref 
kd 
(μg mmol
−1
) 
ksi 
(ml ng
−1
) 
ki 
(μg mmol
−1
  
min
−2
) 
kiir 
(min
−1
) 
kir 
(min
−1
) 
kiar 
(min
−1
) 
gp 
(mmol 
l
−1
 min
−1
) 
F 
(ml
-1
) Residual 
8 1.3 92.1  
± 0.0159 
0.017  
± 0.359 
16.5  
± 0.25 
3.08  
± 0.249 
9.17  
± 0.00137 
3.72  
± 0.328 
0.00022  
± 3.17 
0.0399  
± 0.00385 
0.0292 
9 1.4 1.25  
± 1.8 
0.0248  
± 99.4 
2.68  
± 0.489 
6.16  
± 2.54 
0.729  
± 1.41 
4.16  
± 98.4 
0.000335  
± 2.07 
0.017  
± 1.18 
0.0297 
10 2.12 0.945  
± 0.127 
0.0476  
± 0.115 
2.56  
± 0.000339 
5.03  
± 0.0676 
1.45  
± 0.0376 
3.84  
± 0.0508 
0.000204  
± 3.28 
0.0178  
± 0.0446 
0.0563 
11 3.14 0.235  
± 0.0883 
0.0489  
± 0.083 
1.85  
± 0.476 
9.92  
± 0.00682 
0.638  
± 0.477 
3.94  
± 0.0378 
0.000214  
± 3.16 
0.0262  
± 0.0287 
0.0295 
Table 8.8: IVGTT overnight fasted
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8.8.2 Discussion of IVGTT 
The main differences are between the eight hour fasted and the other groups, 
especially  the four hour fasted and fed. There are statistically significant 
differences (p<0.05)  between: 
 the eight hour fasted and the four hour fasted in ki, kiir and kir 
 and the eight hour and fed animals in ksi, ki and kir. 
These points are extremely interesting and show that there is a change in the 
insulin system due to changes in the fasting states. Changes in the insulin 
sensitivity (ksi) could be down to changes in lipid levels. High levels of lipids have 
been known to cause decreases in insulin sensitivity because they have an 
inhibitory effect on glucose uptake (see section 3.5). For changes of insulin 
sensitivity over time, see Chapter 8. Lipid levels were not measured in this 
experiment. Changes in insulin parameters could be due to blood flow changes 
(Chapter 7). 
Parameters that have got a good fit are kd, ki, kiir and kir. This means that the 
combination of this model and this test can produce an accurate measure for the 
first and second phases of insulin secretion. ksi and kiar have low confidences 
suggesting that measuring insulin sensitivity in this combination is not reliable. 
This is expected as glucose clearance may be saturated. F and gp also show low 
confidence. This may be due to an ambiguity in the system about where  the 
glucose is entering the system.  
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Subjects 15 and 16 have many parameters with very low confidences. This is 
expected as the system has not been challenged with an IVGTT. From the data, 
subjects 76 and 77 appear to have responded incorrectly to the glucose stimulus. 
This may be due to the glucose not entering the system correctly so the subjects 
appear similar to subjects 15 and 16 and, therefore, have low parameter 
confidences. 
8.8.3 Hyperglycaemic Clamp Results 
Table 8.9  to Table 8.11 and Figure 8.9 to Figure 8.11 are parameter fits using 
(RuthClamp) in Chapter 4. 
 
Figure 8.9: Hyperglycaemic clamp parameter fit of a single subject 
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Figure 8.10: Hyperglycaemic clamp parameter fit of glucose for all subjects 
 
Figure 8.11: Hyperglycaemic clamp parameter fit of insulin for all subjects
Chapter 8: Short Term Modelling 
191 
Data-
base 
ID 
Subject 
Ref 
kd 
(μg mmol
−1
) 
ksi 
(ml ng
−1
) 
ki 
(μg mmol
−1
  
min
−2
) 
kiir 
(min
−1
) 
kir 
(min
−1
) 
kiar 
(min
−1
) 
gp 
(mmol 
l
−1
 min
−1
) 
F 
(ml
-1
) 
Residual 
48 3 0.618  
± 0.349 
0.0257  
± 0.212 
2.42  
± 0.0257 
4.77  
± 0.00176 
0.159  
± 0.0471 
7.36  
± 0.115 
0.000198  
± 0.000051 
0.0043  
± 0.0729 
0.0771 
49 1 4.26  
± 0.101 
0.0326  
± 3 
0.461  
± 2.59 
45.3  
± 2.59 
1.04E-07 
± 17.5 
7.29  
± 3.01 
0.000209  
± 1.17 
0.00538  
± 0.0178 
0.0271 
50 2 4.09  
± 0.0489 
0.0381  
± 0.0983 
1.21  
± 0.00899 
7.56  
± 0.00608 
0.077  
± 0.0202 
4.37  
± 0.0446 
0.000224  
± 0.00225 
0.00724  
± 0.0491 
0.0232 
52 4 0.406  
± 0.471 
0.0381  
± 0.0531 
4.42  
± 0.0517 
4.45  
± 0.00315 
0.311  
± 0.0409 
4.51  
± 0.0244 
0.000223  
± 0.908 
0.00675  
± 0.0266 
0.0459 
53 5 1.41  
± 0.326 
0.0307  
± 0.0919 
4.41  
± 0.00288 
4.21  
± 4.56E-05 
0.217  
± 0.000297 
5.16  
± 0.0442 
0.000213  
± 1.78 
0.00672  
± 0.0427 
0.101 
54 6 1.76  
± 0.00332 
0.029  
± 0.0391 
0.945  
± 0.162 
38.8  
± 0.12 
0.0045  
± 0.0609 
5.78  
± 0.0312 
0.000371  
± 1.28 
0.00489  
± 0.0188 
0.0209 
55 7 1.22  
± 0.273 
0.0253  
± 0.000268 
2.76  
± 6.95E-05 
4.44  
± 0.0016 
0.143  
± 3.72E-05 
7.48  
± 5.39E-05 
0.0002  
± 0.000353 
0.00518  
± 0.024 
0.137 
Table 8.9: Hyperglycaemic clamp four hour fasted 
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Data-
base 
ID 
Subject 
Ref 
kd 
(μg mmol
−1
) 
ksi 
(ml ng
−1
) 
ki 
(μg mmol
−1 
 min
−2
) 
kiir 
(min
−1
) 
kir 
(min
−1
) 
kiar 
(min
−1
) 
gp 
(mmol 
l
−1
 min
−1
) 
F 
(ml
-1
) 
Residual 
42 14 
 
1.26  
± 0.118 
0.0337  
± 2.18 
2.77  
± 1.74 
4.41  
± 1.91 
0.327  
± 0.688 
5.43  
± 2.18 
0.000198  
± 1.3 
0.0028  
± 0.102 
0.376 
43 15 1.48  
± 0.102 
0.0459  
± 0.995 
2.49  
± 0.0612 
4.84  
± 0.00202 
0.245  
± 0.0861 
4.06  
± 0.983 
0.0002  
± 3.79 
0.00426  
± 0.0678 
0.146 
44 16 1.55  
± 0.0633 
0.0401  
± 2.78 
1.53  
± 0.656 
8.33  
± 0.628 
0.0883  
± 0.336 
4.53  
± 2.77 
0.000138  
± 0.251 
0.0032  
± 0.083 
0.369 
45 17 1.34  
± 0.182 
0.0291  
± 0.138 
3.36  
± 0.0487 
3.56  
± 0.00174 
0.124  
± 0.084 
6.37  
± 0.0722 
0.000201  
± 0.000051 
0.00479  
± 0.0599 
0.19 
47 18 27.9  
± 0.108 
0.017  
± 3.39 
1.7  
± 8.11 
35.8  
± 8.11 
0.0318  
± 0.136 
21.3  
± 3.39 
0.00269  
± 0.078 
0.000996  
± 0.0597 
0.111 
Table 8.10: Hyperglycaemic clamp eight hour fasted 
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Data-
base 
ID 
Subject 
Ref 
kd 
(μg mmol
−1
) 
ksi 
(ml ng
−1
) 
ki 
(μg mmol
−1
  
min
−2
) 
kiir 
(min
−1
) 
kir 
(min
−1
) 
kiar 
(min
−1
) 
gp 
(mmol 
l
−1
 min
−1
) 
F 
(ml
-1
) 
Residual 
36 9 2.84  
± 0.182 
0.024  
± 0.000594 
3.42  
± 0.00018 
4.19  
± 0.00201 
0.123  
± 0.000133 
7.73  
± 0.000144 
0.000206  
± 0.00119 
0.0049  
± 0.0183 
0.112 
37 10 1.28  
± 0.513 
0.0000914  
± 65 
1.17  
± 13.2 
12.1  
± 13.2 
0.00126  
± 0.513 
2190  
± 61 
0.00536  
± 0.104 
0.0000501  
± 0.564 
0.155 
39 12 1.91  
± 0.0841 
0.035  
± 1.06 
1.05  
± 3.41 
19.8  
± 3.42 
0.000816  
± 0.393 
7.39  
± 1.06 
0.000235  
± 0.618 
0.00288  
± 0.0525 
0.103 
40 13 50.3  
± 0.0672 
0.00139  
± 13.4 
1.16  
± 8.78 
15.4  
± 8.87 
0.0648  
± 0.0532 
135  
± 13.5 
0.000243  
± 1.87 
0.000737  
± 0.0592 
0.108 
Table 8.11: Hyperglycaemic clamp fed 
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8.8.4 Discussion of hyperglycaemic clamp 
There is a statistically significant difference (p<0.05) for the results of the fed and 
eight hour fasted animals against the four hour fasted subjects for F (input gain 
of glucose – bioavailability/volume of distribution). This shows that the input 
gain of glucose has changed between different fasting states. In the eight hour 
fasted animals it has a greater input gain (0.0057 ml-1), see Table 8.10. In the four 
hour fasted animals a smaller input gain was recorded (0.00411 ml-1), see Table 
8.9. This could be explained by there being missing glucose compartments in the 
model, in the case of the eight hour fasted animals all the glucose in extra 
compartments has been utilised whereas in the four hour case this has not 
happened.  
There is a statistically significant difference (p<0.05) for the results of the fed 
against the other animals for kiar (insulin action clearance rate). This shows that 
the insulin action clearance rate has changed between different fasting states. In 
the fed animals, the insulin action rate is highest which means that insulin acts 
for a shorter time. 
The parameter fitting of the hyperglycaemic clamps worked well as the fits were 
close to the observed data. In some cases the fits did not match as closely as they 
could. This may have been because animal systems were under a lot of stress, 
therefore some animals might have acted erratically. Towards the end of the 
experiment, at 90 minutes, there is a large peak for most animals. This was due 
to an injection of Streptozotocin. This was done to release all the insulin from the 
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β-cells in order to measure how much insulin was left in the cells. This data point 
was left in as, in most cases, it was indistinguishable from the other data. 
The residuals were low for most subjects and the confidences in the parameters 
were also high, except for ksi. This could be due to insulin dependent glucose 
clearance being saturated. The confidence in ki for fed animals was low but also, 
in general, the parameters were more erratic than other animal states, for 
example database ID 40 had a large kd. Looking at the graph, it can be seen that 
insulin secretion was increasing dramatically throughout the experiment while 
glucose infusion was relatively constant.  
This study was also used with the C-peptide model, below, and the results are 
given in Chapter 7. 
8.8.5 OGTT Results 
In an OGTT experiment, the glucose is given orally and therefore takes a period 
of time to enter the system post absorption. It was therefore necessary to add 
this time delay into the model. Two attempts were made at modelling this delay. 
It is standard [13] to use a string of compartments to model the gut. One and 
two compartments were trialled on the data, however when parameter fitting 
was performed, the second compartment’s parameters were fitted so that they 
had no impact on the resulting model output, i.e. the flow rate between 
compartments was set very low. As shown below, a one-compartment model for 
the gut is enough to adequately fit the data with the given data set. The data 
used is from (StevenOGTT); day 8 was used because it was at the end of the 
Chapter 8: Short Term Modelling 
196 
experiment and would show the greatest difference between the animals used. 
The insulin secretion rates were taken from IVGTT data as the time points taken 
in these experiments were not taken at short enough intervals to be able to 
capture those parameters. 
Glucose
Gut
Food Intake
gp gabs
 
Figure 8.12: Gut Glucose Model for Short Term Model 
The model is shown in Figure 8.12 and the system equations are given by: 
       
  
                             
       
  
                     
8.16 
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Parameter Description Units 
gabs Glucose absorption from gut min
-1 
F Volume of distribution / bioavailability of 
glucose (Input gain of glucose) 
ml-1 
u(t) Input of glucose to the gut mmol min
-1 
Table 8.12: Gut Parameters for Short Term  
8.8.6 Fitting OGTT  
Figure 8.13 to Figure 8.15 and Table 8.13 to Table 8.16 are the results from 
parameter fitting (StevenOGTT). 
 
Figure 8.13: OGTT parameter fit for a single subject 
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Figure 8.14: OGTT parameter fit of glucose for all subjects 
 
Figure 8.15: OGTT parameter fit of insulin for all subjects 
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Subject 
ref 
ksi 
(ml ng−1) 
kir 
(min−1) 
kiar 
(min−1) 
gp 
(mmol l−1 min−1) 
kabs 
(min-1) 
Residual 
4 0.148 ± 1.22 3.82 ± 0.0393 1.51 ± 1.18 0.138 ± 0.132 0.222 ± 0.154 0.0875 
7 0.0828 ± 0.0968 1.92 ± 0.0698 1.69 ± 0.0921 0.0887 ± 0.222 0.143 ± 0.183 0.155 
9 0.222 ± 1.34 2.08 ± 0.0621 2.01 ± 0.605 0.412 ± 0.69 0.419 ± 1.05 0.203 
13 0.027 ± 1.74 1.79 ± 0.0223 1.22 ± 1.62 0.0608 ± 0.205 211 ± 30.7 0.0293 
20 0.0914 ± 0.855 1.71 ± 0.0755 1.73 ± 0.532 0.26 ± 0.36 0.611 ± 0.979 0.263 
22 0.0265 ± 0.686 0.534 ± 0.123 4.72 ± 0.668 0.0373 ± 0.395 4040 ± 2.02 0.57 
28 0.0212 ± 0.044 2.45 ± 0.193 0.562 ± 0.00604 0.115 ± 0.543 0.427 ± 0.0979 0.187 
30 0.14 ± 0.299 14.1 ± 0.0241 1.72 ± 0.301 0.112 ± 0.298 0.297 ± 0.345 0.509 
34 0.103 ± 0.49 2.12 ± 0.0341 1.61 ± 0.477 0.183 ± 0.108 0.218 ± 0.125 0.0741 
39 0.0657 ± 0.188 2.64 ± 0.046 1.22 ± 0.0575 0.131 ± 0.0976 0.379 ± 0.183 0.115 
Table 8.13:  OGTT Research Methods Diet 1 Glucose Tolerance Test 
Chapter 8: Short Term Modelling 
200 
Subject 
ref 
ksi 
(ml ng−1) 
kir 
(min−1) 
kiar 
(min−1) 
gp 
(mmol l−1 min−1) 
kabs 
(min-1) 
Residual 
2 0.072 ± 0.406 1.1 ± 0.0699 2.2 ± 0.434 0.151 ± 0.26 0.255 ± 0.225 0.215 
8 0.0679 ± 0.00262 1.76 ± 0.0277 2.71 ± 0.0339 0.113 ± 0.0755 0.298 ± 0.0994 0.376 
10 0.122 ± 1.08 2.83 ± 0.0321 1.08 ± 0.979 0.351 ± 0.193 0.251 ± 0.209 0.0547 
17 0.408 ± 0.0593 3.57 ± 0.000121 3.95 ± 0.145 0.12 ± 0.126 0.231 ± 0.155 0.0592 
16 0.0695 ± 2.85 1.56 ± 0.0448 1.32 ± 2.76 0.212 ± 0.146 0.238 ± 0.173 0.11 
21 0.102 ± 0.207 1.73 ± 0.0953 1.71 ± 0.176 0.529 ± 0.1 0.341 ± 0.132 0.319 
25 0.145 ± 2.67 3.74 ± 0.0481 0.77 ± 2.44 0.186 ± 0.215 0.224 ± 0.0692 0.119 
35 0.00701 ± 0.192 4.24 ± 0.0567 0.212 ± 0.177 0.0153 ± 0.394 1070 ± 0.274 0.156 
32 0.145 ± 8.44 2.9 ± 0.0476 2.27 ± 8.45 0.136 ± 0.199 0.255 ± 0.541 0.0892 
37 0.078 ± 0.826 3.34 ± 0.128 3.11 ± 0.597 0.0853 ± 0.417 0.258 ± 0.294 0.545 
Table 8.14: OGTT Research Methods Diet 1 Meal Tolerance Test 
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Subject 
ref 
ksi 
(ml ng−1) 
kir 
(min−1) 
kiar 
(min−1) 
gp 
(mmol l−1 min−1) 
kabs 
(min-1) 
Residual 
1 0.0471 ± 0.00379 1.01 ± 0.000032 3.6 ± 0.00159 0.101 ± 0.0651 0.255 ± 0.039 0.0767 
6 0.0719 ± 0.0317 1.65 ± 0.0239 3.32 ± 0.0713 0.187 ± 0.102 0.189 ± 0.161 0.0376 
11 0.0246 ± 0.155 0.637 ± 0.0338 3.3 ± 0.0779 0.108 ± 0.0972 0.507 ± 0.338 0.0587 
14 0.0441 ± 0.294 0.992 ± 0.0524 3.03 ± 0.184 0.113 ± 0.133 0.232 ± 0.136 0.19 
18 0.061 ± 1.64 1.42 ± 0.0642 2.68 ± 1.64 0.167 ± 0.211 0.232 ± 0.188 0.203 
24 0.03 ± 0.629 0.7 ± 0.167 5.8 ± 0.356 0.0335 ± 0.889 0.1 ± 0.58 0.462 
26 0.0341 ± 2.13 0.357 ± 0.107 4.24 ± 2.12 0.0661 ± 1.18 0.0247 ± 0.134 0.388 
31 0.042 ± 0.592 0.913 ± 0.0881 4.16 ± 0.386 0.0598 ± 0.753 0.271 ± 0.242 0.199 
33 0.0391 ± 1.14 2.66 ± 0.0517 1.44 ± 1.11 0.119 ± 0.215 0.286 ± 0.184 0.154 
38 0.0251 ± 0.0342 0.278 ± 0.0272 7.13 ± 0.0803 0.0939 ± 0.121 0.206 ± 0.121 0.0467 
Table 8.15: OGTT High Fat Diet Glucose Tolerance Test 
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Subject 
ref 
ksi 
(ml ng−1) 
kir 
(min−1) 
kiar 
(min−1) 
gp 
(mmol l−1 min−1) 
kabs 
(min-1) 
Residual 
3 0.0612 ± 0.206 1.04 ± 0.151 4.69 ± 0.0886 0.0864 ± 0.163 0.497 ± 0.988 0.203 
5 0.051 ± 0.0901 1.49 ± 0.00591 3.37 ± 0.118 0.117 ± 0.0558 0.206 ± 0.245 0.172 
12 0.0491 ± 4.49 1.23 ± 0.0374 3.54 ± 4.43 0.0463 ± 0.294 0.389 ± 0.322 0.061 
15 0.0538 ± 0.0912 1.07 ± 0.0715 2.84 ± 0.092 0.168 ± 0.111 0.278 ± 0.209 0.219 
19 0.0373 ± 0.367 0.619 ± 0.0423 4.56 ± 0.306 0.0636 ± 0.243 0.24 ± 0.328 0.081 
23 0.116 ± 0.164 2.46 ± 0.0526 1.28 ± 0.196 0.412 ± 0.255 0.0416 ± 0.197 0.123 
27 0.0658 ± 0.0678 1.53 ± 0.0279 2.59 ± 0.0773 0.15 ± 0.13 0.445 ± 0.127 0.0505 
29 0.0307 ± 0.68 0.409 ± 0.0589 4.95 ± 0.551 0.14 ± 0.208 0.00234 ± 0.475 0.3 
36 0.0624 ± 0.124 1.24 ± 0.0523 4.45 ± 0.0177 0.109 ± 0.205 0.734 ± 0.146 0.11 
40 0.0269 ± 0.637 0.207 ± 0.0422 8.45 ± 0.532 0.0848 ± 0.192 0.382 ± 0.464 0.0932 
Table 8.16: OGTT High Fat Diet Meal Tolerance Test 
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8.8.7 Discussion of OGTT 
The main differences are between the high fat diet and the non-high fat diet. 
There is a significant difference (p<0.05) on the parameter insulin sensitivity (ksi). 
This shows that a high fat diet has a measurable effect on insulin sensitivity. This 
is exactly what would be expected (see Chapter 3). 
Insulin clearance (kir) and insulin action clearance (kiar) are significant differently 
(p<0.05) lower in the high fat diet (except for RM1GTT with kir; this could be 
because subject 30 was an outlier).  
Glucose production (gp) is significantly different (p<0.05) between RM1GTT and 
the high fat diet (HDGTT and HFDMTT).  
Glucose absorption (kabs) is not statistically significantly different between groups 
showing that diet does not seem to affect glucose absorption rate. 
Very few data points were taken in this test so, from the model stand point, 
there is uncertainty in how fast the glucose could enter the system. This could 
explain why there is variable confidence in the kabs parameter. The ksi parameter 
also shows signs of uncertainty for similar reasons. The rest of the parameters 
show a reasonable level of confidence. 
From the graphs, Figure 8.13 to Figure 8.15, it can be seen that there is a large 
peak of insulin within the first 15 minutes. This has been simulated to be the case 
as the parameters have been taken from the IVGTT. Due to limitations in the 
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experiment, it was not possible to take readings so close to the dose being given. 
This would be interesting for future study.  
8.9 C-peptide 
As seen in previous chapters, Chapter 5 and Chapter 7, there has been a well-
defined model developed for C-peptide kinetics [57]. It is a simple step to 
combine this C-peptide model into the model presented above. To do this, we 
state that the insulin secretion seen previously is the real insulin secretion before 
the insulin is cleared by the liver; so the GSIS terms from the model above are 
the terms for C-peptide secretion. This assumes that the output seen in the 
periphery is a fraction of that seen in the portal vein. In this model the term S(t) 
is the secretion of insulin and C-peptide in molar quantities because, as stated 
previously, insulin and C-peptide are secreted in equal molar quantities. The 
system model is shown in Figure 8.16 and S(t) is given by: 
  
               
     
  
 
8.17 
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Figure 8.16: Full C-peptide Short Term Model 
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In Chapter 7, hepatic blood flow changes were used to model changes in insulin 
clearance. In this situation, it was decided not to include this model because, if 
another factor alters insulin appearance in the periphery and insulin clearance, 
this will produce misleading results in the model. Therefore, it is more relevant 
to show the fraction of insulin appearance in the periphery and clearance. 
Parameter estimation was performed in the same way with the C-peptide part of 
the model on data sets (AliceIVGTT), and (RuthClamp). The results can be seen in 
Figure 8.17 to Figure 8.20. The parameters are in Table 8.17 and the system 
equations are given by: 
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Parameter Description Units 
     Fraction of C-peptide observed compared to 
insulin 
min 
      Flow of C-peptide from compartment 2 to 
compartment 1 
min−1 
      Flow of C-peptide from compartment 1 to 
compartment 2 
min−1 
     Clearance rate of C-peptide min
−1 
Table 8.17: C-Peptide Parameters for Short Term Model 
 
Figure 8.17 IVGTT parameter fit of a single subject 
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Figure 8.18 IVGTT parameter of glucose for all subjects 
 
Figure 8.19 IVGTT parameter fit of all subjects with insulin and C-peptide 
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Figure 8.20 Clamp individual fit of a single subject 
All the data for hyperglycaemic clamp fitting are given in Appendix 4. 
8.9.1 Conclusions 
It can be seen there are good fits with all the above experiments (IVGTT, 
hyperglycaemic clamp and OGTT) both with and without C-peptide present. 
Being able to predict exactly where to take measurements to get the best 
confidence with the parameters allows scientists to optimise the readings taken 
and therefore to get the most out of the experiments performed. Taking fewer 
readings on animals also reduces the animals’ stress, which is good from the 
point of view of both animal welfare and reliability of data. The way to work out 
the optimal point to take readings is through sensitivity analysis. 
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8.10 Sensitivity analysis 
The concept of sensitivity analysis was introduced in Chapter 2. This model is 
designed primarily for use with acute/short-term experiments. These 
experiments are usually quite intense, however due to limitations such as blood 
sample volumes, the logistics of working with many animals and other 
constraints mentioned in Chapter 4. large numbers of time points are not always 
available. Therefore it is important to know when are the most informative times 
to sample. 
Sensitivity analysis was performed on this model using automatic differentiation. 
In this context, automatic differentiation involves differentiating the model with 
respect to the parameters at the same time as simulating the model. This has 
several advantages over differentiation: it is less tedious and error-prone than 
manual differentiation and allows alterations to the model to be reflected in the 
differentiation immediately. 
The automatic differentiation method used here is performed by a piece of 
MATLAB code written by [24] which uses substitution of functions and operators 
to perform successive differentiations using the chain rule. As this method is 
analytical it therefore provides an exact solution, not an approximation. As it is 
done with parameter substitution, it is fast. This creates a set of differential 
equations, defined in equation 2.27 from section 2.7, which can be simulated at 
the same time as the model differential equations. There is little or no noticeable 
difference in performance when simulating these ODEs alongside the model 
Chapter 8: Short Term Modelling 
211 
ODEs. The MATLAB code used to generate this matrix has been included in 
Appendix 6. 
This produces results that show the effect that each parameter has on each 
state. These can be shown as either absolute effects on the state by the 
parameter or as relative effects of changing the parameter on the state. As the 
parameters in this model have a large range of magnitudes, showing relative 
parameter effects is more relevant. These can then be summed for each state to 
view a combined sensitivity of state against time. This is useful for seeing which 
time points are most beneficial for sampling. 
 
Figure 8.21 Relative sensitivity analysis of insulin on an IVGTT 
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Figure 8.22 Relative sensitivity analysis of glucose on an IVGTT 
 
Figure 8.23 Sum of relative sensitivities of all parameters on insulin on an IVGTT 
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Figure 8.24: Sum of relative sensitivities of all parameters on glucose on an IVGTT 
 
Figure 8.25 Relative sensitivity analysis of glucose on a hyperglycaemic clamp 
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Figure 8.26: Relative sensitivity analysis of insulin on a hyperglycaemic clamp 
 
Figure 8.27 Sum of relative sensitivities of all parameters of insulin on a hyperglycaemic 
clamp  
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Figure 8.28 Sum of relative sensitivities of all parameters of glucose on a hyperglycaemic 
clamp 
Overall from the sensitivity analysis (Figure 8.21 to Figure 8.28) it is evident that, 
for most parameters, it is best to measure in the early stages of the experiment, 
i.e. within the first 20 minutes. It also shows, however, that there is merit in 
measuring the system when it has reached a steady state, especially for the 
hyperglycaemic clamp. In all experiments, gp is the least influential parameter 
and F is the most influential parameter.  
It is valuable to note that the relative sensitivities  of all parameters except for gp  
have similar magnitudes and, therefore, from these experiments the parameter 
confidence should be high. 
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8.11 Conclusions 
The aim of this chapter was to design a mathematical model for the glucose 
homeostatic system that was mechanistic, had key parameters that could 
identify disease, could predict future experiments and help with experimental 
design. The model should also be universal, i.e. not confined to a specific test 
such as an IVGTT; not have an explicit parameter for steady state values; it 
should be stable and minimal in form.  
The model presented is mechanistic as it contains parameters, such as kd which 
represents docked insulin granules in the cell. A reduction in such a parameter 
could represent a failure in the β-cells to produce insulin. Other disease states 
can be seen mechanistically in other parameters such as ksi, changes in insulin 
sensitivity; ki, changes in gradual insulin secretion; and gp, changes in normal 
constant glucose production. When the model is run on fasted and unfasted 
animals, key parameters change which match the biological system. These 
factors will be discussed further in Chapter 9.  
That this model can predict other experiments was shown above by using 
parameters from the IVGTT which gave a reasonable fit to the OGTT. This model 
is, therefore, not restricted to a single test. 
The model does not have any parameters for steady state but reaches a steady 
state naturally.  
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The model went through a  process of model minimisation to refine the key 
parameters.  
The model can help with experimental design through sensitivity analysis, 
allowing key time points to be picked for measurements. 
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Chapter 9: Long Term Modelling 
This chapter is concerned with the simulation of disease progression over the 
longer term (i.e. days and months). The model used is based on the β-cell Mass 
Model [119]. It incorporates the short-term model previously discussed in 
Chapter 8 to show how it is possible to have a complete model that can 
represent both short-term and long-term aspects of the glucose-insulin system. 
The model output is compared to (not fitted to using an optimisation algorithm) 
Zucker and ZDF data collected at AstraZeneca, Alderley Park, Cheshire. 
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9.1 β-cell Mass Model 
This model is based on a model created in 2000 by Topp et al.[119]. These 
authors set up a three compartment model, with the compartments 
representing insulin, glucose and β-cell mass (see  
Figure 9.1). 
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Figure 9.1: β-cell mass model diagram 
The model and analysis concentrated primarily on long-term, rather than short-
term, aspects of the system, i.e. changes which occur over days rather than 
minutes or hours. Therefore the glucose and insulin concentrations in this model 
could be considered as the basal levels of glucose and insulin. The differential 
equation describing rate of change of glucose in the model includes terms 
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representing the rate of appearance of glucose minus glucose effectiveness and 
insulin sensitivity, and is given by: 
      
  
                     
9.1 
 
where G(t) is glucose concentration, R0 is the net rate of production at zero 
glucose,    is the total glucose effectiveness at zero insulin and    is the total 
insulin sensitivity. 
The differential equation describing rate of change of insulin has terms 
representing insulin secretion, based on glucose and β-cell mass in a Hill 
function, and a clearance function, and is given by: 
      
  
 
       
         
       
9.2 
 
The differential equation describing rate of change of β-cell mass comprises 
terms representing the natural death rate of β-cells, a rate of growth of β-cells 
based on the level of glucose, and a decrease in β-cells which is also based on 
glucose, and is given by: 
      
  
                   
       
9.3 
The combination of the parameters d0, r1 and r2 create a system which can adapt 
to changing levels of glucose. For example, if the glucose level is below 
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100mg/dl, the β-cell mass will decrease which will in turn lower insulin and 
return glucose to an acceptable level (i.e. 100mg/dl); if the glucose level lies 
between 100 and 250mg/dl, β-cell mass will increase, meaning insulin will 
increase and glucose levels will decrease towards 100mg/dl. With glucose below 
250mg/dl the system adapts, based on glucose levels; with glucose levels over 
250mg/dl, glucose toxicity comes into play and reduces β-cell mass, which leads 
to decreased insulin levels and results in ever-increasing glucose levels in a 
runaway situation, see Figure 9.2. 
 
Figure 9.2: β-cell growth and death rates due to glucose 
9.2 Data 
ZDF and Zucker data were taken from (JoChronic) and glucose and insulin profiles 
were taken on several days over a 40 day study. As the model was in 
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concentration units of mg dl-1 for glucose and µU ml-1 for insulin, all data have 
been converted to these units from the mM and ng ml-1 that were originally 
used. 
9.3 Modifications 
9.3.1 Incorporating Short-Term Model 
The short-term model presented in Chapter 8 was incorporated into this long-
term model, with a few modifications. The first is insulin secretion: as it is related 
to β-cell mass, integral and derivative terms have been incorporated in the long-
term model for β-cell mass. The second is insulin action, which was removed as 
time points in the long-term model are hours apart (as opposed to minutes in the 
short-term model) so the fast dynamics of the insulin action are not present in 
the data in Chapter 8 (see equation 9.4). The third modification involved 
removing glucose effectiveness, as discussed earlier in Chapter 8. 
Finally, as the animals used here were in a diseased state and hyperinsulinaemic, 
i.e. insulin was saturating glucose disposal compared to a normal, insulin-
sensitive rat, Michaelis-Menten type kinetics were incorporated and applied to 
insulin sensitivity. KM was set to 100mg/dl of insulin, following the same 
assumptions as the β-cell Mass Model that that is the stable equilibrium point, 
therefore Vmax is assumed to be twice the steady-state sensitivity of insulin. 
These adjustments mean that the parameters in the short-term model are not 
exactly equivalent to those in the long-term model. The modified system 
equations are therefore given by: 
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9.4 
 
9.3.2 Meal Feeding 
As with the short-term modelling of OGTT in Chapter 8, this model required the 
addition of a single compartment to represent a delay in the intake of food into 
the system. Unlike an OGTT, however, glucose was taken in differently; instead 
of being given a single dose at a specific time, animals were eating over a four 
hour period. The assumption was made that, as rats had been fasted for an 
extended period of time, the rate of feeding would be high at the start of the 
feeding period and would slow down over the course of the four hour period. A 
trapezoidal function was therefore used for the rate of feeding. This trapezoidal 
function was normalised to have an area of one, with a single parameter for the 
steepness of the slope - see Figure 9.3. This trapezoidal function could then be 
multiplied by the actual amount of glucose ingested to give an input to the gut 
compartment. This is given by: 
         
  
  
                            
            
                
              
  
9.5 
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where 
   
 
              
           
   
 
              
             
              
  
This, together with the gut compartment and an appropriate value for gabs (gut 
absorption), produces glucose concentrations that lie within approximately 10% 
of the mean of the data. Figure 9.3 shows a typical meal feed produced by 
trapezoidal function. 
 
Figure 9.3: Gut glucose concentration as produced by the trapezoidal function 
9.3.3 Renal Clearance 
As explained above, when a subject’s glucose level is above 250mg/dl, the β-cell 
Mass Model shows a runaway reduction in β-cell mass. Some of the animals from 
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which data for this model were obtained are hyperinsulinaemic and 
hyperglycaemic (i.e. with glucose levels above 250mg/dl), and do not see a rapid 
decay in β-cell mass as would be predicted by the β-cell Mass Model, but instead 
see only a small reduction in β-cell mass. 250mg/dl is either coincidentally (or by 
design but unmentioned by the creators of the model) close to renal clearance of 
glucose [156], which is not included in the β-cell Mass Model. In previous 
models, such as the AIDA Model and Cobelli’s Model, detailed in Chapter 5, renal 
clearance has been incorporated; it was therefore also incorporated in the long-
term model here and represented by a piecewise function for renal clearance 
with parameter values taken from the AIDA model, as follows: 
        
              
 
       
              
  
9.6 
 
9.3.4 Disease Progression 
9.3.4.1 Insulin Sensitivity 
It was hypothesised that a way of introducing disease progression into the model 
would be to represent insulin sensitivity by a decaying exponential function 
[119].This hypothesis was adopted for the long-term model presented here. It 
was also noted in the experimental data that the ratio between insulin and 
glucose (i.e. insulin sensitivity) changed over time, reinforcing the need for this 
adaptation. Thus the system equation for insulin sensitivity is given by: 
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9.7 
 
9.3.4.2 First-Phase Insulin Secretion 
It is apparent from the Zucker and ZDF data collected at AstraZeneca that basal 
insulin secretion varies between groups of animals and over time. It is also 
apparent that the first-phase insulin secretion changes and, in the case of the 
meal-fed animals, it decreases in comparison to the basal level of insulin 
secretion. Therefore the model was modified so that the level of first-phase 
insulin secretion changes over time. This was done in a similar way to the 
modification made for insulin sensitivity, i.e. using a decaying exponential 
function. This was not intended to reflect a specific reason behind change in first-
phase insulin secretion, only to quantify the rate of change. Thus the system 
equation for first-phase insulin secretion is given by: 
       
  
           
9.8 
 
9.4 Software Tool 
A simple software tool was created to perform the simulation of this model, see 
Figure 9.4,  the code for which is given in Appendix 5. It was set-up so that the 
experimental data could be visualised and the model simulated. It was written in 
MATLAB using the in-built GUI editor (see Appendix 5). As this model is stiff (see 
Chapter 2), the ODE solver ode23tb was used, which is an implicit Runge-Kutta 
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algorithm. This solver simulates a response representing a 40 day period within a 
few seconds. The software allows parameters to be changed and re-simulated 
easily. It does not have any parameter fitting capabilities and is purely used for 
simulation given realistic parameter values and initial conditions. See Table 9.1 
below. 
 
Figure 9.4: Long term modelling simulation tool 
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Parameter Description Value Units Source 
Initial Conditions 
g0 Starting level of glucose 100 mg dl
-1 [119] Data 
i0 Starting level of insulin 500 µU ml
-1 Data 
b0 Starting level of β-cell mass 300 mg [119] 
ggut Starting level of gut glucose 0 mg dl
-1 Assuming empty gut 
Insulin Kinetics 
kd (kd0) First-phase insulin secretion -differential (starting 
value) 
0.7 µU ml -1mgdl-1 Chapter 8 
ki Second-phase insulin secretion -integral 4000 µU ml 
-1mgdl-1 
day-2 
Chapter 8 
kiir Second-phase insulin secretion time constant 3600 day
-1 Chapter 8 
k Insulin clearance 432 d-1 [119] 
cd First-phase insulin secretion decay  day
-1 See above 
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Parameter Description Value Units Source 
Glucose Kinetics 
R0 Net rate of glucose production  mg dl
-1 d-1 [119]  
km km of insulin sensitivity  mg dl
-1 See above 
SI (SI0) Insulin sensitivity (starting value) 0 ml µU
-1 d-1 [119] 
cSI Insulin sensitivity decay 0 day
-1 [119] 
β-cell Kinetics 
d0 Natural β-cell death  d
-1 [119] 
r1 Rate constant of β-cell growth  mg
-1 dl d-1 [119] 
r2 Rate constant of β-cell death  mg
-2 dl2 d-1 [119] 
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Parameter Description Value Units Source 
Glucose gut kinetics 
gabs Glucose absorption from the gut 24 day
-1 See above [118] 
gslope Slope of trapezoidal function  fraction (unit-less) See above 
tstart Feeding start time  day Data 
tend Feeding end time  day Data 
gfed Glucose ingested  mg Data 
Table 9.1: Parameters in long-term model 
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9.5 Comparison with Experimental Data 
The model was compared with real experimental data to see if it produced 
realistic results. As this model could be considered to be over-parameterised for 
the system modelled, parameter optimisation via an optimisation algorithm is 
unlikely to be successful so was not used. Therefore, changes in parameters are 
educated estimates of changes to biological mechanisms in order to 
demonstrate that this model can produce responses that compare well with real 
data. 
9.5.1 Zucker Chow Fed Rat Experimental Protocol 
In this situation, a Zucker rat is meal fed with a chow diet; 7.42% Fat vs 42% for 
High Fat diet which is low fat but provides the same calorific intake as the high 
fat diet given to animals later in this chapter. In this situation the Zucker rat is 
hyperinsulinaemic, but maintains reasonable glycaemic control, i.e. insulin is 
above the normal level - such as that of a Han Wistar rat - glucose returns to the 
basal level of 80-100mg dl-1 
9.5.1.1 Necessary Changes in Parameters 
As these animals were hyperinsulinaemic, it is reasonable to lower insulin 
sensitivity and alter kd, ki, kiir and k. The parameter values used are given in Table 
9.2. 
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Parameter Value 
kd 0.7 µU ml 
-1mgdl-1 
ki 4000 µU ml 
-1mgdl-1 day-2 
kiir 3600 day
-1 
k 70 d-1 
Table 9.2: Parameters altered based on Zucker chow fed data 
Note that the values have not changed from Table 9.1 as those values were set in 
this model. The results from this can be seen in Figure 9.5 to Figure 9.7. 
9.5.1.2 Long-term Graphs 
 
Figure 9.5: Zucker chow fed data - whole study simulations with insulin mean values and 
standard errors in black and simulated insulin in red 
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Figure 9.6: Zucker chow fed data - whole study simulations with glucose mean values 
and standard errors in black and simulated glucose in blue 
 
9.5.1.3 Day Graphs 
Day 3 
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Day 14 
 
Day 28 
 
Day 38 
 
Figure 9.7: Zucker chow fed data - day simulations with real data in black, simulated 
insulin in red and simulated glucose in blue 
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The above graphs, Figure 9.5 to Figure 9.7, show that this model can produce 
realistic results for the Zucker chow fed, meaning that it represents animals in a 
non-diseased state.  
9.5.2 Zucker High Fat Fed Rat Experimental Protocol 
The only difference from the previous experimental set-up here is that the diet 
was changed to the 42% fat content diet. The model was set up identically; the 
profiles were initially similar, but changed throughout the study. 
9.5.2.1 Necessary Changes in Parameters 
It was anticipated that insulin sensitivity would decrease over time, however this 
did not take into account the fact that first-phase insulin secretion was also 
decreasing and therefore cd was decreased accordingly. The parameter values 
used are given in Table 9.3. The results from this can be seen in Figure 9.8 to 
Figure 9.10. 
Parameter Value 
SI 0.02 day
-1 
cd 0.06 day
-1 
Table 9.3: Parameters altered based on Zucker high fat fed data 
9.5.2.2 Long-term Graphs 
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Figure 9.8: Zucker high fat fed data - whole study simulations with insulin mean values 
and standard errors in black and simulated insulin in red 
 
Figure 9.9: Zucker high fat fed data - whole study simulations with glucose mean values 
and standard errors in black and simulated glucose in blue 
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9.5.2.3 Day Graphs 
Day 3 
 
Day 14 
 
Day 28 
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Day 38 
 
Figure 9.10: Zucker high fat fed data - day simulations with real data in black, simulated 
insulin in red and simulated glucose in blue 
Figure 9.8 to Figure 9.10 show that, by altering a few parameters, we can 
simulate a Zucker rat going into a diseased state which means that we can 
experiment with changing certain physiological parameters of a rat to see the 
resulting effect.  
9.5.3 ZDF Chow Fed Rat Experimental Protocol 
In this situation, it was noted that the chow diet seemed to improve the 
condition of the ZDF animals. 
9.5.3.1 Necessary Changes in Parameters 
In this study, both glucose and insulin sensitivity remained constant throughout. 
Insulin, however, decreased but, as the animals were hyperinsulinaemic, insulin 
disposal was saturated so falling levels of insulin had no effect on glucose levels. 
The only aspect which did change throughout the experiment, therefore, was 
first-phase insulin secretion, which decreased. The only change required to the 
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original base set of parameters was first-phase insulin secretion decay, cd, which 
was set at 0.04 day-1. The results can be seen in Figure 9.11 to Figure 9.13. 
9.5.3.2 Long-term Graphs 
 
Figure 9.11: ZDF data - whole study simulations with insulin mean values and standard 
errors in black and simulated insulin in red 
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Figure 9.12: ZDF data - whole study simulations with glucose mean values and standard 
errors in black and simulated glucose in blue 
9.5.3.3 Day Graphs 
Day 16 
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Day 27  
 
Day 38 
  
Figure 9.13: ZDF data - day simulations with real data in black, simulated insulin in red 
and simulated glucose in blue 
Figure 9.11 to Figure 9.13 show that this model can produce reasonable 
predictions of the diseased state. These animals, however, are in a highly 
diseased state and so are metabolically stressed which means that the insulin 
secretion is exacerbated and this is not captured by this model. The insulin levels 
are very high and well above the saturation of insulin sensitivity so this two-
phase insulin secretion has little or no effect on the glucose profile. 
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9.5.4 Conclusions and Discussion 
Here, the short-term and long-term models have been combined to produce a 
fully-coupled, continuous model of the glucose-insulin system. It has been shown 
that glucose and insulin models can be combined to simulate a reasonable 
representation of the long-term dynamics and disease progression of subjects. 
As this model is over-parameterised and there are only data from two 
compartments, it is difficult to draw any firm biological conclusions because the 
same graphs could be produced from different sets of parameters. However, 
parameters which have been altered to produce the results mechanistically 
make sense in the biological context. This makes the model a potentially useful 
predictive or experimental tool rather than an analytical tool. 
The model does not explain biologically certain aspects of the system, in 
particular insulin sensitivity decreasing in the Zucker high fat fed animal. It does 
not provide a mechanistic reason for this decrease, therefore further modelling 
work should be carried out to link in possible causes such as lipid metabolism; 
the effects of lipids on the glucose-insulin system were mentioned in Chapter 3 
and could be incorporated into this model. The other aspect which is not covered 
is why first-phase insulin secretion decreases whereas second-phase insulin 
secretion seems to remain in-line with basal levels. Again, the model does not 
provide an explanation for the reason behind this. 
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Chapter 10: Software Tool for Modelling Glucose,  
Insulin and C-peptide Dynamics 
10.1 Aim and Purpose 
A software tool to allow the use of modelling in their day-to-day operations is an 
important deliverable for AstraZeneca. It is important to AstraZeneca that non-
mathematical scientists are able to perform modelling and simulation to allow 
them to use the concept of modelling in the same way that they use statistics. 
They can use it as a tool to analyse and predict system outcomes, to give more 
information about the data they have collected, to produce more meaningful 
conclusions and to gain a better understanding of the underlying biology of a 
system. 
There are various requirements to ensure that the software tool is useful to non-
mathematical scientists at AstraZeneca. The software tool must be robust so that 
it does not produce erroneous results. It must be simple to use and present 
results in an appropriate form for non-mathematical scientists to interpret. It 
must be well-integrated into the existing AstraZeneca set-up so that using the 
software will not create additional work and it will be seen as an easily 
accessible, accepted and worthwhile tool. 
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10.2 Specification 
The functions the software tool will perform will be as follows: 
 Simulations of the glucose, insulin and C-peptide system given a set of 
parameters. 
o Be able to select the most appropriate model. 
 It will be able to fit data to a model to produce parameters.  
o The fitted parameters will be given confidence values. 
o Given groups of data, it will be able to calculate statistical 
significance between the groups. 
 It will be able to produce graphs of the results for individual and grouped 
data. 
It will take data from these sources: 
 Toolkits used by the department, e.g. the CVGI toolkit. 
 A plain spreadsheet. 
It will be able to run on a standard build of AstraZeneca computer which is of 
Windows Vista 32-bit with various specifications. 
It will be user-friendly so that a non-mathematician will be able to use it and 
understand the results. 
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10.3 Software Construction 
10.3.1 Overview 
MATLAB [4] was used to construct the software tool as it provides functions and 
features, such as ODE solvers and optimisation algorithms, which are essential 
for modelling and simulation in this context. It also provides a method of 
outputting data graphically for the end user to make results easier to interpret. 
However, MATLAB lacks more advanced programming features, such as object-
orientation, needed for developing a complete modelling tool. In addition, if 
every person that wishes to use the tool had to have a full licence for MATLAB 
with toolkits, this would be very cost-prohibitive. The way round this is to use the 
MATLAB compiler to create a stand-alone application which can be accessed 
from other programming languages. This gives the advantage that the 
functionality of MATLAB can be used alongside the programming features of a 
language such as Java, and also means that the application can be freely 
distributed without the need for a full MATLAB licence for each individual user. 
MATLAB can be compiled to work with a range of programming languages; in this 
case Java was used as it provided all the desired features, such as object-
orientation, and was the language with which the author was most familiar. 
10.3.2 Structure 
The overall structure of the software tool is shown in Figure 10.1, below.
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Java  (Class Name.java)
Start (Start)
Compile the Models 
(makemodelfunction)
Simulated (simulate)Run Fits (JavaFitting)
Modelling GUI (Modelling)
Select Database and select the 
required data
(SelectDatabases)
Parameter Fit (doFitting/
minGen)
Results (results)
Results per Group 
(resultsgroup)
Results for All (resultsall)
Data Processing (dataProcess)
Plot Data (plotDataFun)
Plot Simulated 
(plotSimulated)
Matlab  (functionname.m)
 
Figure 10.1: General overview of code structure
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10.3.2.1 MATLAB Components 
The MATLAB components primarily perform the arithmetic and data display 
functions. One component performs graphical display for parameters and 
immediate simulations of the model and model simulation. Another performs 
fitting and formats results. 
These components are separate to allow fitting and results formatting to be 
executed on a remote system if required in the future (e.g. if fitting is too 
numerically intensive for the user’s machine). This would be possible as Java can 
be used to control both MATLAB components and the RMI (Remote Method 
Invocation) interface could divide workload between separate machines as 
required. Note that this aspect has not currently been implemented, but the 
structure of the MATLAB components would allow for this in the future. 
10.3.2.2 Java Components 
The Java project is split into five packages. interfaces contains any Java 
interfaces required, including the database connection interface which is 
extended for each standard framework (e.g. the IVGTT toolkit). structures 
contains any nodes used in the database section of the Java components, such as 
objects containing groups, profile and subjects. fitting contains the link 
between the two MATLAB components. gui contains graphical interfaces for 
the user to select certain parts of the databases. Finally, start sets up the 
environment to run MATLAB in Java. 
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10.4 Software Function 
10.4.1 Model Input 
Models are input to the software tool in a standard format developed in XML. 
This format requires a list of states, parameters with initial estimates and 
differential equations which define the model. The data in this format are 
interpreted by MATLAB to create functions called by an integration algorithm 
when the model is simulated. An example of the XML format are given in Figure 
10.2. 
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<model> 
    <name>ID Model</name> 
    <states> 
 
        <state> 
            <name>glucose plasma</name> 
            <symbol>G</symbol> 
            <equation> 
                dGdt =gp -IA*G*si 
            </equation> 
            <observable /> 
            <initial> 
                G0 
            </initial> 
 
            <input>IV</input> 
            <inputequation> 
                F 
            </inputequation> 
 
        </state> 
        <state> 
            <name>Insulin Integral</name> 
            <symbol>II</symbol> 
            <equation> 
                dIIdt = G-II*kiir 
            </equation> 
            <initial> 
                G0/kiir 
            </initial> 
 
        </state> 
        <state> 
            <name>Insulin</name> 
            <symbol>I</symbol> 
            <equation> 
                dIdt = kd*max((dGdt),0) + II*ki - kir*I 
            </equation> 
            <observable/> 
            <initial> 
                I0 
            </initial> 
 
        </state> 
        <state> 
            <name>Insulin Action</name> 
            <symbol>IA</symbol> 
            <equation> 
                dIAdt = I-IA*kiar 
            </equation> 
            <initial> 
                I0/kiar 
            </initial> 
        </state> 
    </states> 
 
 
    <parameters> 
        <parameter> 
            <name>kd</name> 
            <value>1.7968 </value> 
     <description>1st Phase Insulin 
Secretion</description> 
        </parameter> 
        <parameter> 
            <name>si</name> 
            <value>0.026</value> 
<description>Insulin Sensivity</description> 
        </parameter> 
        <parameter> 
            <name>ki</name> 
            <value>1</value> 
<description>2nd Phase Insulin Secretion</description> 
        </parameter> 
        <parameter> 
            <name>kiir</name> 
            <value>12</value> 
<description>2nd Phase Insulin Secretion Delay (time 
constant)</description> 
        </parameter> 
        <parameter> 
            <name>kir</name> 
            <value>0.7</value> 
<description>Insulin Clearance</description> 
        </parameter> 
        <parameter> 
            <name>kiar</name> 
            <value>7.00</value> 
<description>Insulin Action Delay (Time 
Constant)</description> 
        </parameter> 
        <parameter> 
            <name>gp</name> 
            <value>0.0002</value> 
<description>Glucose Production</description> 
        </parameter> 
        <parameter> 
            <name>F</name> 
            <value> 0.024 </value> 
<description>Bioaviabiliy of Glucose</description> 
        </parameter> 
    </parameters> 
 
</model> 
 
Figure 10.2: Example model XML code 
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10.4.2 Data Input 
The vast majority of data at AstraZeneca are stored in spreadsheets, with each 
different user having their own spreadsheet design and layout. There have been 
attempts to standardise the spreadsheet formats. One example is the CVGI 
toolkit which is used for storing data from OGTT experiments, however this does 
not include IVGTT or hyperglycaemic clamp data. It stores data in a Microsoft 
Access database which is easily accessible and data are easy to extract via an 
Excel spreadsheet front-end. There is also an IVGTT toolkit which also stores data 
in a database (Oracle, rather than Microsoft Access), again with an Excel front 
end which produces an easily readable spreadsheet. This toolkit is used with 
IVGTT data, but can also be extended for hyperglycaemic clamp data. 
OGTT, IVGTT and hyperglycaemic clamp data can all be used within the model 
presented in Chapter 8. It is therefore useful, to save data re-entry, to be able to 
extract data from the CVGI and IVGTT toolkits directly. This saves time and 
prevents copying errors entering the data, as well as simplifying use of the 
software tool from the user’s point of view. The software tool therefore imports 
data from these sources and uses Java to transform them to fit in a common 
framework. Different methods are required to import data from different 
sources: for example, the CVGI toolkit imports data via a Microsoft Access ODBC 
(Open Database Connectivity) driver then uses an ODBC-JDBC (Java Database 
Connectivity) bridge which allows the data to be transferred into Java.  
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Data from all the different sources are placed into a standard framework of Java 
objects. This ensures that MATLAB can deal with data from all sources easily and 
consistently. It also allows for easy data manipulation, including selecting data by 
the group of animals and selecting which groups of animals should be compared. 
10.4.2.1 Additional Data Processing 
For most experiments, the data input are sufficient for modelling directly. 
However hyperglycaemic clamp data are unique in that there are two sets of 
data that are recorded for glucose: blood glucose concentration and plasma 
glucose concentration. As explained in Chapter 4, haemacel is used to stabilise 
the volume of distribution in the subject. This can affect blood glucose 
measurements, but plasma glucose measurements remain unaffected. Plasma 
glucose measurements are taken less frequently than blood glucose 
measurements, however at each time point a plasma glucose measurement is 
taken there is also a blood glucose measurement taken. This allows the ratio 
between plasma and blood glucose levels to be calculated at these time points. 
The software tool takes the mean of these ratios over the course of the 
experiment. The mean ratio is then used to correct blood glucose measurements 
– which are taken more frequently and therefore provide more data points – and 
it is these corrected blood glucose measurements which are used for fitting. 
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10.4.3 Interface 
The interface was made as simple as possible to make parameter fitting 
straightforward for the user. The tool has two screens: a main screen, shown in 
Figure 10.3, and a data selection screen, shown in Figure 10.4. 
 
Figure 10.3: Software tool – main display screen shot 
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Figure 10.4: Software tool – select database screen shot 
10.4.4 Parameter Estimation 
The software tool performs parameter estimation by the Quasi-Newton 
algorithm [36]. It goes through each subject in turn performing the parameter fit, 
simulating the model using ode15s algorithm [30] and fitting using GLS 
(Generalised Least Squares, described in Chapter 2). For each subject it produces 
graphs of fits of insulin and glucose data (and C-peptide where applicable) and 
creates an Excel spreadsheet containing fitted parameter values. It also 
calculates parameter confidence values using equations 2.23 and 10.2 via the 
Hessian matrix, H, derived from the unconstrained fit function in MATLAB 
(fminunc) as described further in Chapter 2, given by: 
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           10.1 
where   is the set of parameter estimates, N  is the number of time points, n  is 
the number of parameters fitted, E  is the output from the residual function and 
H  is the Hessian matrix. In addition: 
 
         
   
 
         10.2 
for          where      
   
 
 
 
 is a two-tailed Student's t distribution for 
confidence level α  and N-np  degrees of freedom. 
10.4.5 Statistical Analysis 
As well as providing parameter estimates for a given model and data set, the 
software tool also performs a two-tailed Student’s t-test on every combination of 
sets of parameter values. This is provided to the user in an Excel spreadsheet so 
they can see if there are any statistically significant differences between groups 
that are reflected in the parameter estimates. 
10.5 Software Use 
The hope is that this software tool will be used by AstraZeneca in their day-to-
day analysis. 
10.6 Conclusions 
This software tool will allow non-mathematical based scientists to access 
complex modelling without the need for vast amounts of expertise in modelling. 
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It will help to improve their decisions about experiments they perform as well as 
enabling them to obtain more detailed  information from previously gathered 
data. 
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Chapter 11: Conclusions and Discussion 
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11.1 Discussion 
The main model in the field of glucose-insulin dynamics has previously been the 
Minimal Model developed by Bergman et al. [111] It can only be used in an 
IVGTT. It is structurally identifiable for insulin and glucose being observable as 
well as just glucose on its own (under certain assumptions). It does not reach a 
steady state value after the experiment has finished. The parameters in the 
model may not have any physiological relevance, such as h, the threshold value 
for insulin release. It was thus necessary to develop or find a new model that 
would cater for more tests. 
There are other models in the field that bring useful insights into the glucose and 
insulin system. However no one model does everything that is required for this 
thesis, therefore it was necessary to develop a new model. 
In developing a new model it was, therefore, necessary to investigate the glucose 
and insulin system with as much data as possible. C-peptide was also collected at 
AstraZeneca. This was useful for working out the level of insulin secretion as it 
was suspected that insulin clearance may not be constant. The fraction of insulin 
observed in the ad-lib fed animals was statistically significantly higher than the 8 
and 16 hour fasted animals. This meant that it was important to include C-
peptide in a mathematical model of the glucose and insulin system. 
It was observed that the insulin response to a glucose stimulus was similar to 
that of a proportional-integral-derivative controller that is found in engineering 
systems. The system equations were changed slightly to fit in better with a 
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biological system as , for example, in this biological system there is no error 
signal. Other elements of the model were taken from the minimal model and 
others. The model then was further reduced by removing the proportional 
control in the model. This model was structurally identifiable. This model was 
successfully applied to IVGTTs and hyperglycaemic clamps. With the addition of a 
compartment for all absorption it was also successfully applied to OGTTs. 
It was also useful to be able to model the progression of long term changes of 
subjects into diabetes. Using a combination of Topp et al [119] and the short 
term model it was possible to simulate (not to parameter fit) the varying 
different factors that could result in diabetes. Therefore it was possible to use 
this as a tool for testing hypotheses to see whether certain parameter changes 
over time would lead to the disease progression as expected. For example, it was 
able to demonstrate what would happen with a gradual decrease in insulin 
sensitivity. 
A software tool was made that allowed AstraZeneca staff to parameter fit their 
data to IVGTTs, hyperglycaemic clamps and OGTTs. It could also be used on other 
experiments not yet thought of. The models that could be fitted were the 
integral derivative model, with and without C-peptide and with or without 
glucose absorption.  
11.2 Conclusion 
The aim of this thesis was to develop an integrated mathematical model of 
glycaemic control that predicts both short-term and long-term glucose 
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regulation. This thesis has covered these two requirements in Chapter 8 and 
Chapter 9. 
An additional aim to this thesis was to make it understandable to any person 
with an interest. This has hopefully has been accomplished by a thesis that does 
not require wide knowledge of either biology or mathematics to understand and 
a software tool that can be used by anyone. 
The objectives of this thesis were mostly met as follows: 
Objectives Where/how they were met 
“To review and evaluate the different 
mathematical models of glycaemic 
control.” 
This was met in Chapter 5. 
"To modify/develop existing mathematical 
models and determine how existing 
glucose and insulin data from animal (rat 
and mouse) studies fit.” 
This was done throughout the thesis but 
specifically in Chapter 6, Chapter 8 and 
Chapter 9. 
"To apply the new model to the evaluation 
of glucose stimulated insulin secretion 
using new data.” 
This was done in Chapter 8. 
"To develop an integrated desktop utility 
for modelling and analysing glycaemic 
control and insulin secretion in animal 
This was done in Chapter 10. 
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Objectives Where/how they were met 
models of diabetes.” 
"To develop methods for determining 
pancreatic degeneration and function from 
measurable, but indirect, parameters such 
as glucose, C-peptide and insulin levels.” 
This was done in Chapter 7 and Chapter 9. 
"To include in the model physiological 
control parameters that address counter-
regulatory systems, such as lipid levels and 
β-cell mass.” 
This was done in Chapter 9. Lipid levels 
were not specifically dealt with but they 
can be seen as a factor that affects insulin 
sensitivity. It should be an area of future 
work however, due to lack of time and 
data, it was not done on this occasion. β-
cell mass was covered but not measured 
due to the difficulty in obtaining the data. 
"To apply the model to the design of 
future studies evaluating pancreatic 
changes and effects on glycaemic control.” 
This was mainly done by designing 
experiments to measure C-peptide 
secretion which in turn helps future 
understanding of insulin secretion. The 
software tool allows for future 
experiments that have not yet been 
designed to be used with the model. 
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11.3 Future Work 
Insulin sensitivity has a major role in type-2 diabetes. It is therefore important 
that changes to it are properly understood. Lipids are the main contributing 
factor to changes in insulin sensitivity (see Chapter 9). Therefore for long term 
modelling it will be important to look into them in greater depth to understand 
their relationship with diabetes disease progression.  
The primary aim of this thesis was to design a mathematical model for glucose 
and insulin secretion. The parameter fitting was based on individual subjects. It 
would provide more mathematically robust results if population modelling using 
this model was performed. This work was planned to be done by AstraZeneca (as 
of 2013 some of this work has been done [157]). 
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Appendix 1: Data Collection 
Contents of the CD: 
A database with the data collected for this thesis as well as the original data 
from: 
AliceIVGTT 
AmieIVGTT 
GeorgiaIVGTT 
JoChronic 
RuthClamp 
RuthCPeptide 
StevenOGTT 
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Appendix 2: Minimal Model 
Contents: 
Structural Identifiability Taylor Series 
Approach in Mathematica 4 state model 
with 2 observables 
Page 
275 + 
CD 
Structural Identifiability Taylor Series 
Approach in Maple 4 state model with 2 
observables 
Page 
277 + 
CD 
Structural Identifiability Taylor Series 
Approach in Maple 4 state model with 1 
observable 
Page 
279 + 
CD 
Graphs and results from parameter fitting CD 
MATLAB Code CD 
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SI Taylor Series Approach 
Edmund Watson (E.M.Watson@warwick.ac.uk) 
Setting up the Model 
Minimal Model for Glucose and Insulin 
x'[t_] :=- p2*x[t] + p3*(i[t]-ib) 
g'[t_]:=x[t]*g[t]+p1*(gb-g[t]) 
i'[t_]:=-n*i[t]+Gamma*(g[t]-h)*m[t] 
m'[t_]:=1 
x[0] = 0; 
g[0]=Go; 
i[0]=Io; 
m[0]=0; 
yg[t_] :=  g[t]; 
yi[t_] := i[t]; 
subst = {p1  p1b , p2  p2b, p3  p3b,h hb, n  nb , 
Gamma  Gammab,Io  Iob,Go  Gob};  
Creating the Coefficients 
k is the number of coefficients wanted to be created. 
As there are 2 observable states, there are 2 sets of produced coefficients, ya 
and yb.  
 
k=4; 
ya = {yg[0],D[yg[t],t]}; 
For[j = 2,j<k,ya= Join[ya,{D[ya[[j]],t]} ] ; j++] 
yi[0]; 
yb = {yi[0],D[yi[t],t]}; 
For[l = 2,l<k,yb= Join[yb,{D[yb[[l]],t]} ] ; l++] 
TableForm[Simplify[ya]] 
TableForm[Simplify[yb]] 
coeffs ={ ya,yb} /. t0; 
coeffsPBar = coeffs /. subst; 
eqns = coeffs - coeffsPBar; 
 
{ {Go}, 
{gb p1+g[t] (-p1+x[t])}, 
{gb p1 (-p1+x[t])+g[t] (p1
2
-ib p3+p3 i[t]-(2 p1+p2) 
x[t]+x[t]2)}, 
{Gamma p3 g[t]2 m[t]+gb p1 (p12-2 ib p3+2 p3 i[t]-2 (p1+p2) 
x[t]+x[t]2)-g[t] (p13-3 ib p1 p3-ib p2 p3+Gamma h p3 m[t]+p3 
i[t] (n+3 p1+p2-3 x[t])-3 p12 x[t]-3 p1 p2 x[t]-p22 x[t]+3 
ib p3 x[t]+3 p1 x[t]2+3 p2 x[t]2-x[t]3)}} 
{ {Io}, 
{-n i[t]+Gamma (-h+g[t]) m[t]}, 
{n2 i[t]+Gamma (-h+h n m[t]+gb p1 m[t])+Gamma g[t] (1-m[t] 
(n+p1-x[t]))}, 
{-n3 i[t]-Gamma (-h n-2 gb p1+m[t] (h n2+gb p1 (n+p1)-gb p1 
x[t]))+Gamma g[t] (-n-2 p1+2 x[t]+m[t] (n2+n p1+p12-ib p3+p3 
i[t]-(n+2 p1+p2) x[t]+x[t]2))}} 
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Solving the parameters 
 soln = Simplify 
[Solve[eqns0,{p1b,p2b,p3b,hb,nb,Gammab,Iob, Gob}]] 
 {{hbh,p2bp2,GammabGamma, 
IobIo,nbn,p3bp3,GobGo,p1bp1}}  
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Taylor Series 
Minimal Model 
Setting up the Model 
> 
 
 
 
>  
> Creating the Coefficients  
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> Finding the Result  
> coeffentsb := subs({p1 = p1b, p2 = p2b, p3 = p3b, h = hb, Gamma = Gammab, 
x1o = x1ob, x3o = x3ob, n = nb}, coeffents);  
results := coeffents-coeffentsb; 
 
 
>  
 
>  
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Identifiability Analysis  
Edmund Watson + James Chapman 
x[t_]:={x1[t],x2[t],x3[t],x4[t]} 
 
x1'[t_]:= f[x[t],p][[1]] 
x2'[t_]:= f[x[t],p][[2]] 
x3'[t_]:= f[x[t],p][[3]] 
x4'[t_]:= f[x[t],p][[4]] 
 
x1[0]= 0; 
x2[0]= G0; 
x3[0]= J0; 
x4[0]= 0; 
xbar[t_]:={Xbar[t],Gbar[t],Jbar[t],Kbar[t]} 
Xbar'[t_]:= f[xbar[t],pbar][[1]] 
Gbar'[t_]:= f[xbar[t],pbar][[2]] 
Jbar'[t_]:= f[xbar[t],pbar][[3]] 
Kbar'[t_]:= f[xbar[t],pbar][[4]] 
 
 
Xbar[0]= 0; 
Gbar[0]= Gbar0; 
Jbar[0]=Jbar0; 
Kbar[0]= 0; 
 
p :={p2,p3,p1,n,h,,ib,gb,G0,J0} 
pbar :={p2bar,p3bar,p1bar,nbar,hbar,bar,ib,gb,Gbar0,Jbar0} 
 
 
System  f (x(t, p), p) 
 
f[x_,p_]:={-p[[1]] x[[1]]+ p[[2]](x[[3]] - p[[7]]),-x[[1]] x[[2]] 
+ p[[3]](p[[8]] -x[[2]]),-p[[4]] x[[3]]+ p[[6]](x[[2]]-
p[[5]])x[[4]],1} 
 
h[x_]:={0,1,0,1}  x 
 u1[x_] := h[x][[2]]; 
u1bar[x_] :=h[x][[2]]; 
 
 
u2[x_] := h[x][[4]]; 
u2bar[x_] :=h[x][[4]]; 
 
 
mu3 = Map[D[u1[x[t]],#]&,x[t]].f[x[t],p]; 
mu3bar = Map[D[u1bar[x[t]],#]&,x[t]].f[x[t],pbar]; 
u3[x_]:=mu3 /. {x1[t] 
x[[1]],x2[t]x[[2]],x3[t]x[[3]],x4[t]x[[4]]} 
u3bar[x_]:=mu3bar /. {x1[t] 
x[[1]],x2[t]x[[2]],x3[t]x[[3]],x4[t]->x[[4]]} 
 
mu4 = Map[D[u3[x[t]],#]&,x[t]].f[x[t],p]; 
mu4bar = Map[D[u3bar[x[t]],#]&,x[t]].f[x[t],pbar]; 
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u4[x_]:=mu4 /. {x1[t] 
x[[1]],x2[t]x[[2]],x3[t]x[[3]],x4[t]x[[4]]} 
u4bar[x_]:=mu4bar /. {x1[t] 
x[[1]],x2[t]x[[2]],x3[t]x[[3]],x4[t]->x[[4]]} 
 
H[x_] := {u1[x],u2[x],u3[x],u4[x]} 
Hbar[x_] := {u1bar[x],u2bar[x],u3bar[x],u4bar[x]} 
 
Jacob :=  Transpose[Map[D[H[x[t]],#]&,x[t]]] 
MatrixForm[Jacob] 
MatrixForm[Jacob /. t0] 
 
 (_{ 
  {0, 1, 0, 0}, 
  {0, 0, 0, 1}, 
  {-x2[t], -p1-x1[t], 0, 0}, 
  {-p1 (gb-x2[t])+p2 x2[t]-(-p1-x1[t]) x2[t]+x1[t] x2[t], (-p1-
x1[t])2+p2 x1[t]-p3 (-ib+x3[t]), -p3 x2[t], 0} 
 }_) 
 (_{ 
  {0, 1, 0, 0}, 
  {0, 0, 0, 1}, 
  {-G0, -p1, 0, 0}, 
  {G0 p1-(-G0+gb) p1+G0 p2, p12-(-ib+J0) p3, -G0 p3, 0} 
 }_) 
MatrixRank[Jacob/. t0] 
4 
[x_] := {1,2,3,4} 
 
eqns = Simplify[H[[x[t]]]-Hbar[x[t]]] 
Simplify[ Solve[eqns0, {1,2,3,4}]]; 
 
{2-x2[t],4-x4[t],gb (p1-p1bar)-(p1+1) 2+(p1bar+x1[t]) x2[t],-
(p1+1) (gb p1-(p1+1) 2)+2 (ib p3+p2 1-p3 3)+(p1bar+x1[t]) 
(gb p1bar-(p1bar+x1[t]) x2[t])-x2[t] (p2bar x1[t]+p3bar (ib-
x3[t]))} 
[x_] := {1,2,3,4}/. Solve[eqns0, {1,2,3,4}][[1]] /. 
{x1[t] x[[1]],x2[t]x[[2]],x3[t]x[[3]],x4[t]->x[[4]]} 
eqnzero = (x[t]  /. {t0}) -( [xbar[t]] /. {t0}) 
resultszero = Simplify[Solve[eqnzero0 , p]] 
{-((gb p1-Gbar0 p1-gb p1bar+Gbar0 p1bar)/Gbar0),G0-Gbar0,J0-
1/(Gbar0 p3) (-((gb p1bar (gb p1-Gbar0 p1-gb p1bar+Gbar0 
p1bar))/Gbar0)+gb p1 p2-Gbar0 p1 p2-gb p1bar p2+Gbar0 p1bar 
p2+Gbar0 ib p3-Gbar0 ib p3bar+Gbar0 Jbar0 p3bar),0} 
 
 
{{G0Gbar0,J0(ib p3-ib p3bar+Jbar0 
p3bar)/p3,gbGbar0},{G0Gbar0,J0(ib p3-ib p3bar+Jbar0 
p3bar)/p3,p1p1bar}} 
 equation[n_] :=Simplify[f[[x[t]],p][[n]] -
Total[Map[D[[x[t]][[n]],#]&,x[t]]]f[x[t],pbar][[n]]] 
 equation[1] 
 -((gb (p1-p1bar) (gb p1bar+ib p3bar+x1[t] (p2bar-x2[t])-p1bar 
x2[t]-p3bar x3[t]))/x2[t]2) 
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 equan =Simplify[f[[x[t]],p] -
Transpose[Map[D[[x[t]],#]&,x[t]]].f[x[t],pbar]]; 
 equan[[3]] 
 1/(p3 x2[t]3) (2 gb3 p1bar2 (-p1+p1bar)+gb2 (p1-p1bar) p1bar (n+3 
p1bar+p2+3 x1[t]) x2[t]-gb (p1-p1bar) x2[t]2 (n p1bar+p1bar2+n 
p2+p1bar p2-ib p3bar+(n+2 p1bar+p2-p2bar) x1[t]+x1[t]2+p3bar 
x3[t])+(p3 -p3bar bar) x2[t]4 x4[t]+x2[t]3 (n p1 p2-n p1bar p2-
ib n p3+ib n p3bar+ib p2 p3bar-ib p2bar p3bar+(n-p2bar) (-
p2+p2bar) x1[t]+(-n+nbar-p2+p2bar) p3bar x3[t]-h p3  x4[t]+hbar 
p3bar bar x4[t])) 
Simplify[equation[3]-equan[[3]]] 
1/(p3 x2[t]3) ((-p2+p2bar) bar x2[t]4 x4[t]+2 gb2 (p1-p1bar) p1bar 
(gb p1bar+nbar x3[t]+hbar bar x4[t])+x2[t]3 (-ib p2 p3bar+ib 
p2bar p3bar+p2bar (-p2+p2bar) x1[t]+(p2-p2bar) (nbar+p3bar) x3[t]-
gb p1 bar x4[t]+gb p1bar bar x4[t]+hbar p2 bar x4[t]-hbar p2bar 
bar x4[t])+gb (p1-p1bar) x2[t]2 (p1bar2+p1bar p2-ib 
p3bar+x1[t]2+(nbar+p3bar) x3[t]+hbar bar x4[t]+p1bar bar 
x4[t]+p2 bar x4[t]+x1[t] (2 p1bar+p2-p2bar+bar x4[t]))-gb (p1-
p1bar) x2[t] (3 gb p1bar2+gb p1bar p2+nbar (p1bar+p2) x3[t]+2 gb 
p1bar bar x4[t]+hbar p1bar bar x4[t]+hbar p2 bar x4[t]+x1[t] (3 
gb p1bar+nbar x3[t]+hbar bar x4[t]))) 
 equationt[1]  
 -((gb (p1-p1bar) (gb p1bar+ib p3bar+x1[t] (p2bar-x2[t])-p1bar 
x2[t]-p3bar x3[t]))/x2[t]2) 
  
 1/p3 (-ib n p3+ib n p3bar+n (-p2+p2bar) x1[t]+(-n p3bar+nbar (p2-
p2bar+p3bar)) x3[t]-h p3  x4[t]+hbar p2 bar x4[t]-hbar p2bar 
bar x4[t]+hbar p3bar bar x4[t]+p3  x2[t] x4[t]-p2 bar x2[t] 
x4[t]+p2bar bar x2[t] x4[t]-p3bar bar x2[t] x4[t]) 
  
cf3a1 = Simplify[Coefficient[equation3a, {x1[t]}]/.{x2[t] 
0,x3[t]0 , x4[t]0}]; 
cf3a2 = Simplify[Coefficient[equation3a, {x2[t] x4[t]}]/.{x1[t] 
0,x3[t]0 }]; 
cf3a3= Simplify[Coefficient[equation3a, { x3[t]}]/.{x2[t] 
0,x1[t]0 , x4[t]0}]; 
cf3a4= Simplify[Coefficient[equation3a, {x4[t] }]/.{x2[t] 
0,x1[t] 0,x3[t]0 }]; 
cf3a5= Simplify[equation3a/.{x2[t] 0,x1[t] 0,x3[t]0 
,x4[t]0}]; 
Simplify[equation3a -(x1[t]*cf3a1+x2[t] x4[t] 
*cf3a2+x3[t]*cf3a3+x4[t]*cf3a4 + cf3a5)] 
 
 {0} 
 cf2 = Simplify[Coefficient[equation[1], 
{x1[t]/x2[t]^2}]/.{x3[t]0 , x4[t]0}]; 
cf3 = Simplify[Coefficient[equation[1], 
{x3[t]/x2[t]^2}]/.{x1[t]0 , x4[t]0}]; 
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cf1= Simplify[Coefficient[equation[1], {x1[t]/x2[t]}]/.{x3[t]0 , 
x4[t]0}]; 
cf4= Simplify[Coefficient[equation[1], 
{1/x2[t]}]/.{x1[t]0,x3[t]0 , x4[t]0}]; 
cf5= Simplify[Coefficient[equation[1], 
{1/x2[t]^2}]/.{x1[t]0,x3[t]0 , x4[t]0}]; 
Simplify[equation[1] - ( 
cf2*x1[t]/x2[t]^2+cf3*x3[t]/x2[t]^2+cf1*x1[t]/x2[t]+ 
cf4/x2[t]+cf5/x2[t]^2 )] 
 
 {0} 
 solutions = {cf1,cf2,cf3,cf4,cf5,cf3a1,cf3a2,cf3a3,cf3a4,cf3a5} 
 {{gb (p1-p1bar)},{gb (-p1+p1bar) p2bar},{gb (p1-p1bar) p3bar},{gb 
(p1-p1bar) p1bar},{-gb (p1-p1bar) (gb p1bar+ib p3bar)},{(n (-
p2+p2bar))/p3},{(p3 -(p2-p2bar+p3bar) bar)/p3},{(-n p3bar+nbar 
(p2-p2bar+p3bar))/p3},{(-h p3 +hbar (p2-p2bar+p3bar) 
bar)/p3},(ib n (-p3+p3bar))/p3} 
 results = Simplify[Solve[solutions0 , p]] 
 Solve::svars: Equations may not give solutions for all "solve" 
variables. More… 
 {{gb0,n0,0,p2p2bar-
p3bar,p3p3bar},{p1p1bar,n0,0,p2p2bar-
p3bar,p3p3bar},{gb0,n0,0,p2p2bar-
p3bar},{p1p1bar,n0,0,p2p2bar-
p3bar},{gb0,nnbar,hhbar,bar,p2p2bar,p3p3bar},{p1p1bar,n
nbar,hhbar,bar,p2p2bar,p3p3bar},{ib0,gb0,nnbar,hhbar,
(p3bar bar)/p3,p2p2bar},{nnbar,ib0,gb0,hhbar,(p3bar 
bar)/p3,p2p2bar},{p1p1bar,ib0,nnbar,hhbar,(p3bar 
bar)/p3,p2p2bar}} 
 MatrixForm[results] 
 (_{ 
  {{gb0,n0,0,p2p2bar-p3bar,p3p3bar}}, 
  {{p1p1bar,n0,0,p2p2bar-p3bar,p3p3bar}}, 
  {{gb0,n0,0,p2p2bar-p3bar}}, 
  {{p1p1bar,n0,0,p2p2bar-p3bar}}, 
  {{gb0,nnbar,hhbar,bar,p2p2bar,p3p3bar}}, 
  {{p1p1bar,nnbar,hhbar,bar,p2p2bar,p3p3bar}}, 
  {{ib0,gb0,nnbar,hhbar,(p3bar bar)/p3,p2p2bar}}, 
  {{nnbar,ib0,gb0,hhbar,(p3bar bar)/p3,p2p2bar}}, 
  {{p1p1bar,ib0,nnbar,hhbar,(p3bar bar)/p3,p2p2bar}} 
 }_) 
 test1 = gf2*x1[t]/x2[t]^2+gf3*x3[t]/x2[t]^2+gf1*x1[t]/x2[t]+ 
gf4/x2[t]+gf5/x2[t]^2 
test2 = Simplify[D[test1,t]]; 
test3 = Simplify[D[test2,t]]; 
test4 = Simplify[D[test3,t]]; 
test5 = Simplify[D[test4,t]]; 
 
syseqn = {test1,test2,test3,test4,test5}; 
 
 gf5/x2[t]2+(gf2 x1[t])/x2[t]2+gf4/x2[t]+(gf1 x1[t])/x2[t]+(gf3 
x3[t])/x2[t]2 
 Solve[syseqn  0,{gf1,gf2,gf3,gf4,gf5}] 
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 {{gf10,gf20,gf30,gf40,gf50}} 
 test31 =x1*gf31+x2 x4 *gf32+x3*gf33+x4*gf34 + gf35 /.{ x1  
x1[t],x2x2[t],x3x3[t],x4x4[t]} 
test32 = Simplify[D[test31,t]]; 
test33 = Simplify[D[test32,t]]; 
test34 = Simplify[D[test33,t]]; 
test35 = Simplify[D[test34,t]]; 
syseqn3a = {test31,test32,test33,test34,test35}; 
 
gf35+gf31 x1[t]+gf33 x3[t]+gf34 x4[t]+gf32 x2[t] x4[t] 
 
Solve[syseqn3a  0,{gf31,gf32,gf33,gf34,gf35}] 
{{gf350,gf340,gf310,gf320,gf330}} 
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Appendix 3: C-peptide 
Contents of the CD: 
MATLAB code 
Results 
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Appendix 4: Short Term Modelling 
Contents: 
Observability Rank Criterion Page 286 
+ CD 
Lie Symmetries PID Page 288 
+ CD 
Minimised ID – Similarity 4 state Page 291 
+ CD 
Minimised ID – Similarity 6 state Page 293 
+ CD 
Failed Structural Identifiability CD 
Results CD 
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Observability Rank Criterion 
Minimal Model 
Model Definition 
 x[t] := {x1[t],x2[t],x3[t]} 
p :={x10,x20,x30,Ro,Ego,Si,kp,ki,kd,n,intn} 
f[x_,p_]:={p[[4]]- (p[[5]] +(p[[6]] *x[[2]]))*x[[1]], 
p[[7]]*x[[1]]  -p[[10]]*x[[2]] + x[[3]]*p[[8]]+ p[[9]]*x[[1]]', 
x[[1]]- p[[11]]*x[[3]]} 
 
h[x_] := {1,0,0,0} 
Observability Rank Criterion 
Lie derivation  
 c =Map[D[h[x[t]] .x[t],#]&,x[t]] 
{{0,0,0,0}.{x1[t],x2[t],x3[t]}+{1,0,0,0}.{1,0,0},{0,0,0,0}.{x1[t],
x2[t],x3[t]}+{1,0,0,0}.{0,1,0},{0,0,0,0}.{x1[t],x2[t],x3[t]}+{1,0,
0,0}.{0,0,1}} 
 ca = c.f[x[t],p] 
 c.{Ro-x1[t] (Ego+Si x2[t]),kp x1[t]-n x2[t]+ki x3[t]+kd 
x1[t]
,x1[t]-intn x3[t]} 
 ob1 =  Map[D[ca[[1]],#]&,x[t]]; 
 MatrixForm[ob1] 
 (_{ 
  {-x2[t]}, 
  {-p1-x1[t]}, 
  {0}, 
  {0} 
 }_) 
 ob1a = ob1.f[x[t]] 
{(-p1-x1[t]) (p1 (gb-x2[t])-x1[t] x2[t])-x2[t] (-p2 x1[t]+p3 (-
ib+x3[t]))} 
 ob2  =   Map[D[ob1a[[1]],#]&,x[t]]; 
 MatrixForm[ob2] 
 (_{ 
  {-p1 (gb-x2[t])+p2 x2[t]-(-p1-x1[t]) x2[t]+x1[t] x2[t]}, 
  {(-p1-x1[t])2+p2 x1[t]-p3 (-ib+x3[t])}, 
  {-p3 x2[t]}, 
  {0} 
 }_) 
 ob2a = ob2.f[x[t]] 
{(p1 (gb-x2[t])-x1[t] x2[t]) ((-p1-x1[t])2+p2 x1[t]-p3 (-
ib+x3[t]))+(-p1 (gb-x2[t])+p2 x2[t]-(-p1-x1[t]) x2[t]+x1[t] x2[t]) 
(-p2 x1[t]+p3 (-ib+x3[t]))-p3 x2[t] (-n x3[t]+ (-h+x2[t]) x4[t])} 
 ob3  =   Map[D[ob2a[[1]],#]&,x[t]]; 
 MatrixForm[ob3] 
 (_{ 
  {(p2-2 (-p1-x1[t])) (p1 (gb-x2[t])-x1[t] x2[t])-p2 (-p1 (gb-
x2[t])+p2 x2[t]-(-p1-x1[t]) x2[t]+x1[t] x2[t])-x2[t] ((-p1-
x1[t])2+p2 x1[t]-p3 (-ib+x3[t]))+2 x2[t] (-p2 x1[t]+p3 (-
ib+x3[t]))}, 
  {(-p1-x1[t]) ((-p1-x1[t])2+p2 x1[t]-p3 (-ib+x3[t]))+(2 p1+p2+2 
x1[t]) (-p2 x1[t]+p3 (-ib+x3[t]))-p3  x2[t] x4[t]-p3 (-n x3[t]+ 
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(-h+x2[t]) x4[t])}, 
  {n p3 x2[t]-p3 (p1 (gb-x2[t])-x1[t] x2[t])+p3 (-p1 (gb-x2[t])+p2 
x2[t]-(-p1-x1[t]) x2[t]+x1[t] x2[t])}, 
  {-p3  x2[t] (-h+x2[t])} 
 }_) 
 H := {c,ob1,ob2,ob3} 
 MatrixForm[H] 
 (_{ 
  {0, 1, 0, 0}, 
  {-x2[t], -p1-x1[t], 0, 0}, 
  {-p1 (gb-x2[t])+p2 x2[t]-(-p1-x1[t]) x2[t]+x1[t] x2[t], (-p1-
x1[t])2+p2 x1[t]-p3 (-ib+x3[t]), -p3 x2[t], 0}, 
  {(p2-2 (-p1-x1[t])) (p1 (gb-x2[t])-x1[t] x2[t])-p2 (-p1 (gb-
x2[t])+p2 x2[t]-(-p1-x1[t]) x2[t]+x1[t] x2[t])-x2[t] ((-p1-
x1[t])2+p2 x1[t]-p3 (-ib+x3[t]))+2 x2[t] (-p2 x1[t]+p3 (-
ib+x3[t])), (-p1-x1[t]) ((-p1-x1[t])2+p2 x1[t]-p3 (-ib+x3[t]))+(2 
p1+p2+2 x1[t]) (-p2 x1[t]+p3 (-ib+x3[t]))-p3  x2[t] x4[t]-p3 (-n 
x3[t]+ (-h+x2[t]) x4[t]), n p3 x2[t]-p3 (p1 (gb-x2[t])-x1[t] 
x2[t])+p3 (-p1 (gb-x2[t])+p2 x2[t]-(-p1-x1[t]) x2[t]+x1[t] x2[t]), 
-p3  x2[t] (-h+x2[t])} 
 }_) 
 MatrixForm[H0 = H /. {x1[t]  0,x2[t]g0,x3[t]i0,x4[t]0}] 
 (_{ 
  {0, 1, 0, 0}, 
  {-g0, -p1, 0, 0}, 
  {g0 p1-(-g0+gb) p1+g0 p2, p12-(i0-ib) p3, -g0 p3, 0}, 
  {(-g0+gb) p1 (2 p1+p2)-p2 (g0 p1-(-g0+gb) p1+g0 p2)+2 g0 (i0-ib) 
p3-g0 (p12-(i0-ib) p3), i0 n p3+(i0-ib) (2 p1+p2) p3-p1 (p12-(i0-
ib) p3), g0 n p3-(-g0+gb) p1 p3+(g0 p1-(-g0+gb) p1+g0 p2) p3, -g0 
(g0-h) p3 } 
 }_) 
 Dimensions[H0] 
 {4,4} 
 MatrixRank[H0] 
 4 
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Lie Symmetries PID 
 
SetDirectory["C:/Documents and Settings/Edmund Watson/My 
Documents/Subversion/Documents/PhD/Mathematica/Symmetry/IntroToSym
metry"]; 
Needs["SymmetryAnalysis`IntroToSymmetry`"]; 
 inputequation1="D[x1[t],t]-p[4]+ (p5[t] +(p6[t] *x4[t]))*x1[t]"; 
inputequation2="D[x2[t],t] -p[7]*x1[t]  +p10[t]*x2[t] - 
x3[t]*p8[t]- p9[t]*D[x1[t],t]"; 
inputequation3="D[x3[t],t]-x1[t]+ p11[t]*x3[t]"; 
inputequation4="D[x4[t],t]-x2[t]+p12[t]*x4[t]"; 
inputequation5="D[p4[t],t]"; 
inputequation6="D[p5[t],t]"; 
inputequation7="D[p6[t],t]"; 
inputequation8="D[p7[t],t]"; 
inputequation9="D[p8[t],t]"; 
inputequation10="D[p9[t],t]"; 
inputequation11="D[p10[t],t]"; 
inputequation12="D[p11[t],t]"; 
inputequation13="D[p12[t],t]"; 
 rulesarray={"D[x1[t],t]->-(-p4[t]+ (p5[t] +(p6[t] 
*x4[t]))*x1[t])", 
   "D[x2[t],t] ->-(-p7[t]*x1[t]  +p10[t]*x2[t] - x3[t]*p8[t]- 
p9[t]*x1[t])", 
   "D[x3[t],t]->-(-x1[t]+ p11[t]*x3[t])", 
   "D[x4[t],t]->x2[t]-p12[t]*x4[t]","D[p4[t],t]->0", 
   "D[p5[t],t]->0","D[p6[t],t]->0","D[p7[t],t]->0","D[p8[t],t]-
>0","D[p9[t],t]->0","D[p10[t],t]->0","D[p11[t],t]-
>0","D[p12[t],t]->0"}; 
 independentvariables={"t"}; 
dependentvariables={"x1","x2","x3","x4","p4","p5","p6","p7" 
,"p8","p9","p10","p11","p12"}; 
 frozennames={""}; 
p=1; 
r=0; 
xseon=1; 
internalrules=1; 
 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation1,rulesarray,internalrules]; 
zdeterminingequations1=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation2,rulesarray,internalrules]; 
zdeterminingequations2=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation3,rulesarray,internalrules]; 
zdeterminingequations3=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation4,rulesarray,internalrules]; 
zdeterminingequations4=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation5,rulesarray,internalrules]; 
zdeterminingequations5=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation6,rulesarray,internalrules]; 
Appendices  
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zdeterminingequations6=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation7,rulesarray,internalrules]; 
zdeterminingequations7=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation8,rulesarray,internalrules]; 
zdeterminingequations8=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation9,rulesarray,internalrules]; 
zdeterminingequations9=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation10,rulesarray,internalrules]; 
zdeterminingequations10=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation11,rulesarray,internalrules]; 
zdeterminingequations11=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation12,rulesarray,internalrules]; 
zdeterminingequations12=zdeterminingequations; 
FindDeterminingEquations[independentvariables,dependentvariables,f
rozennames,p,r,xseon,inputequation13,rulesarray,internalrules]; 
zdeterminingequations13=zdeterminingequations; 
zdeterminingequations=Join[zdeterminingequations1,zdeterminingequa
tions2,zdeterminingequations3,zdeterminingequations4,zdetermininge
quations5,zdeterminingequations6,zdeterminingequations7,zdetermini
ngequations8,zdeterminingequations9,zdeterminingequations10,zdeter
miningequations11,zdeterminingequations12,zdeterminingequations13]
; 
 
SolveDeterminingEquations[independentvariables,dependentvariables,
r,xseon,zdeterminingequations,1] 
TableForm[xsefunctions] 
TableForm[etafunctions] 
 { 
 {xse1[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=a10 + a12*z10 + a13*z11 + a14*z12 + a15*z13 + 
a16*z14 + a111*z6 + a112*z7 + a113*z8 + a114*z9} 
} 
 { 
 {eta1[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0}, 
 {eta2[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0}, 
 {eta3[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0}, 
 {eta4[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0}, 
 {eta5[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=b50 + b52*z10 + b53*z11 + b54*z12 + b55*z13 + 
b56*z14 + b511*z6 + b512*z7 + b513*z8 + b514*z9}, 
 {eta6[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0}, 
 {eta7[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0}, 
 {eta8[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=b80 + b82*z10 + b83*z11 + b84*z12 + b85*z13 + 
b86*z14 + b811*z6 + b812*z7 + b813*z8 + b814*z9}, 
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 {eta9[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0}, 
 {eta10[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0}, 
 {eta11[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0}, 
 {eta12[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0}, 
 {eta13[z1_, z2_, z3_, z4_, z5_, z6_, z7_, z8_, z9_, z10_, z11_, 
z12_, z13_, z14_]=0} 
} 
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Minimised ID – Similarity 4 state 
 
g'[t_]:=-ia[t]*g[t]*si+gp  
j'[t_]:=-n*j[t]+ii[t]*ki+kd*g'[t] 
ii'[t_]:=g[t]-ii[t]*kiir 
ia'[t_] := j[t] - kair*ia[t] 
x1[0] = x1o; 
x2[0] = 0; 
x3[0] = x3o; 
y1 = j[t]; 
y = g[t];   
p ={si,gp,n,ki,kd,kiir,kair}; 
 G=Append[{},Map[D[y /. t->0,#]&,p]]; 
calrow:=Module[{},y = D[y,t]; r = Map[D[y /. t->0,#]&,p]; G = 
Append[G,r]] 
For[i=1,i<7,i++,calrow] 
 
H=Append[{},Map[D[y1 /. t->0,#]&,p]]; 
calrow:=Module[{},y = D[y,t]; r = Map[D[y /. t->0,#]&,p]; G = 
Append[G,r]] 
For[i=1,i<7,i++,calrow] 
 
 
 $Aborted 
 MatrixForm[G] 
Dimensions[G] 
G = Append[G,H] 
Dimensions[G] 
  
 {7,7} 
 MatrixRank[G] 
 6 
 gr = RowReduce[G] 
gs = Simplify[gr] 
 
 
{{1,0,0,0,0,0,0},{0,1,0,0,0,0,0},{0,0,1,0,0,0,0},{0,0,0,1,0,0,0},{
0,0,0,0,1,0,0},{0,0,0,0,0,1,0},{0,0,0,0,0,0,1},{0,0,0,0,0,0,0}} 
 
{{1,0,0,0,0,0,0},{0,1,0,0,0,0,0},{0,0,1,0,0,0,0},{0,0,0,1,0,0,0},{
0,0,0,0,1,0,0},{0,0,0,0,0,1,0},{0,0,0,0,0,0,1},{0,0,0,0,0,0,0}} 
 MatrixForm[ns = NullSpace[G]] 
 {} 
 z = {z1[t],z2[t],z3[t],z4[t],z5[t],z6[t]}; 
 DSolve[{z1'[t]ns[[1]][[1]], z1[0]==1},{z1[t]},t] 
 {{z1[t]1}} 
 z1 = 1;z2 = 2;z3 = 3;z4 = 4;z5 = 5;z6 = 6;z7 = 7 + t; z8 = 
8;z9 = 9;z10 = 10; 
 
psi1[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]],z[[6]],z[[7]]+t,z
[[8]],z[[9]],z[[10]]} 
psi2[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]],z[[6]]+t,z[[7]],z
[[8]],z[[9]],z[[10]]} 
psi3[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]]+t,z[[6]],z[[7]],z
[[8]],z[[9]],z[[10]]} 
Appendices  
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psi4[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]]+t,z[[5]],z[[6]],z[[7]],z
[[8]],z[[9]],z[[10]]} 
psi5[t_,z_]:={z[[1]]+t,z[[2]],z[[3]],z[[4]],z[[5]],z[[6]],z[[7]],z
[[8]],z[[9]],z[[10]]} 
psi6[t_,z_]:={z[[1]],z[[2]]+t,z[[3]],z[[4]],z[[5]],z[[6]],z[[7]],z
[[8]],z[[9]],z[[10]]} 
psi7[t_,z_]:={z[[1]],z[[2]],z[[3]]+t,z[[4]],z[[5]],z[[6]],z[[7]],z
[[8]],z[[9]],z[[10]]} 
psi8[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]],z[[6]],z[[7]],z[[
8]]+t,z[[9]],z[[10]]} 
psi9[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]],z[[6]],z[[7]],z[[
8]],z[[9]]+t,z[[10]]} 
psi10[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]],z[[6]],z[[7]],z[
[8]],z[[9]],z[[10]]+t} 
 
  = 
psi1[1,psi2[2,psi3[3,psi4[4,psi5[5,psi6[6,psi7[7,psi8[8,ps
i9[9,psi10[10,{1,2,3,4,5,6,7,8,9,10}]]]]]]]]]] 
{1+5,2+6,3+7,4+4,5+3,6+2,7+1,8+8,9+9,10+10} 
 inv = Simplify[Solve[p==,{1,2,3,4,5,6,7,8,9,10}]] 
 {{5p1-1,6p2-2,7p3-3,4h-4,3n-5,2Gamma-6,1Io-
7,8Go-8,9gb-9,10ib-10}} 
  inv= inv  /. {1  0,2 0,3 0,4 0,5 0,6 0,7 0,8 
0,9 0,10 0} 
{{5p1,6p2,7p3,4h,3n,2Gamma,1Io,8Go,9gb,10ib}
} 
   
  
Appendices  
293 
 
Minimised ID – Similarity 6 state 
g'[t_]:=-ia[t]*g[t]*si+gp  
j'[t_]:=-n*j[t]+fac*(ii[t]*ki+kd*g'[t]) 
ii'[t_]:=g[t]-ii[t]*kiir 
ia'[t_] := j[t] - kair*ia[t] 
cp1'[t_]:= -cr*cp1[t] -k12*cp1[t]+k21*cp2[t] + ii[t]*ki+kd*g'[t] 
cp2'[t_] := +k12*cp1[t]-k21*cp2[t] 
g[0] = go; 
j[0] = io; 
ii[0] = iio; 
ia[0] =iao; 
cp1[0] = cp1o; 
cp2[0] =cp2o; 
y = j[t]; 
y1 = g[t]; 
y2 = cp1[t]; 
p ={si,gp,n,ki,kd,kiir,kair,fac,cr,k12,k21}; 
 G=Append[{},Map[D[y /. t->0,#]&,p]]; 
calrow:=Module[{},y = D[y,t]; r = Map[D[y /. t->0,#]&,p]; G = 
Append[G,r]] 
For[i=1,i<12,i++,calrow] 
 
  
MatrixForm[G] 
  
 MatrixRank[G] 
 7 
 gr = RowReduce[G] 
gs = Simplify[gr] 
 
 
{{1,0,0,0,0,0,0},{0,1,0,0,0,0,0},{0,0,1,0,0,0,0},{0,0,0,1,0,0,0},{
0,0,0,0,1,0,0},{0,0,0,0,0,1,0},{0,0,0,0,0,0,1},{0,0,0,0,0,0,0}} 
 
{{1,0,0,0,0,0,0},{0,1,0,0,0,0,0},{0,0,1,0,0,0,0},{0,0,0,1,0,0,0},{
0,0,0,0,1,0,0},{0,0,0,0,0,1,0},{0,0,0,0,0,0,1},{0,0,0,0,0,0,0}} 
 MatrixForm[ns = NullSpace[G]] 
 {} 
 z = {z1[t],z2[t],z3[t],z4[t],z5[t],z6[t]}; 
 DSolve[{z1'[t]ns[[1]][[1]], z1[0]==1},{z1[t]},t] 
 {{z1[t]1}} 
 z1 = 1;z2 = 2;z3 = 3;z4 = 4;z5 = 5;z6 = 6;z7 = 7 + t; z8 = 
8;z9 = 9;z10 = 10; 
 
psi1[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]],z[[6]],z[[7]]+t,z
[[8]],z[[9]],z[[10]]} 
psi2[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]],z[[6]]+t,z[[7]],z
[[8]],z[[9]],z[[10]]} 
psi3[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]]+t,z[[6]],z[[7]],z
[[8]],z[[9]],z[[10]]} 
psi4[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]]+t,z[[5]],z[[6]],z[[7]],z
[[8]],z[[9]],z[[10]]} 
psi5[t_,z_]:={z[[1]]+t,z[[2]],z[[3]],z[[4]],z[[5]],z[[6]],z[[7]],z
[[8]],z[[9]],z[[10]]} 
psi6[t_,z_]:={z[[1]],z[[2]]+t,z[[3]],z[[4]],z[[5]],z[[6]],z[[7]],z
[[8]],z[[9]],z[[10]]} 
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psi7[t_,z_]:={z[[1]],z[[2]],z[[3]]+t,z[[4]],z[[5]],z[[6]],z[[7]],z
[[8]],z[[9]],z[[10]]} 
psi8[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]],z[[6]],z[[7]],z[[
8]]+t,z[[9]],z[[10]]} 
psi9[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]],z[[6]],z[[7]],z[[
8]],z[[9]]+t,z[[10]]} 
psi10[t_,z_]:={z[[1]],z[[2]],z[[3]],z[[4]],z[[5]],z[[6]],z[[7]],z[
[8]],z[[9]],z[[10]]+t} 
 
  = 
psi1[1,psi2[2,psi3[3,psi4[4,psi5[5,psi6[6,psi7[7,psi8[8,ps
i9[9,psi10[10,{1,2,3,4,5,6,7,8,9,10}]]]]]]]]]] 
{1+5,2+6,3+7,4+4,5+3,6+2,7+1,8+8,9+9,10+10} 
 inv = Simplify[Solve[p==,{1,2,3,4,5,6,7,8,9,10}]] 
 {{5p1-1,6p2-2,7p3-3,4h-4,3n-5,2Gamma-6,1Io-
7,8Go-8,9gb-9,10ib-10}} 
  inv= inv  /. {1  0,2 0,3 0,4 0,5 0,6 0,7 0,8 
0,9 0,10 0} 
{{5p1,6p2,7p3,4h,3n,2Gamma,1Io,8Go,9gb,10ib}
} 
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Appendix 5: Long Term Modelling 
 
The CD contains the GUI for long term modelling.
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Appendix 6: Software Tool for Modelling Glucose, 
Insulin and C-peptide Dynamics 
 
Software tool is on the CD. 
 
 
